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Abstract 
Patients who require platelet transfusion support but have become sensitised to Human 
Leucocyte Antigens (HLA) or Human Platelet Antigens (HPA) require suitably matched or 
selected products to ensure an adequate increase in their platelet count following transfusion. 
In England this affects approximately 1500 individuals per annum, with over 25,000 matched 
or selected platelet units provided for these patients.   
Provision of compatible products is often challenging, and requires significant resources from 
the blood service, with approximately 5000 apheresis platelet donors genotyped for HLA and 
HPA each year. Current typing technology results in restricted HLA and HPA genotypes for both 
patients and donors, thereby limiting the ability to provide fully compatible products. This 
study set out to develop and implement next generation sequencing (NGS) technology to 
enhance the HLA and HPA definition of both platelet donors and recipients. 
An NGS based method was designed and developed for high throughput, allele level HLA class I 
genotyping and used to evaluate the impact of NGS technology on the selection of platelet 
donors using HLA epitope matching (HEM). In addition, an alternative NGS approach was 
designed to simultaneously sequence the six genes that code for glycoproteins expressing HPA 
in order to define all known HPA systems in both donor and patient samples. 
Allele level HLA-A, -B and –C genotypes were generated for 519 platelet donors by NGS. A 
critical evaluation of algorithms used to predict alleles from low to medium resolution HLA 
types demonstrated that NGS was more accurate when determining HLA epitopes for the 
selection of platelets by HEM. The HLA genotyping data obtained was used to establish 
previously undefined HLA allele and haplotype frequencies in the English platelet donor 
population. This thesis also includes the first reported NGS based method for the simultaneous 
genotyping of HPA-1 to HPA-29, with the additional capability of novel HPA detection.  
NGS has been shown to significantly improve the definition of both HLA and HPA genetic 
systems and will provide a number of future benefits for laboratories and the patients they 
support, including provision of well matched transfusion products, the detection of rare or 
novel polymorphisms and increased knowledge of HLA and HPA frequencies. 
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1. Introduction 
For the majority of patients who require a transfusion of blood or blood components the main 
consideration for compatibility is likely to be the ABO and Rh blood group systems (Williamson 
and Devine, 2013). However, following exposure during transfusion, transplantation or 
pregnancy some individuals may become sensitised to other blood borne antigens such as 
those expressed on leucocytes and platelets i.e. Human Leucocyte Antigens (HLA) and Human 
Platelet Antigens (HPA), with the majority of individuals producing antibodies to HLA rather 
than HPA (Vassallo and Norris, 2016). These patients then require HLA and/or HPA matched or 
selected products to avoid adverse transfusion reactions resulting from the presence of these 
donor specific antibodies (Brown and Navarrete, 2011). The provision of these products is 
often difficult and can require significant resources from the blood service (Kopko et al., 2015). 
1.1 Human Leucocyte Antigens (HLA)  
Human leucocyte antigens (HLA) are transmembrane glycoproteins intimately involved in the 
adaptive immune response, presenting processed peptide from pathogens or altered self to 
the immune system (Dyer et al., 2013). There are two main types of HLA molecule, HLA class I 
and HLA class II, differentiated by their molecular structure and function and both 
characterised by their extensive polymorphism (Dyer et al., 2013). The genes coding for the 
HLA are located within the Major Histocompatibility Complex (MHC) on the short arm of 
chromosome 6 (Figure 1.1).  
Figure 1.1 Schematic showing the HLA regions of the human MHC. Organisation of the 
classical HLA genes contained with the class I and II regions of the human MHC with three main 
class I genes called HLA-A, -B and –C shown in red. HLA class II genes HLA-DR, -DQ and –DP are 
shown in yellow and are clustered with genes encoding molecules involved with antigen 
processing and presentation. The so-called class III region encodes other proteins associated 
with the innate immune system. Copyright © 2008 From Janeway’s immunobiology by Murphy 
et al. Adapted with permission of Garland Science/Taylor & Francis Group LLC.  
 
The MHC was first discovered in mice as a tumour resistant locus over 60 years ago, with its 
equivalent in humans identified and named HLA following the description of alloantibodies 
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against antigens expressed by human leucocytes (Shiina et al., 2017). The MHC has now been 
sequenced in 70 mammalian and non-mammalian species, with more than 7000 non-human 
alleles reported to the ImmunoPolymorphism Database (IPD)-MHC database (Maccari et al., 
2017). In comparison, over 16,000 HLA alleles have been recorded to date (Robinson et al., 
2015) with the majority reported in just the past eight years (Figure 1.2). Expression of HLA 
class II molecules is mainly restricted to, but not exclusively, specialized antigen presenting 
cells whereas the classical HLA class I molecules, namely HLA-A, -B & -C, are expressed by the 
majority of tissues and nucleated blood cells, (Brown and Navarrete, 2011). Non-nucleated 
platelets also express HLA class I molecules but not HLA class II, hence the focus on HLA class I 
for this study. 
 
Figure 1.2 The number of HLA alleles recorded on the IMGT/HLA database. The total number 
of HLA alleles recorded in the IMmunoGeneTics(IMGT) HLA database following each update, 
from release v1 in December 1998 to v3.27 in January 2017 (Robinson et al., 2015). 
 
1.1.1 HLA class I gene structure 
HLA class I genes code for the heavy chain of the HLA class I molecule, which is a heterodimer 
consisting of a heavy chain and light chain (beta-2 microglobulin). HLA-class I genes consist of 
seven or eight exons. Exon 1 encodes the leader sequence with exons 2 and 3 encoding the 
alpha-1 and alpha-2 domains, which form the peptide binding groove. Exon 5 encodes the 
transmembrane region with the cytoplasmic tail encoded by exons 6 and 7 (Figure 1.3).  
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Figure 1.3 Cartoon showing a typical HLA class I gene and the structures each exon encodes. 
Exons 2 and 3 encode the alpha 1 and 2 domains, which form the peptide binding grove. The 
alpha 3 domain is encoded by exon 4, with the transmembrane region and cytoplasmic tail 
encoded by exons 5 and 6/7, respectively. 
 
1.1.2 HLA class I nomenclature 
HLA nomenclature follows a prescribed format, with the naming of HLA alleles the 
responsibility of the WHO Nomenclature Committee for Factors of the HLA System (Marsh et 
al., 2010). All alleles begin with the HLA prefix, followed by the gene name. Thereafter, each 
allele is assigned at least a four digit number, with the first field indicating the allele group and 
second field the specific HLA protein (Figure 1.4).  
 
    HLA-A*01:01:01:02N 
Figure 1.4 Nomenclature of HLA alleles. All alleles begin with the HLA prefix followed by the 
gene name. At least two fields follow the separator, the first denoting the HLA allele group and 
the second the specific HLA protein. Some alleles also have a third field which represents 
synonymous nucleotide substitutions in the coding regions and the fourth field is reserved for 
differences in non-coding regions. Any suffix present relates to changes in expression. Adapted 
with permission of AMERICAN SOCIETY OF HEMATOLOGY from Definitions of histocompatibility 
typing terms, Nunes et al., 118, 23, 2011; permission conveyed through Copyright Clearance 
Centre, Inc. 
Gene 
Field 1 
Field 2 
Field 3 
Field 4 
Suffix HLA prefix 
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The third field relates to synonymous DNA substitutions within the coding region and the 
fourth field is reserved for non-coding differences in the 5’ or 3’ un-translated region (UTR) or 
introns. Some HLA alleles also have a suffix which denotes changes in expression, the most 
common being ‘N’ representing a null allele (Marsh et al., 2010). HLA can be determined at 
different levels of resolution depending on the method employed (Table 1.1).  Low resolution 
DNA based typing is defined as first field or 2-digit resolution and generally equates to 
serological antigens. Medium or intermediate resolution is the reporting of a subset of HLA 
alleles in the form of an HLA string. HLA alleles that encode the same amino acid sequence are 
said to be at high resolution and can be reported as ‘P-groups’ or ‘G-groups’, where alleles 
included have identical amino acid or nucleic acid sequences, respectively, in exons 2 and 3. 
HLA defined at the allele level has a unique DNA sequence (Nunes et al., 2011). 
Resolution Description Example 
Low First field only  B*39 
Medium ‘String’ of possible HLA alleles B*39:01:07/39:06:01/39:06:02/39:34/39:4
2/39:62/39:64/39:73 
High  ‘P group’ – alleles with  identical 
amino acid sequence in exons 2 & 
3 
B*39:02P 
(B*39:02:01/39:02:02:01/39:02:02:02/39:0
2:02:03) 
High ‘G group’ – alleles with identical 
nucleotide sequence in exons 2 & 
3 
B*39:06:02G 
(B*39:06:02:01/39:06:02:02/39:06:02:03) 
Allele Unique nucleotide sequence B*39:01:01:01 
Table 1.1 Levels of resolution for HLA typing. HLA types can be reported at low, medium, high 
or allele level, depending on the method used to define and the resolution required. The alleles 
included in the example ‘P’ and ‘G’ groups are shown in parenthesis (Marsh et al., 2010). 
 
1.2 Human platelet antigens (HPA) 
Platelets are anuclear cell fragments derived from large precursor cells called megakaryocytes 
in the bone marrow that express numerous cell surface receptors and adhesion molecules 
which assist interaction with white blood cells (leucocytes) and damaged endothelium 
(George, 2000). Some of the most important molecules expressed on platelets are integrins, 
formed by heterodimeric transmembrane polymorphic glycoproteins involved in cell signaling 
(Jenne et al., 2013). These glycoproteins include GPIa/IIa and GPIIb/IIIa which bind collagen 
and fibrinogen respectively as well as the GPIb-V-IX complex that mediates binding to von 
Willebrand factor, a critical factor in the maintenance of haemostasis by promoting platelet 
aggregation (Jenne, Urrutia and Kubes, 2013). Defects in GPIIIa and its associated glycoprotein 
IIb can lead to the rare autosomal recessive bleeding disorder, Glanzmann thrombasthenia 
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(Buitrago et al., 2015). The glycoproteins expressing HPA are encoded by six genes, detailed in 
Table 1.2.  
Glycoprotein Gene Chromosome  No. of exons Size of gene 
 
GPIIIa ITGB3 17 15 97,541bp 
GPIIb ITGA2B 17 30 24,324bp 
GP1a ITGA2 5 30 112,454bp 
GP1bα GP1BA 17 2 9734bp 
GP1bβ GP1BB 22 2 8232bp 
CD109 CD109 6 33 132,533bp 
Table 1.2 Genes that encode glycoproteins (GP) expressing human platelet antigens. Includes 
details of the respective chromosomes, number of exons present and total number of bases per 
gene. 
 
According to the ImmunoPolymorphism Database (IPD) there are currently 29 HPA systems 
described (Robinson et al., 2013). The majority of HPA  are localised on the IIIa subunit of the 
highly abundant glycoprotein, GPIIb/IIIa (Curtis and McFarland, 2014), as represented in Figure 
1.5. With the exception of HPA-14bw, which is defined by a 3 base pair (bp) deletion, each HPA 
system is characterised by a single nucleotide polymorphism (SNP) resulting in an amino acid 
substitution in the corresponding protein (Lucas, 2013), summarised in Table 1.3. HPA 
nomenclature is sequential, based on the order of discovery and the development of 
alloantibodies produced by exposed individuals lacking the respective antigen. The major allele 
of each system is designated ‘a’ and the minor, less frequent allele called ‘b’; for example HPA-
1a and HPA-1b with a frequency of 98% and 28% respectively in Caucasian populations (Curtis 
and McFarland, 2014). The ‘w’ assignation after the antigen name (e.g. HPA-14bw) indicates 
no reported alloantibody against the antithetical antigen (Metcalfe et al., 2003).  
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Figure 1.5. Cartoon representing the glycoprotein GPIIIa/GPIIb and respective HPA systems. 
The approximate location of 16 of the 29 human platelet antigen (HPA) systems expressed on 
glycoprotein GPIIIa/GPIIb. PSI=plexin/semaphoring/integrin; IEGF =Integrin epidermal growth 
factor domain; β-TD=β terminal domain. Adapted with permissions from Transfusion and 
Transplantation Science 2003, Page 192, Oxford University Press, and Practical Transfusion 
Medicine Third Edition, 2009, John Wiley and Sons, Inc. 
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System Gene Antigen Amino acid Nucleotide rs number 
(dbSNP) 
Exon  Chr position 
(GRCh37) 
HPA-1 ITGB3 HPA-1a Leu33 176T rs5918 3 45360730 
HPA-1 ITGB3 HPA-1b Leu33>Pro 176T>C rs5918 3 45360730 
HPA-1 ITGB3 HPA-1c Leu33>Val 175C>G None 3 45360729 
HPA-2 GP1BA HPA-2a Thr145 482C rs6065 2 4836381 
HPA-2 GP1BA HPA-2b Thr145>Met 482C>T rs6065 2 4836381 
HPA-3 ITGA2B HPA-3a Ile843 2621T rs5911 26 42453065 
HPA-3 ITGA2B HPA-3b Ser843 2621T>G rs5911 26 42453065 
HPA-4 ITGB3 HPA-4a Arg143 506G rs5917 4 45361953 
HPA-4 ITGB3 HPA-4b Arg143>Gln 506G>A rs5917 4 45361953 
HPA-5 ITGA2 HPA-5a Glu505 1600G rs1801106 13 52358757 
HPA-5 ITGA2 HPA-5b Glu505Lys 1600G>A rs1801106 13 52358757 
HPA-6w ITGB3 HPA-6bw Arg489>Gln 1544G>A rs13306487 10 45369788 
HPA-7w ITBG3 HPA-7bw Pro407>Ala 1297C>G rs121918448 10 45369541 
HPA-8w ITGB3 HPA-8bw Arg636>Cys 1984C>T rs151219882 12 45377914 
HPA-9w ITGA2B HPA-9bw Val837>Met 2602G>A rs74988902 26 42453084 
HPA-10w ITGB3 HPA-10bw Arg62>Gln 263G>A rs200358667 3 45360817 
HPA-11w ITGB3 HPA-11bw Arg633>His 1976G>A rs377302275 12 45377906 
HPA-12w GPIBB HPA-12bw Gly15>Glu 119G>A  rs375285857 2 19711485 
HPA-13w ITGA2 HPA-13bw Thr799>Met 2483C>T rs79932422 20 52369001 
HPA-14w ITGB3 HPA-14bw del_Lys del1909-
1911  
n/a 11 45376893-5 
HPA-15 CD109 HPA-15a Ser682 2108C rs10455097 19 74493432 
HPA-15 CD109 HPA-15b Tyr682 2108A rs10455097 19 74493432 
HPA-16w ITGB3 HPA-16bw Thr140>Ile 497C>T rs74708909 4 45361944 
HPA-17w ITGB3 HPA-17bw Thr195>Met 662C rs770992614 5 45363673 
HPA-18w ITGA2 HPA-18bw Gln716>His 2235G>T rs267606593 17 52366090 
HPA-19w ITGB3 HPA-19bw Lys137>Gln 487A>C rs80115510 4 45361934 
HPA-20w ITGA2B HPA-20bw Thr619>Met 1949C>T rs78299130  20 42455875 
HPA-21w ITGB3 HPA-21bw Glu628>Lys 1960G>A rs70940817 12 45377890 
HPA-22w ITGA2B HPA-22bw Lys164>Thr 584A>C rs142811900 5 42462694 
HPA-23w ITGB3 HPA-23bw Arg622>Trp 1942C>T rs139166528 12 45377872 
HPA-24w ITGA2B HPA-24bw Ser472>Asn 1508G>A rs281864910 15 42457790 
HPA-25w ITGA2 HPA-25bw Thr1087>Met 3347C>T rs771035051 28 52382870 
HPA-26w ITGB3 HPA-26bw Lys580>Asn 1818G None 11 45376801 
HPA-27w ITGA2B HPA-27bw Leu841>Met 2614C>A rs149468422 26 42453072 
HPA-28w ITGA2B HPA-28bw Val740>Leu 2311G>T rs368953599 23 42453713 
HPA-29w ITGB3 HPA-29bw Thr33>Met 98C>T None for 
CRCh37 
2 45351803 
Table 1.3 The human platelet antigen (HPA) system: Details of the genes encoding each HPA 
antigen alongside the respective amino acid and nucleotide variants. Also listed is the location 
of each HPA polymorphic position, including the respective exon, chromosomal position (Chr 
position) and rs number (where available from dbSNP), based on data from the human genome 
assembly GRCh37.  
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1.3 Clinical relevance of HLA and HPA in transfusion 
Individuals can become alloimmunised to HLA and or HPA following exposure during 
transfusion, pregnancy or transplantation (Brown and Navarrete, 2011), leading to the 
production of HLA and or HPA antibodies. HLA antibodies in the transfused blood product can 
result in the rare but potentially fatal transfusion associated acute lung injury (Brown and 
Navarrete, 2011). Post transfusion purpura is a rare transfusion-related complication due to 
alloimmunisation of the patient against platelet antigens leading to acute thrombocytopenia. 
In 2016, there were no reported cases of either transfusion associated acute lung injury or 
post transfusion purpura in the UK (Bolton-Maggs, 2017). More commonly, HLA or HPA 
alloantibodies present in the patient lead to complications such as immunological platelet 
refractoriness and foetal or neonatal alloimmune thrombocytopenia (Lucas, 2013). Binding of 
HLA or HPA alloantibodies to platelets can lead to a decrease of platelet function and survival 
(Pavenski et al., 2012). 
1.3.1 Immune platelet refractoriness (IPR) 
Platelet refractoriness is a failure to achieve a satisfactory response following random platelet 
transfusions (Stanworth et al., 2015) and is usually defined as an incremental rise in platelet 
count of 10 x 109/l or less, 1 hour or up to 24 hours post transfusion (Brown and Navarrete, 
2011). This can lead to a number of adverse outcomes, including increased risk of bleeding, 
decreased patient survival as well as longer hospital stays and associated in-patient costs 
(Stanworth et al., 2015). Platelet refractoriness can result from non-immune causes such as an 
enlarged spleen, bleeding or infection leading to decreased platelet survival, which need to be 
excluded prior to further investigation (Slichter et al., 2005).  
Immune platelet refractoriness (IPR) usually results from the presence of donor-specific HLA 
antibodies and can be successfully treated by the provision of HLA selected platelets (Brown 
and Navarrete, 2011). A small percentage of patients fail to respond to HLA selected products 
and will be subsequently examined for the presence of antibodies to HPA, which usually occur 
in conjunction with HLA antibodies although they can occur independently (Stanworth et al., 
2015). If necessary, patients can be provided with HLA and/or HPA compatible platelet support 
(Lucas, 2013), as summarised in Figure 1.6. In the financial year 2016/17, over 25,000 HLA and 
or HPA selected platelet units were issued for patients in England. 
  
23 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.6 Summary of the laboratory investigation for platelet refractoriness. Patients failing 
to respond to random platelet transfusions are referred for HLA antibody screening. Where HLA 
antibodies are detected, HLA selected platelets are provided. If HLA antibodies are absent, or 
the patient is failing to respond to HLA selected platelets, the patient will be screened for 
antibodies to HPA and provided with HLA and HPA selected platelets as appropriate. Adapted 
with permission from Brown and Navarrete, Clinical relevance of the HLA system in blood 
transfusion, John Wiley and Sons. © 2011 International Society of Blood Transfusion. 
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1.3.2 Foetal or neonatal alloimmune thrombocytopenia 
Foetal or neonatal alloimmune thrombocytopenia (FNAIT) is a severe bleeding disorder of the 
foetus and neonate resulting from the destruction of platelets by maternal alloantibodies 
directed against paternally inherited antigens expressed on foetal platelets (Bertrand and 
Kaplan, 2014).  Alloantibodies involved in FNAIT are predominantly against HPA (Lucas, 2013), 
although other antigens such as GPIV have been implicated (Xia et al., 2014). FNAIT occurs in 
approximately 1 in 1000 live births (Lucas, 2013) and can result in intracranial haemorrhage 
leading to death or disability, with severity linked to the number of pregnancies (Delbos et al., 
2016) and history of earlier siblings (Wienzek-Lischka et al., 2015; Wienzek-Lischka et al., 
2017). Diagnosis of FNAIT is vital to manage both the index case and any subsequent 
pregnancies and usually follows presentation in a neonate less than 48 hours old with 
unexplained bruising and petechiae (red or purple spots on the skin) but who otherwise 
appears healthy (Bertrand and Kaplan, 2014).  
Maternal antibodies to HPA-1a are the most common cause of FNAIT, with HPA-1a 
immunisation occurring in 1 in 365 pregnancies (Ghevaert et al., 2007). HPA antibody 
screening was performed on over 500 maternal samples for suspected FNAIT in the financial 
year 2016/17 in England. Overall, greater than 95% of serologically confirmed FNAIT cases 
result from maternal-foetal incompatibility for HPA-1, -2, -3, -5 and -15 with the remainder 
caused by low frequency HPA (Pavenski et al., 2013). Transfusion of the affected foetus or 
neonate with platelets that do not express the antigen implicated (see section 1.3.3.) results in 
prolonged platelet survival compared to transfusion with random platelets (Lucas, 2013).  
1.3.3 Transfusion support for patients with HLA and or HPA alloantibodies 
Patients refractory to platelets and those affected by FNAIT require HLA and/or HPA matched 
platelets in order to obtain a satisfactory incremental rise in their platelet count (Pavenski et 
al., 2012). Numerous strategies are available for the selection of platelets to support these 
patients including the use of cross-match negative donors, of antigen avoidance and of HLA 
and or HPA matched products (Kopko et al., 2015), summarised in Table 1.4. 
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Method of platelet 
selection 
Advantages 
 
Disadvantages 
Cross-match negative  Rapid availability 
 Does not require a pool of 
HLA & HPA typed donors 
 
 Risk of further 
sensitisation 
 Not suitable for long 
term platelet support 
 Challenging for highly 
sensitised patients 
Antigen avoidance  Increases number of 
potential donors 
 Risk of further 
sensitisation  
 Challenging for highly 
sensitised patients 
HLA/HPA matching  Suitable for long term 
platelet support 
 Reduced risk of 
sensitisation 
 Time consuming 
 Patient must be HLA & 
HPA typed 
 Requires large panel of 
HLA & HPA typed donors 
HLA epitope matching  Increases number of 
potential donors 
 Requires high resolution 
HLA typing of patient and 
donor 
Table 1.4 Summary of options for selecting compatible platelets. Advantages and 
disadvantages of the four approaches used for the selection of platelets for patients with 
immune platelet refractoriness resulting from antibodies to HLA 
 
1.3.3.1 Cross-match negative 
Cross-matching is performed by incubating donor platelets with recipient serum followed by 
detection of any bound antibody using labelled antiglobulins (Vassallo et al., 2014).  Cross-
matched platelets have the advantage of being readily available (Rioux-Masse et al., 2014) and 
are cheaper and easier to obtain than having a pool of HLA typed donors (Lee and Ayob, 2015). 
However, there are concerns that not matching for HLA risks further alloimmunisation as 
platelets are likely to be incompatible with the recipient’s own HLA type (Vassallo et al., 2014) 
and is therefore not suitable for patients requiring long term platelet support (Brown and 
Navarrete, 2011). Sixty percent of US blood centres surveyed provide a cross-matched platelet 
product, although many reported problems with availability of cross-matching assays (Kopko 
et al., 2015). 
1.3.3.2 Antigen avoidance 
Selecting platelets on the basis of avoiding specificities for which the recipient has antibodies 
has been shown to be as effective as HLA matching (Petz et al., 2000). This approach has the 
advantage of increasing the number of donors available for patients compared to HLA 
matching, although it may be problematic when supporting highly sensitised patients (Kopko 
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et al., 2015). As with crossmatching, there are risks associated with broadening a recipient’s 
antibody profile, as platelet transfusions may not be well matched (Petz et al., 2000). 
1.3.3.3 HLA matching 
Generally HLA selection is performed for HLA-A and –B only as the role of HLA-C in IPR remains 
uncertain (Brown and Navarrete, 2011). HLA antigen matched platelets are provided according 
to two match grades: an A grade when donor and recipient are HLA compatible or a B grade 
where one or more mismatched HLA antigens are present, denoted by B1, B2, B3 and B4 for 
one, two, three or four mismatches, respectively (Brown and Navarrete, 2011). Searching for 
the best donor using this strategy can be a protracted process, particularly for blood centres 
without large donor panels (Kopko et al., 2015) and also increases the cost of managing 
patients (Lee and Ayob, 2015). National Health Service Blood and Transplant (NHSBT) has a 
panel of over 11,000 donors who regularly give their own platelets via an automated cell 
separating process known as apheresis,  to facilitate HLA matching for patients with IPR 
(Brown and Navarrete, 2011). 
1.3.3.4 HLA epitope matching 
HLA epitope-based matching (HEM) is a more recent approach based on compatibility of 
antigenic determinants (Duquesnoy, 2011). HLA epitope matching employs a predictive 
computer algorithm, such as ‘HLAMatchmaker’, for donor and recipient compatibility, 
quantifying mismatched antigenic determinants, so called ‘eplets’ (Duquesnoy, 2008) or 
antibody-verified epitopes recorded in the International HLA Epitope Registry website 
(Duquesnoy et al., 2014). Eplets are described as polymorphic linear or discontinuous amino 
acid residues at critical antigen/antibody binding sites of the HLA molecule. The HEM algorithm 
is based on the assumption that patients will not make antibody against eplets or epitopes 
shared between the donor and their own HLA type or to inaccessible parts of the HLA molecule 
(Duquesnoy, 2008).  Previous studies have shown that the number of eplet mismatches is 
inversely proportional to the increase in platelet count following platelet transfusion (Brooks, 
MacPherson and Fung, 2008).  The sharing of epitopes between different alleles enables 
permissive mismatching and should only require donor panels of ‘reasonable size’ compared 
to using fully HLA matched platelets (Rubinstein, 2010). 
1.4 HLA and HPA genotyping – current state 
Patients refractory to platelets and those affected by FNAIT require HLA and/or HPA matched 
platelets in order to obtain a satisfactory incremental rise in their platelet count (Pavenski et 
al., 2012). Hence techniques that can accurately and cost effectively define the HLA and HPA 
type of both patients and donors are required. As platelets only express HLA class I antigens, 
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genotyping of platelet donors and recipients is limited to HLA-A and HLA-B in most 
laboratories, due to uncertainty about the clinical relevance of HLA-C in IPR (Brown and 
Navarrete, 2011). Molecular techniques for HLA typing are well established, having been in 
routine use for over 20 years (Erlich, 2012). Due to lack of highly specific antisera free from 
HLA antibodies and the advent of the polymerase chain reaction (PCR), serological HPA 
phenotyping has also been largely superseded by DNA-based genotyping (Curtis and 
McFarland, 2009).  
NHSBT laboratories receive both patient and donor samples from hospitals and blood 
collection centres. Different approaches are taken for HLA and HPA genotyping dependent on 
the number of samples, resolution required and clinical urgency, summarised in Table 1.5. 
 
Method Genotyping 
application 
Sample 
type 
HLA 
Resolution 
Turnaround 
time 
(hours) 
Cost 
per 
test 
Sample 
throughput 
PCR-SSP HLA  
HPA 
Patient Low 2-3 ££ Low 
PCR-SSOP HLA Donor & 
Patient 
Low/Medium 6-8 £ Low or high 
PCR-SBT HLA 
HPA 
Patient High 24-72 £££ Low 
Taqman 
 
HPA Donor n/a 48 £ High 
Table 1.5 Molecular techniques used for HLA and HPA genotyping. The genetic system and 
sample type tested by each Polymerase chain reaction (PCR) based method, alongside the 
typical time taken to obtain a result. Cost per test is indicated using a comparative approach, 
with £ = inexpensive, ££ = medium cost and £££ = most expensive. The throughput of samples 
for each approach is designated high or low, with high throughput determined as processing in 
batches of up to 96 samples and low throughput as processing single or small numbers of 
samples. PCR-SSP = PCR using sequence specific primers; PCR-SSOP = PCR using sequence 
specific oligonucleotide probes; PCR-SBT = PCR by sequencing based typing 
 
 
1.4.1 Patient genotyping 
Patients are referred to NHSBT for the investigation of IPR and FNAIT which can be urgent in 
nature, for example when the patient is bleeding (West, 2016). In addition, samples from 
individuals requiring long-term platelet support are sent for HLA and HPA genotyping to 
ensure suitably matched products are provided, thereby avoiding the risk of sensitisation 
(Murphy et al., 1986). In England, approximately 900 patients are HLA typed each year during 
investigation for platelet refractoriness. 
28 
 
1.4.1.1 Patient HLA typing 
Patients with IPR are HLA typed by PCR based methods utilising sequence specific primers 
(PCR-SSP) or sequence specific oligonucleotide probes (PCR-SSOP) (Brown and Navarrete, 
2011). PCR-SSP uses gel electrophoresis to determine the presence or absence of amplicons 
for each HLA allele group tested. In contrast, PCR-SSOP requires the hybridisation of HLA locus 
specific amplicons with sequence specific oligonucleotide probes attached to a solid support 
followed by fluorescence based detection to determine the HLA type. These methods have a 
quick turnaround time and are suitable for small sample numbers. They produce low to 
medium resolution HLA types by focusing on polymorphisms within exons 2 and 3 of the HLA 
class I genes, where the majority of allelic diversity is located (Erlich, 2012). 
1.4.1.2 Patient HPA typing 
HPA typing, alongside screening for HPA antibodies, is performed only if IPR patients 
subsequently fail to increment with HLA matched platelets; it is uncommon for HPA antibodies 
to cause IPR independently (Brown and Navarrete, 2011). PCR-SSP is a commonly used method 
for HPA genotyping these patients, being both fast and reliable (Nogués, 2011).  
Suspected FNAIT cases are investigated by determining maternal and paternal disparity for the 
more frequent HPA genotypes, also using methods such as PCR-SSP (Arinsburg et al., 2012), 
although at NHSBT PCR sequencing based typing (PCR-SBT) of HPA-1, -2, -3, -4, -5, -6, -9 and -
15 is routinely employed for FNAIT investigations (West, 2016). Further analysis is required 
should no difference be detected for the common variants. This may involve extensive study, 
sequencing entire genes which can be a protracted process when searching the large HPA 
genes (Poles et al., 2013; Stafford et al., 2008). For example, the gene encoding GPIIIa, on 
which the majority of HPA are expressed, consists of 15 exons and is almost 100,000 bases 
long (see Table 1.2).  
1.4.2 Donor genotyping 
Providing suitable platelet transfusions for patients adversely affected by the presence of 
alloantibodies requires a large panel of HLA- and HPA-defined platelet donors (Pavenski et al., 
2012). Approximately 5000 apheresis donors per annum are currently recruited by NHSBT for 
this purpose, with each donor typed for both HLA and HPA on two separate occasions for 
quality reasons. This level of commitment to donor enrolment requires high-throughput 
genotyping techniques (Lucas, 2013). 
1.4.2.1 Donor HLA typing 
HLA class I typing of platelet donors is currently performed using reverse PCR-SSOP in a 96 well 
plate format, making it suitable for automation for high throughput typing. In separate PCR 
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reactions, amplification of exons 2 and 3 of the HLA-A, -B and-C genes is followed by 
hybridisation with locus specific, fluorescently tagged microspheres that are coated with up to 
100 probes, targeting sequence motifs across the respective exons. Where complementary 
sequences are present, bound PCR amplicons are detected by utilising xMAP® technology 
followed by analysis of probe patterns using interpretation software (Dalva and Beksac, 2007). 
PCR-SSOP typically produces a low to medium resolution HLA type (Nunes et al., 2011) which is 
sufficient for the selection of platelets for patients with IPR, based on their HLA type and 
antibody profile (Brown and Navarrete, 2011). 
1.4.2.2 Donor HPA typing 
To date, only genotypes of the HPA-1, -2, -3, -4, -5 and -15 systems are determined for 
apheresis platelet donors, selected originally due to their frequency and clinical relevance 
(Lucas, 2013). The Taqman™ assay is utilised for this high-throughput HPA typing due to its 
capacity for automated readout (Lucas, 2013). Briefly, for each HPA tested, PCR amplification 
using primers flanking the SNP of interest is performed in the presence of two labeled probes, 
one corresponding with the ‘a’ allele and the other specific for the ‘b’ allele. Displacement of 
an annealed probe by Taq polymerase during primer extension generates a fluorescent signal 
that can be measured. Using two different dyes for the two allele specific probes enables 
distinction between the alleles by their emission spectra (Nunes et al., 2011).  
 
1.5 Requirement for the improvement of HLA and HPA genotyping 
1.5.1 Increasing the resolution of HLA genotyping 
A prospective, randomised non-inferiority trial is currently underway within NHSBT to compare 
the efficacy of HLA epitope-matched (HEM) platelets for transfusion with standard HLA 
selected platelets for alloimmunised patients who require regular platelet transfusions but for 
whom a fully HLA matched donor is not available (ISCTRN23996532). The necessity for utilising 
HEM may increase as a result in a reduction in the availability of single platelet units. NHSBT 
recently announced a ‘Platelet Supply’ project, initiated following recommendations by The 
Advisory Committee on the Safety of Blood, Tissues and Organs to remove the current 
requirement of collecting 80% of platelets by apheresis. As part of a drive for efficiency savings 
in the blood supply chain, the plan was to reduce apheresis to 60% of existing collection levels 
by the end of 2015/16, with the further potential to reduce to as low as 40% thereafter 
(Ronaldson and Ashford, 2014). Whilst this strategy will align the percentage of platelet 
concentrates collected by apheresis in England with other European countries (Berger et al., 
2016), it will limit available units for patients with HLA and or HPA antibodies. Using HEM 
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should increase the number of platelet donors suitable for these patients when fully HLA 
matched units are unavailable (Pai et al., 2010).  
If HEM becomes routine practice, high resolution (i.e. allele level) HLA typing of platelet donors 
may be necessary because the matching algorithm requires information on amino acid 
sequence (Duquesnoy, 2008). However, implementation of this new approach will require a 
change to the current method used, described in 1.4.2.1, due to inadequate resolution of HLA 
class I typing. Pai et al., 2010 reported using HEM for the selection of platelet donors based on 
epitopes predicted from low resolution HLA types produced by PCR-SSOP (Pai et al., 2010). 
However, accurate comparison of donor and patient intra- and inter-locus HLA is likely to 
require high resolution or allele level typing (Duquesnoy, 2011). Conventionally, high 
resolution HLA typing is achieved using Sanger sequencing but due to the increasing number of 
characterised HLA alleles this method often produces ambiguous results due to limited  
sequence data generated for regions of the HLA genes and lack of phase within and between 
exons for heterozygous samples (Erlich, 2015). In addition, costs and logistical constraints 
make sequencing based typing (SBT) unsuitable for high throughput HLA genotyping. 
 
1.5.2 Expansion of HPA genotyping 
There is increasing evidence that HPA genotypes not routinely defined in patients or apheresis 
platelet donors are more clinically significant than originally thought, with a growing number 
of publications reporting maternal alloimmunisation against ‘rare’ platelet antigens (Peterson 
et al., 2012; Jallu et al., 2013; Bertrand et al., 2013a; Lucas et al., 2016; Sullivan et al., 2015). In 
one study, 6.6% of fathers of infants from 244 suspected cases of FNAIT were found to have 
low frequency HPA following sequencing of genes encoding glycoproteins GPIIIa/IIb (Peterson 
et al., 2014). This percentage of FNAIT due to rare HPA antibodies was considerably greater 
than the 0.7% identified in 1054 cases, reported several years earlier (Ghevaert et al., 2009). It 
has been suggested in the past (Ouwehand, 2005) and again more recently (Santoso and 
Tsuno, 2015) that laboratory investigations should not be limited to the more common HPA 
systems.  
Extending the existing PCR-SSP and Taqman™ techniques to include all 29 HPA systems would 
prove problematic as some HPA SNPs are adjacent to other polymorphic positions which can 
result in mistyping (Kengkate et al., 2015). Therefore, expansion of the current HPA repertoire 
will require an alternative approach, capable of defining all known HPA SNPs alongside 
scalability for high-throughput. 
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1.5.3 HPA whole gene sequencing 
Occasionally, an investigation for a rare or possibly unique HPA allele is required in cases of 
suspected FNAIT, where routine HPA typing and antibody screening proves uninformative 
(Lucas, 2013). As indicated in section 1.4.1, this can necessitate the sequencing of one or more 
HPA genes, which is complex and time consuming due to their length. Investigation of 
suspected FNAIT cases should be performed with urgency (Lucas, 2013), so reducing the time 
taken to search for a candidate mutation would be advantageous. It is possible to develop 
Sanger sequencing to determine the majority of, if not all, known HPA alleles as a first line test 
(Hong et al., 2017), but this requires significant development and validation of multiple primer 
sets due to the location of each HPA system (Lane et al., 2016). In addition, without 
sequencing each entire gene, Sanger sequencing may also fail to identify and or define novel 
HPA mutations without further development (Finning et al., 2016).  
1.6 Next Generation Sequencing  
Next Generation Sequencing (NGS) is a recent innovation in sequencing technology with the 
ability to produce large amounts of data relatively quickly and cheaply, capable of generating a 
high proportion of an individual’s genetic sequence in a single experiment (Metzker, 2010). 
When combined with novel DNA bar-coding technology, which consists of sample specific 
combinations of short oligonucleotides, NGS can be used to target specific regions of the 
genome from many different individual samples in one pool (Shiina et al., 2012).  
The term ‘next generation sequencing’ refers to a range of sequencing technologies developed 
during the past decade rather than a single technique (Muzzey, Evans and Lieber, 2015) and 
typically consists of (i) template preparation (ii) sequencing and imaging followed by (iii) data 
analysis, with each NGS technology taking a distinct approach (Metzker, 2010). DNA 
sequencing by NGS requires prepared templates of high molecular weight double stranded 
DNA that have been fragmented using methods such as sonication, nebulisation or enzymatic 
fragmentation (Knierim et al., 2011). Unique sample identifiers, so called DNA barcodes, along 
with platform-specific adapters are then ligated to the fragments generated, which facilitates 
immobilisation of each fragment to a solid surface or support and downstream sequencing 
(Figure 1.7).  
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Figure 1.7 DNA library preparation for the Illumina MiSeq. Fragmentation of double stranded 
DNA is followed by the ligation of partial adapters that serve as primer binding sites. A limited 
cycle PCR then adds sample specific indices incorporating P5 and P7 ends to each fragment, 
along with the MiSeq sequencing primer sequences, to allow clonal amplification and paired 
end sequencing on a MiSeq flow cell. 
 
The majority of NGS approaches then require in-situ clonal amplificiation of each prepared 
DNA template in order to provide signal enhancement prior to sequencing (Metzker, 2010). 
For the Illumina MiSeq, clonal amplification of each bound fragment occurs on a glass slide 
which allows positional separation of the clusters that form (Figure 1.8) that remain constant 
during the sequencing reaction (Muzzey, Evans and Lieber, 2015).  
 
 
 
Figure 1.8 Cluster formation on a glass slide following clonal amplfication. Each fragment 
bound to the MiSeq flow cell forms discrete clusters in fixed positions following clonal 
amplification. This facilitates signal amplificiation during the subsequent sequencing reaction. 
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Sequencing of the amplified templates consists of sequencing by synthesis (akin to Sanger 
sequencing), sequencing by ligation or using chemistries such as ion-semiconductor 
sequencing, depending on the platform employed (Muzzey, Evans and Lieber, 2015). This 
results in the production of multiple overlapping short sequences that can be subsequently 
assembled and analysed (Zhang et al., 2011), an example of which is shown in Figure 1.9, 
hence the alternative title ‘massively parallel sequencing’ sometimes cited (Yang et al., 2017). 
Data analysis generally consists of either variant calling following the alignment of sequencing 
reads to a reference genome and/or utlising denovo genome assembly algorithms (Sims et al., 
2014).  
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Figure 1.9 Alignment and analysis of sequencing reads. (A) shows the overlapping assembly of 
sequencing reads spanning an entire HLA gene; (B) shows more detail of the overlapping 
assembly for exon 2; (C) shows the individual base calls for each overlapping sequence. The 
pink and yellow colours of each fragment in the images represent fragments from two different 
sequences in a heterozygous sample. 
 
A 
B 
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1.6.1 HLA genotyping by NGS 
Over the past five years, a number of approaches to HLA typing by NGS have been reported, 
ranging from the imputation of HLA types from genomic sequence data to targeted HLA 
sequencing using bench top NGS platforms, each with their respective advantages and 
disadvantages summarised in Table 1.6. 
 
NGS approach Advantages Disadvantages 
WGS/WES  Provides MHC haplotype data 
 Use of generic WGS/WES 
protocol 
 
 Requires complex imputation 
algorithms 
 Slow analysis 
 Up to 20% error rate 
 Not suitable for high throughput 
Targeted exon   Fragmentation not required 
 Fast preparation protocol 
 Suitable for high throughput 
 Cost effective 
 Results in ambiguous HLA types  
 Susceptible to PCR artefacts 
 Risk of allele imbalance or 
dropout 
 
Whole gene   Unambiguous 3rd or 4th field 
level typing 
 Suitable for high throughput 
 
 
 Protracted library preparation 
 Risk of allele imbalance or 
dropout 
 
Table 1.6 Advantages and disadvantages of NGS approaches reported for HLA typing. 
Reported NGS based approaches for HLA typing have included whole genome sequencing 
(WGS), whole exome sequencing (WES), targeted HLA exon sequencing or whole HLA gene 
sequencing.  
 
1.6.1.1 HLA imputation from whole genome or exome sequence data 
Large scale whole genome sequencing (WGS) or whole exome sequencing (WES) endeavours 
are not primarily intended for individual genotyping but rather for population genetic studies 
(Major et al., 2013). However, is it possible for classical HLA types to be imputed from such 
data by using statistical prediction algorithms (Bauer et al., 2016). Earlier reports indicated 
unacceptably high prediction errors of up to 20% due to insufficient read depth (Major et al., 
2013) or lack of reference data from ethnically diverse populations (Dilthey et al., 2013). Some 
mistyping also resulted from the homology of HLA-A, -B and -C genes with pseudogenes, 
leading to mis-alignment of sequence fragments (Major et al., 2013). More recently, Dilthey et 
al. described use of ‘HLA*PRG’, a computer algorithm that infers HLA types from WGS data. 
This program considers both genes and pseudogenes and has a reported accuracy of 99.4%. 
However, the requirement of high computational power taking 30-250 central processing unit 
hours per sample (Dilthey et al., 2016) is not acceptable for routine clinical application.  
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1.6.1.2 Targeted HLA sequencing 
For the majority of HLA typing laboratories, facilities for WGS or WES are unavailable. A more 
practical approach to HLA typing by NGS is the use of targeted sequencing. This requires the 
isolation of all or part of the HLA gene, typically by PCR amplification, although targeted 
enrichment capture assays have also been reported (Wittig et al., 2015). Numerous 
approaches have been described for PCR-based HLA typing by NGS, from targeting one or 
more exon to sequencing the entire gene (Figure 1.10) 
 
 
 
 
 
 
Figure 1.10 A typical primer map for the amplification of HLA class I genes. PCR primers can 
be designed to amplify exons individually, as represented by the red, orange and green arrows, 
or can target the entire HLA gene, indicated with the purple arrows. 
 
One of the benefits of using exon specific amplification is that template fragmentation and or 
ligation steps are not usually required due to the size of the amplicon and inclusion of 
multiplex identifiers during amplification (De Santis et al., 2013). However, the amplification 
strategy employed for exon only sequencing will determine the level of HLA typing resolution 
achieved. Lange et al. reported a cost effective, high throughput exon-based NGS method 
using micro fluidics for sample preparation. However, because only exons 2 and 3 of the HLA 
genes were sequenced, the results obtained were at a resolution equating to that obtained by 
Sanger sequencing (Lange et al., 2014). Similarly, sequencing just exons 2, 3 and 4 of the HLA 
class I genes produces ambiguous results in over 85% of samples (Trachtenberg and Holcomb, 
2013). It is possible to increase the HLA typing resolution to the ‘G’ group level by targeting 
more exons (Cereb et al., 2015), but primer design will be limited by polymorphisms within 
introns of the HLA genes (De Santis et al., 2013). Exon specific amplicon approaches to HLA 
typing by NGS are also susceptible to sequencing artefacts such as primer dimers and PCR 
mediated recombination (Holcomb et al., 2014; Schofl et al., 2017). 
Restricting the sequencing of HLA genes to exon regions will inevitably result in ambiguity due 
to lack of phase. However, using whole HLA gene amplification allows phasing across the 
entire region and therefore reduces the likelihood of any HLA ambiguity. Primers are located in 
5’UTR Exon1 Exon2 Exon3 Exon4 Exon5 Exon6 Exon78 3’UTR 
Targeted exon 
amplification 
Whole gene amplification 
HLA class I gene 
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less polymorphic positions, with exons and introns amplified in a single fragment (Wang et al., 
2012). Early reports of HLA typing by NGS based on whole gene sequencing suggested this 
approach may have a limited throughput, with only a few samples included in a sequencing 
run (Shiina et al., 2012; Hosomichi et al., 2013). This was in part due to the platform employed 
but also because each amplicon had separate DNA barcode identifiers. Although this made 
data analysis more straightforward by reducing the risk of misalignment of fragments to 
homologous regions of other class I genes, it limited the number of samples that could be 
sequenced simultaneously.  More recently others have used identical DNA barcodes to label 
multiple amplicons from the same sample, enabling the pooling of amplicons and 
demonstrating it is possible to increase the throughput to 96 samples or more (Ehrenberg et 
al., 2014; Nelson et al., 2015).  
1.6.1.3 Sequencing platforms 
HLA typing results obtained by NGS are also influenced by the platform employed. One of the 
first NGS-based methods for HLA typing was developed on the Roche 454 FLX (Lind et al., 
2010). This platform had the advantage of generating long sequencing reads, which is 
preferable for HLA typing to ensure sequence reads span each exon, and was the first 
commercial NGS system for HLA typing (Gabriel et al., 2014). However, the Roche 454 system 
produced far fewer reads per run than its competitors, making it much more expensive, and 
has been phased out since 2016 (Erlich, 2015). The Ion Torrent (Thermo Fisher Scientific) 
produces shorter reads to a maximum of 400bp (Erlich, 2015) and also has reported 
sequencing errors from insertions or deletions (indels), particularly at homopolymer sites.  
However, the Ion Torrent has the advantage of a short sequencing run time of approximately 2 
hours and has potential for scalability, with a range of different chips sizes, making it a more 
economical option for some laboratories (Gabriel et al., 2014). The Illumina MiSeq has the 
advantage of using pair end sequencing, which facilitates interpretation of HLA types due to 
improved haplotype phasing (Carapito, Radosavljevic and Bahram, 2016). It is also the platform 
of choice for the majority of commercial HLA typing kits currently available.  
Instruments such as the PacBio RS11 (Pacific Biosciences) and the MinION (Oxford Nanopore) 
are more recent innovations. Both have the capability of producing reads of up to 40kb and 
50kb, respectively, potentially allowing sequencing of entire MHC haplotypes in phase. 
However, errors rates are reportedly much higher than the more established platforms 
(Carapito, Radosavljevic and Bahram, 2016). Approaches to HLA typing using the PacBio system 
have been published by a number of groups (Cereb et al., 2015; Mayor et al., 2015), but due to 
the large size of the instrument and high procurement costs this platform is unlikely to be 
implemented by many routine laboratories. In contrast, the MinION (Oxford Nanopore) is a 
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small, portable device that uses very different technology to other NGS sequencers and, whilst 
still in the development phase for HLA genotyping, has the potential to provide sequencing 
data cheaply and quickly (Carapito, Radosavljevic and Bahram, 2016). 
1.6.2 HPA genotyping by NGS 
With its ability to scrutinise large portions of the genome, NGS has the capacity to 
simultaneously sequence the six genes encoding HPA glycoproteins within a few days, rather 
than the weeks that may be required for investigation by conventional methods. Lane et al. 
described the prediction of red blood cell and platelet antigens from an individual’s genome 
obtained by using paired-end WGS on the Illumina HiSeq platform. However, whilst WGS did 
provide sequence data for each of the six genes coding for HPA, the authors acknowledged this 
approach was impractical and unaffordable for most laboratories and advocated using a 
targeted NGS panel as an alternative method for platelet genotyping (Lane et al., 2016). 
Targeted NGS methods have been reported for HPA genotyping but approaches published to 
date have focused on the more common HPA systems included in a genotyping panel 
alongside blood group antigens (Wienzek-Lischka et al., 2015; Orzinska et al., 2017).  
1.7 Aims and objectives 
This study set out to exploit the advantages offered by the novel NGS technology with the aim 
of enhancing the HLA and HPA definition of both platelet donors and recipients. The objectives 
by which this would be achieved were: 
 Comparison of a commercial HLA amplification protocol (Illumina TruSight™ HLA) with 
an in-house whole gene approach for PCR template generation 
 Establishing a high throughput NGS based method for HLA-A, -B and -C genotyping 
platelet donors and assess its potential impact on the selection of platelet donors 
using HLA epitope-matching (HEM) 
 Designing and developing a multiplex, high throughput NGS based method for HPA 
genotyping  
 Designing and developing an NGS based method to sequence the genes coding for 
glycoproteins that express HPA.  
1.8 Hypothesis 
The use of NGS for HLA and HPA genotyping will enhance the provision of suitable platelet 
transfusions for patients with HLA and/or HPA alloreactive antibodies.  
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2. Methods and Materials 
2.1 Samples 
2.1.1 Donor samples for HLA genotyping 
Informed consent was obtained from each donor in accordance with organisational protocols 
(see Appendix). EDTA blood samples were collected from random apheresis platelet donors at 
NHSBT clinics throughout England. All donors used in this study had been previously typed for 
HLA-A, -B and –C at intermediate resolution using Luminex-based sequence specific 
oligonucleotide technology (LABType®, One Lambda). 
2.1.2 Control DNA for HPA genotyping 
External quality assessment (EQA) DNA samples were selected for their range of genotypes 
from NHSBT DNA archives. EQA samples were originally distributed by the National Institute 
for Biological Standards and Controls, with HPA genotypes of each sample determined by over 
40 international laboratories. Additional anonymised control DNA samples were provided by 
the Australian Red Cross Blood Service. 
2.1.3 Patient DNA for HPA genotyping 
DNA samples previously genotyped for HPA were retrieved from NHSBT DNA archives. They 
were originally obtained from patients or family members following referral to NHSBT for 
investigation of FNAIT or thrombasthenia. Informed consent was obtained by the hospital 
clinical team (see Appendix). 
2.2 DNA extraction of donor samples 
DNA was extracted from 7ml EDTA blood samples and using a DNA mini kit (Qiagen) on the 
QIAsymphony®SP automated platform. Following extraction from a 200µl aliquot of EDTA 
blood, each sample was dissolved in 200µl of elution buffer and dispensed into 96-well plates, 
with 90 samples contained within each plate. Following DNA extraction, sample identifiers 
were automatically added to an XML rack file by the QIAsymphony software v4.0.1. A local 
Microsoft (MS) Access program was then used to extract the sample IDs and respective plate 
positions from the rack file to generate an MS Excel ‘plate map’ used to facilitate downstream 
sample tracking.  
2.3 DNA purification 
Purification of DNA was performed on samples prior to HLA genotyping only and was 
performed either manually or utilising a Biomek FXP laboratory automated workstation 
(Beckman Coulter) prior to quantification. Briefly, 50µl each of DNA and AMPure® XP beads 
(Beckman Coulter) were incubated together for 5 minutes followed by separation from 
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solution using a magnet and the supernatant containing impurities discarded. This was 
followed by two wash steps in 80% ethanol, freshly made from 100% Ethanol (Sigma-Aldrich). 
Purified DNA was finally eluted in 30µl of Ambion® nuclease free water (NFW) purchased from 
Thermo Fisher Scientific.  Any wells that did not contain purified DNA were filled with NFW and 
served as negatives controls. 
2.4 DNA quantification 
The concentration of double stranded DNA (dsDNA) present in each sample was determined 
using one of two fluorescence based assays. This approach for DNA quantification was selected 
over conventional UV absorbance because it is highly selective for dsDNA and therefore 
provided a more accurate assessment of the target concentration required for NGS. In general, 
samples in a 96 well plate format were quantified with the Quant-iT™ kit and concentration of 
DNA contained in tubes was measured using the Qubit®. 
2.4.1 Quant-iT™ Assay kit, Broad Range (Invitrogen) 
A standard curve was generated in accordance with the Quant-iT™ protocol, using 10µl of each 
DNA standard provided (range 0-100ng/µl) diluted in 200µl of working solution (1:200 dilution 
of Quant-iT dye in buffer). Test samples were prepared by adding 4µl of DNA to 206µl of 
Quant-IT BR working solution into the respective well of a black 96-well assay plate. Both 
Standards and test samples were then measured on a FiltermaxF3 plate reader (Molecular 
Devices) at 485mn and analysed using associated Softmax Pro software v6.3.  
2.4.2 Qubit® dsDNA BR assay (Life Technologies) 
Between 2 and 5µl of each DNA sample (dependant on material available) was made up to 
200µl with Qubit® working solution (1:200 dilution of Qubit® dye in buffer) in thin-walled 
0.5ml tubes (Qubit® Assay tubes). DNA sample concentrations were determined using a Qubit® 
2.0 Fluorometer in accordance with the Qubit® dsDNA BR assay protocol. 
2.5 DNA normalisation 
DNA was normalised to the desired concentration either manually or using an automated 
protocol. Manual normalisation was used to prepare DNA samples for the HPA genotyping 
protocol, whereas DNA for HLA sequencing was normalised using the Biomek workstation. 
2.5.1Manual normalisation  
DNA was diluted to the required concentration with 10mM Tris buffer (Buffer EB, Qiagen). 
2.5.2 Automated normalisation 
Values for DNA concentration obtained from the FiltermaxF3 in step 2.4.1 were imported into 
a spreadsheet with embedded macros which calculated the volumes of sample and NFW 
required for dilution of DNA to the desired concentration. The macro produced a Tag Image 
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File Format (TFF) file which was utilised by the Biomek® FXP liquid handling workstation 
(Beckman Coulter) to normalise each sample. Where the concentration was below the 
required input values, DNA was transferred neat.  
2.6 HLA genotyping by Next Generation Sequencing 
2.6.1 PCR amplification of HLA class I genes  
PCR amplification of the HLA-A, -B and –C genes was performed on each sample using either a 
modified TruSight™ HLA Sequencing panel approach (Illumina) or with an in-house protocol. 
The primer binding sites for the TruSight HLA sequencing panel were not disclosed by Illumina, 
but the in-house protocol used primers designed to amplify the entire HLA gene (Figure 2.1). 
 
 
 
Figure 2.1 Location map of in-house PCR primers for HLA class I amplification. Previously 
reported locus specific primers (Shiina et al., 2012) were located in conserved regions flanking 
each target (represented by the purple arrows) to amplify all exons, introns and un-translated 
regions (UTR) of each HLA gene. 
 
2.6.1.1 TruSight™ HLA Sequencing panel 
DNA was amplified using a modified version of the TruSight™ HLA PCR amplification protocol 
for HLA-A, B and –C , using a reduced reaction volume of 10µl compared to the prescribed 
50µl. PCR reactions for each HLA locus were performed in 96-well PCR plates (4titude®) and 
consisted of 5µl of HLA PCR mix, 0.4µl of MasterAmp Extra-Long DNA polymerase, 1µl HLA 
locus specific primer, 2.6µl of NFW and 1µl of DNA at 10ng/µl. Amplification was performed in 
a 9700 thermal cycler (Perkin Elmer) with a ramp rate set to 9600 using the following program: 
94°C for 3 minutes; 35 cycles of 94°C for 30 seconds, 60°C for 2 minutes and 68°C for 15 
minutes; 68°C for 10 minutes; hold at 10°C. 
2.6.1.2 In-house PCR protocol 
Whole gene amplification of HLA-A, -B and -C in 96-well PCR plates (4titude®) was performed 
using previously described primers (Shiina et al., 2012) but with a modified protocol. Each 10µl 
PCR reaction for HLA-A and –B consisted of 50ng purified DNA, 0.5U PrimeSTAR GXL DNA 
polymerase (TaKaRa Bio Inc), 1X PrimerSTAR GXL buffer, 200µM of each dNTP and 4pmol of 
each respective HLA locus specific primer. PCR reactions for HLA-C were as for HLA-A and –B 
but with the addition of 5% DMSO (Sigma-Aldrich). PCR amplification was performed using a 
5’UTR Exon1 Exon2 Exon3 Exon4 Exon5 Exon6 Exon7/
8 
3’UTR 
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C1000 thermal cycler (Bio-Rad). HLA-A and –B conditions consisted of a 2 minute denaturation 
at 94°C followed by 30 cycles of 98°C for 10 seconds, 62°C for 20 seconds and 68°C for 5 
minutes. HLA-C amplification conditions were 94°C at 2 minutes followed by 30 cycles of 98°C 
for 10 seconds, 56°C for 20 seconds and 68°C for 5 minutes. All amplicons were held at 4°C 
until removed from the thermal cycler. 
2.6.2 PCR amplicon assessment 
Prior to pooling, PCR products from the first and last row of each plate were either assessed 
using agarose gel electrophoresis or quantified using a fluorescence-based assay to determine 
if the amplification was successful. In general, gel electrophoresis was used for amplicon 
assessment prior to library preparation with TruSightHLA kits whereas quantification was 
performed if the DNA libraries were prepared using the GenDx protocol. Where either method 
indicated failure of amplification, the PCR for the respective locus was repeated, as described 
in 2.6.1. 
2.6.2.1 Agarose gel electrophoresis 
For each sample evaluated, 2µl of PCR product was run on a 1% agarose gel (w/v) in 0.5X TBE 
buffer (Thermo Fisher Scientific) stained with SafeView nucleic acid stain (NBS Biologicals Ltd). 
Gels were visualised under UV light using the Alpha Imager system and Alpha View software 
v1.3.0.7 to determine the presence or absence of an amplicon. 
2.6.2.2 Quantification of PCR amplicons 
PCR amplicons were quantified with the Quant-iT™ BR Assay (Invitrogen) according to the 
protocol described in 2.4.1. 
2.6.3 Amplicon pooling 
Seven microlitres of amplicon for HLA-A, B and -C from respective PCR plates for each sample 
were added to a clean PCR plate either manually or using a Biomek® NXP multichannel liquid 
handling workstation (Beckman Coulter) so that the resulting pooled plate containing 21µl of 
pooled amplicon in each well of a 96 well plate (Figure 2.2) 
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Figure 2.2 Summary of the PCR amplification and pooling workflow. Once purified and 
normalised, each genomic DNA (gDNA) sample was amplified for HLA-A, -B and –C. Following 
successful amplification, 7µl of each amplicon was pooled into the respective wells of a single 
96 well plate. 
 
2.6.4 DNA library preparation 
Two commercial kits were used to prepare pooled amplicon libraries for sequencing on the 
MiSeq. Both approaches employed enzymatic fragmentation followed by a limited PCR 
amplification before combining each prepared sample to form a pooled amplicon library as 
outlined in Figure 2.3.  
 
 
Figure 2.3 Summary of workflow for DNA library preparation. Enzymatic fragmentation of 
prepared amplicons was followed by adapter ligation. A limited PCR then attached unique 
sample multiplex identifiers and Miseq compatible sequences. Finally each prepared library was 
pooled into a single tube prior to downstream sequencing. A maximum of 180 samples were 
pooled for a single MiSeq run, consisting of libraries from 2 plates with 90 samples per plate. 
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Pooled DNA amplicons were prepared for sequencing by following either a modified version of 
the TruSight™ HLA preparation protocol (Illumina) or using NGSgo® library preparation kits 
(GenDx, Utrecht). The TruSight HLA protocol was initially employed as part of beta testing for 
Illumina, and provided free of charge. During the early stages of this study it was also the only 
library preparation protocol that had more than 96 indexes available.  NGSgo® was selected for 
library preparation following the release of a 384 index set by GenDx. The key differences 
between each protocol are shown in Table 2.1 but each approach resulted in DNA fragments 
prepared from whole HLA gene amplicons labelled with sample-specific combinations of 
indices linked to MiSeq specific adapters in preparation for downstream sequencing. 
 
Process step  TruSight HLA (Illumina) NGSgo® (GenDx) 
Quantification of amplicons N/A Yes 
Purification of amplicons Bead based N/A 
Normalisation of amplicons Bead based Biomek workstation 
Tagmentation Yes Yes 
Index PCR Yes Yes 
Pooling Yes Yes 
Table 2.1 Comparison of commercial kits employed for DNA library preparation. Similarities 
and differences are shown for the key steps of each protocol prescribed by Illumina and GenDx 
for their respective DNA library preparation kits, TruSightHLA™ and NGSgo®, respectively. The 
process starts with pooled whole HLA gene amplicons for each sample and results in a pool of 
up to 90 samples prepared for sequencing HLA-A, -B and –C on the MiSeq NGS platform. 
 
2.6.3.1 TruSight™ HLA sequencing panel library preparation 
Pooled amplicons were treated to remove impurities and small DNA fragments by following 
the Trusight™ HLA PCR clean up protocol but adding only 21µl of sample purification beads 
(SPB) rather than the 45µl indicated to maintain the 1:1 bead to amplicon ratio. Thereafter, 
DNA libraries were prepared according to the TruSight™ HLA sequencing panel library 
preparation guide, version August 2014.  
Briefly, normalisation was achieved using a bead based method with subsequent tagging and 
fragmentation, so called ‘tagmentation’, performed whilst the amplicons were still attached to 
the normalisation beads. Eluted fragments were purified using 0.5X SPB to remove excess 
reagents and smaller fragments. This was followed by PCR amplification of the tagmented 
DNA, utilising Nextera XT Index sets A, B or C (Illumina). Following a final clean up with 0.5X 
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SPB, 5µl from each well were pooled into a single 1.5ml tube for each plate processed to form 
a pooled amplicon library. 
2.6.3.2 NGSgo® Library preparation 
Pooled amplicons were quantified using the Quant-iT™ BR Assay, as described in 2.6.2.1. 
Values obtained from the FiltermaxF3 were then imported into a spreadsheet with embedded 
macros which calculated the volumes of sample and NFW required for normalisation. The 
macro produced TFF which was utilised by a Biomek NXP Span-8 workstation (Beckman 
Coulter) to normalise each sample to 10ng/µl. Where the concentration was below 10ng/µl 
amplicon was transferred neat.  
Following purification and normalisation, DNA libraries were prepared with NGSgo® reagents in 
accordance with manufacturer’s instructions. Briefly, fragmentation, end repair and dA tailing 
of each sample was performed using NGSgo®FragX reagents. Adapter ligation with NGSgo®LibrX 
kits was followed by purification and size selection using 0.45X AMPure beads (Beckman 
Coulter). Indexing PCR utilised unique combinations of barcode indices from the NGSgo®IndX 
384 set. Following a final clean up with 0.6X AMPure beads, 5µl from each well were pooled 
into a single 1.5ml tube for each plate processed to form a pooled amplicon library (PAL). 
2.6.5 Assessment of the pooled amplicon libraries 
Each PAL was assessed by one or both methods prior to sequencing to ensure it contained 
sufficient prepared library of the correct size to obtain a quality sequence. The 2100 
Bioanalyser (Agilent) provided data on fragment size and molarity and was mainly employed in 
earlier experiments and for troubleshooting purposes due to the cost of the Bioanalyser chips. 
The Qubit® measured the total concentration of the library but did not provide data on quality. 
2.6.5.1 2100 Bioanalyser 
A 1µl aliquot of each PAL was assessed using the Agilent High Sensitivity DNA Kit on the 2100 
Bioanalyser system (Agilent Technologies, Inc) in accordance with the manufacturer’s 
instructions. The mean fragment size and profile was determined using the associated 2100 
Expert software v1.03 (Agilent Technologies, Inc). 
2.6.5.2 Qubit® 
Determination of concentration was performed in triplicate using the Qubit® dsDNA HS assay 
(Life Technologies). For each PAL, a 5µl aliquot was made up to 200µl with Qubit® working 
solution in thin-walled 0.5ml tubes (Qubit® Assay tubes) and measured using a Qubit® 2.0 
Fluorometer in accordance with the Qubit® dsDNA HS protocol. 
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2.6.6 Sequencing on the MiSeq 
Each PAL was diluted in NFW as required to produce a final target concentration of 17pM. Ten 
microlitres of diluted PAL was added to an equal volume of freshly prepared 0.1N NaOH in a 
1.5ml tube, mixed and incubated for 5 minutes at room temperature. This was followed by the 
addition of 980µl of Hybridisation buffer (Illumina) to form the diluted amplicon library (DAL), 
inverted to mix. Following preparation and loading of the flow cell, 600µl of DAL was added to 
a thawed v2 MiSeq reagent cartridge and loaded onto the MiSeq platform (Illumina), in 
accordance with the MiSeq system user guide (Illumina). Sample identifiers and their 
respective multiplex indices were recorded along with run parameters on the linked sample 
sheet. MiSeq run parameters were set to 2 x 251 cycles of paired end sequencing using a 
FASTQ only analysis application with adapter trimming. 
2.6.7 Data analysis  
Primary data analysis was performed using MiSeq Reporter v2.5.1 (Illumina) to generate a pair 
of FASTQ files for each sample. FASTQ files generated from the MiSeq run were then analysed 
using HLA specific analysis software, NGSengine (GenDX). The version of software and 
IMGT/HLA database used was dependent on the date analysis was performed. Analysis 
preferences were set to process a maximum of 100,000 reads per FASTQ file, using the 
standard phasing algorithm with a minimum read depth threshold defaulted to 20 bases and 
balance threshold set to 20%.  
 
2.7 HPA genotyping by Targeted Next Generation Sequencing 
2.7.1 Assay Design 
A custom HaloPlex high sensitivity (HS) panel (Agilent Technologies, UK) was created using 
Agilent’s online SureDesign HaloPlex advanced design wizard. Designs were based on hg19 
GRCh37 references sequences (Table 2.2), with target sources obtained from the RefSeq 
database (O'Leary et al., 2016). Target parameters for each gene were set to include all coding 
exons with an extension of 50 bases from the respective 5’ and 3’ ends of each region.  
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Gene  RefSeq Target ID (based on GRCh37 reference sequence) 
 
ITGB3 NM_000212 
GP1BA NM_000173 
ITGA2B NM_000419 
ITGA2 NM_002203 
GP1BB NM_000407 
CD109 NM_133493 
Table 2.2 Target sequences employed for the bespoke HaloPlexHS design. RefSeq target 
identifiers (ID) shown were entered into the Agilent SureDesign Haloplex advanced design 
wizard. Target IDs were based on the GRCh37 reference sequences to ensure compatibility with 
the SureDesign software. 
 
2.7.2 Targeted enrichment  
Using the bespoke HaloPlexHS design as described in 2.7.1, DNA libraries were prepared by 
following the HaloPlex HS target enrichment system protocol vC0 December 2015, outlined in 
figure 2.4. Briefly, genomic DNA (gDNA) was quantified as described in section 2.4 and diluted 
to 1.8ng/µl in 10mM Tris buffer pH 8.5. Each diluted gDNA sample was digested with a panel of 
16 restriction enzymes in the form of eight double digests for 30 minutes at 37°C along with an 
enrichment control DNA sample (ECD) provided with the kit. The restriction digest was 
validated by analysing 1:1 dilutions of inactivated ECD reactions on the 2100 Bioanalyser 
system (Agilent Technologies, Inc) using the Agilent High Sensitivity DNA Kit in accordance with 
the manufacturer’s instructions.  
Once digestion was confirmed, gDNA restriction fragments from each sample were pooled and 
hybridised to the custom HaloPlex HS probe library, with simultaneous incorporation of unique 
indexing primers occurring at 58°C for 2 hours. Following removal from the hybridisation 
buffer using AMPure XP beads (Beckman Coulter, UK), ligation reagents were added to the 
circularised fragments and incubated in a PTC-225 thermal cycler (MJ Research) at 55°C for 10 
minutes to close nicks in the probe-target DNA hybrids.  
Streptavidin labelled Dynabeads (Thermo Fisher Scientific, UK) were used to capture the 
biotinylated targets which were then amplified in a 9700 thermal cycler (Perkin Elmer) using 
the following PCR program: 98°C for 2 minutes; 25 cycles of 98°C for 30 seconds, 60°C for 30 
seconds and 72°C for 1 minute; 72°C for 10 minutes and held at 8°C. PCR products were 
subsequently purified with AMPure XP beads and evaluated with a Bioanalyser 2100 (Agilent 
Technologies, UK) or quantified using a Qubit (Thermo Fisher Scientific, UK), as described in 
2.6.5. 
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2.7.3 Pooling of libraries 
Prepared DNA Libraries were combined for downstream sequencing by either equimolar 
pooling or pooling in equal volumes. Each pooled library was validated with a Bioanalyser 2100 
to assess fragment size and concentration (see 2.6.5) and normalised to approximately 4nM.  
2.7.4 Sequencing on the MiSeq 
Based on the Illumina MiSeq System Denature and Dilute Libraries Guide, 10pM of the pooled 
library was then loaded onto a MiSeq (Illumina) for 2 x 151 paired-end sequencing using either 
a MiSeq compatible Nano or Standard v2 cartridge and flow cell. The MiSeq Reporter (MSR) 
software (Illumina, Cambridge) settings were adjusted to generate FASTQ files for index reads. 
2.7.5 Data analysis 
Primary data analysis was performed using MSR to generate a pair of FASTQ files for each 
sample. FASTQ files generated were then analysed using SureCall NGS data analysis software 
v3.0.3.1 (Agilent Technologies, UK). 
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Figure 2.4 Overview of the HaloPlexHS target-enrichment sequencing sample preparation 
workflow. Sample DNA was first digested and denatured followed by hybridisation with the 
bespoke HaloPlexHS probe library when unique indexing primers were also incorporated. This 
was followed by purification and ligation of targets with each fragment then amplified using 
circularised PCR to prepare libraries for downstream sequencing. ©Agilent Technologies, Inc. 
2nd February 2017. Reproduced with Permission, Courtesy of Agilent Technologies, Inc. 
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3. HLA typing of platelet donors by next generation sequencing 
3.1 Introduction 
Providing suitable platelet transfusions for patients who are refractory to random platelet 
transfusions due to the presence of HLA alloantibodies requires a large panel of HLA defined 
platelet donors (Pavenski, Freedman and Semple, 2012). Approximately 2500 apheresis donors 
per annum are currently recruited by NHSBT for this purpose, with each donor typed for HLA 
on two separate occasions for quality reasons. This level of commitment to maintain an active 
and accurately typed donor panel is high and requires high-throughput genotyping techniques 
(Lucas, 2013).  
Numerous strategies are available for the selection of platelets to support refractory patients 
including the use of (a) cross-match negative (b) antigen avoidance and (c) HLA matched 
products (Kopko et al., 2015). HLA epitope-based matching (HEM) is a more recent approach 
based on compatibility of antigenic determinants, but accurate comparison of donor and 
patient intra and inter locus HLA is likely to require high resolution or allele level typing 
(Duquesnoy, 2011). High resolution HLA typing is typically performed by Sanger sequencing 
but this method is unsuitable for high throughput due to costs and logistical constraints.  
Next Generation Sequencing (NGS) is a novel approach to sequencing, with a massive increase 
in capacity over conventional technology (Metzker, 2010). Consequently, NGS been exploited 
for HLA typing in recent years, with laboratories adopting a variety of strategies ranging from 
imputation of HLA types from WGS data (Bauer et al., 2016) to targeted sequencing of the HLA 
gene (Ehrenberg et al., 2014), reviewed in section 1.6.1. Some of the reported approaches 
define HLA to the allele level, as required for HEM (Duquesnoy, 2008). 
The aim of this initial work was to investigate the feasibility of applying NGS technology for 
HLA typing platelet donors. Included was an investigation of different approaches for PCR 
template generation and for preparation of DNA libraries prior to sequencing on the MiSeq 
NGS platform. Validity of results was provided by the development of stringent acceptance 
criteria and concordance with historical HLA data. 
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3.2 Materials & Methods 
3.2.1 Sample preparation  
Blood samples were collected from 540 random English apheresis platelet donors who had 
been HLA typed on a previous occasion. Samples were sent to the H&I laboratory at NHSBT, 
Colindale and DNA extracted from 200µl blood in batches of 90 samples using the 
QIAsymphonySP. Following extraction DNA was purified using AMPure beads, quantified using 
the Quant-iT™ broad range assay kit and subsequently normalized to 25ng/µl using the Biomek 
FXP laboratory workstation (Figure 3.1), detailed in sections 2.1 to 2.2. 
 
 
Figure 3.1. Summary of donor sample preparation prior to PCR amplification. Following 
platelet donor blood sample collection at NHSBT donor clinics, DNA is extracted, purified, 
measured and normalised to ensure the quantity and quality is optimal for whole HLA gene PCR 
amplification. 
 
3.2.2 PCR amplification 
The first 90 samples prepared (plate #457) were amplified using the TruSight HLA primers, 
which was performed as part of an early access trial using kits supplied by Illumina. However, 
due to the limited amount of reagents provided, instead of using the prescribed 50µl volumes 
the PCR reaction was reduced to 10µl and set up as described in section 2.6.1.1. The remaining 
450 samples contained within 5 plates (#459, #462, #464, #467 & #469) were amplified using 
previously published primers (Shiina et al., 2012) but with an in-house method (section 
2.6.1.2). Modifications from the original conditions were made during optimization and 
Platelet donor sample collection 
•Collected at NHSBT clinics in England 
DNA extraction 
•Using the QIAsymphonySP & DNA mini kits  
DNA purification 
•AMPureXP beads & Biomek FX robot 
DNA quantification 
•Using Quani-iT kits & FiltermaxF3 plate reader 
DNA normalisation 
•Dilution using Biomek FX robot  
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included a change to the reaction volume (10µl instead of 20µl) and adaptation of thermal 
cycling parameters. The addition of 5% DMSO (v/v) in the reaction mix was also required for 
HLA-C reactions. 
3.2.3 PCR assessment and amplicon pooling 
A 2µl aliquot was taken from the first and last row of each amplification plate to determine if 
the amplification had been successful. The method used for this assessment was determined 
by the downstream library preparation protocol, with agarose gel electrophoresis employed 
prior to TruSight library preparation and quantification used before the GenDx library 
preparation protocol (section 2.6.2). Any plates that indicated poor or failed amplification 
were repeated before proceeding. Following successful amplification, 7µl of PCR product 
generated for HLA-A, -B and –C for each sample were pooled to form a single plate of pooled 
amplicon (section 2.6.3). 
3.2.4 Library preparation 
The TruSight HLA library preparation method (section 2.6.3.1) was used to prepare the first 
two plates as reagents were provided free of charge by Illumina as part of an early access trial. 
At that time, Illumina were also the only provider of sufficient indices to allow multiplexing of 
>96 samples in a single MiSeq run. Subsequent libraries were prepared using the NGSgo® 
protocol (section 2.6.3.2) following the release of a 384 set of compatible indices by GenDx. In 
addition this kit had recently been validated for use by the H&I laboratory for sequencing adult 
volunteer haematopoietic stem cell donors for HLA-A, -B, C-, DRB1 and –DQB1. Table 3.1 
summaries the protocol used for each plate. 
Plate ID Amplification protocol Library preparation 
 
#457 TruSightHLA (Illumina) TruSightHLA (Illumina) 
#459 In-house TruSightHLA (Illumina) 
#462 In-house NGSgo® (GenDx) 
#464 In-house NGSgo® (GenDx) 
#467 In-house NGSgo® (GenDx) 
#469 In-house NGSgo® (GenDx) 
Table 3.1. The PCR protocol and library preparation methods used for each plate of DNA. Six 
plates were amplified, with the first plate using Illumina’s PCR primers and the remainder by 
the in-house approach. Library preparation was performed using the TruSightHLA™ kits for 
plates #457 and #459 with the other plates prepared with NGSgo® reagents. 
 
Both library preparation methods required some modification from their prescribed protocols, 
as each was designed by the respective manufacturer to process amplicons from a greater 
number of HLA loci and/or a larger PCR reaction volume than was produced by HLA class I 
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amplifications in this study. Therefore, rather than the preferred approach of combining 
amplicons based on concentration to avoid excess sequencing coverage of one locus to the 
detriment of another, HLA-A, -B and –C were pooled in equal volumes to ensure the minimum 
volume required by the downstream NGSgo® library preparation protocol was met.  
For the TruSightHLA protocol, PCR products were pooled prior to purification and 
normalization, which differed from Illumina’s prescribed process which instructs preparation 
of amplicons separately. This adjustment was made to maximize the number of samples that 
could be sequenced with the reagents provided by Illumina. This change also required a 
modification to the volume of sample purification beads used for the initial purification of 
pooled amplicon which had to be reduced from 45µl to 21µl to maintain the correct 1:1 bead 
to amplicon ratio.  
In order to maintain sample integrity, the index combinations used for each library preparation 
were carefully selected to ensure that each set provided a unique combination for each 
sample sequenced on a single MiSeq flow cell. Details of index combinations used were 
recorded on the respective sample sheets. 
3.2.5 Sequencing on the MiSeq 
To maximize the sequencing capacity of each run of the MiSeq, pooled amplicon libraries 
(PALs) prepared from two plates were combined together for sequencing (Table 3.2). Each PAL 
was assessed and diluted (as detailed in sections 2.6.5 and 2.6.6) prior to combining with its 
pair in equal volumes. The final PAL was then quantified using the Qubit® dsDNA HS assay prior 
to dilution, denaturation and loading onto the MiSeq. 
MiSeq run Plate IDs of the combined PALs 
 
1 #457, #459 
2 #462, #464 
3 #467, #469 
Table 3.2 Details of the pooled amplicon libraries (PALs) combined for each MiSeq run. Plate 
IDs are listed for each PAL and the combination of prepared libraries used for the three MiSeq 
runs. 
 
3.2.6 Data analysis  
FASTQ files generated by Miseq Reporter (MSR) software were transferred from the MiSeq to 
a high specification PC for analysis using HLA specific analysis software. Plates #457 & #459 
were originally analysed with NGSengine v1.8 but were subsequently reanalysed with the later 
release v1.9 along with the remaining plates, to ensure the data was compared to the latest 
sequence data made available with IMGT/HLA 3.20. Each result was scrutinised and reviewed 
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against the acceptance criteria listed in Table 3.3. Mismatched nucleotide positions in either 
exons or introns were inspected to determine if they were genuine mutations or merely 
artefacts, assessing base calls in conjunction with adjacent positions. All homozygous results 
were scrutinised using the statistics data tab of the NGSengine software, which provided a 
visual representation of allele balance across each gene.  
Quality parameter Acceptance criteria 
Average depth of coverage >100 bp 
No. of genotype matches 1 
No. of exon mismatches 0 
No. of intron mismatches 0 
Homozygous  None 
Atypical HLA associations None 
Presence of rare HLA alleles None 
Table 3.3 Quality parameters and respective acceptance criteria for data analysis using 
NGSengine analysis software. Each result was scrutinised against these parameters to review 
sequence quality and accuracy of HLA allele assignment. 
 
3.2.7 HLA concordance with historical HLA types 
Following scrutiny of each result, a concordance check was performed between the HLA types 
generated by NGS and the historical HLA results. Where the historical HLA type consisted of an 
HLA string rather than an individual allele, NGS results were considered concordant as long as 
the determined allele (or alleles if ambiguous) was contained within the historical HLA string. 
For example, an NGS result of HLA-C*03:04:01:01 was considered concordant with the original 
type as it is included in the HLA string determined by PCR-SSOP below, as underlined in bold:  
C*03:02:01;*03:02:02:01;*03:02:02:02;*03:02:02:03;*03:02:03;*03:02:04;*03:02:05;*03:02:0
6;*03:02:07;*03:02:08;*03:02:11;*03:02:12;*03:04:01:01;*03:04:01:02;*03:04:02;*03:04:03;*
03:04:04;*03:04:05;*03:04:06;*03:04:07;*03:04:08;*03:04:09;*03:04:10;*03:04:12. 
For the few historical results that were at first field only, results were considered concordant if 
the first two digits were the same as the original HLA type. 
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3.3 Results 
DNA was extracted and purified resulting in an average concentration of 17.2ng/µl (range from 
0 to 47.9ng/µl). PCR amplification was performed on DNA normalised to 25ng/µl (or used neat 
if below target concentration) 
3.3.1 PCR amplification 
Agarose gel electrophoresis was used to determine the success of PCR amplification for plates 
#457 and #459 only. PCR products of the expected length were observed in aliquots taken 
from the first and last row of each successfully amplified plate (Figure 3.2)   
  
  A:TruSightHLA amplicons from #457 HLA-A       
               A1       B1      C1      D1        E1       F1        G1      H1            A12    B12       
 
 
 B: In-house amplicons from #459 HLA-C 
      A1        B1       C1        D1        E1        F1       G1        H1             A12    B12                   
 
Figure 3.2 Example of HLA PCR amplicons run on a 1% agarose gel. Each lane is labelled with 
the respective plate position. Molecular weight marker (100bp) is highlighted by the red box. 
The top image shows PCR products taken from plate #457, amplified with Illumina’s 
TrusightHLA primers for HLA-A. The bottom  image shows HLA-C amplicons from plate #459, 
generated using in-house PCR  Specific PCR products are approximately 4kb in size. No positive 
control was included as all samples had been previously HLA typed and expected to contain a 
PCR product. Negative controls are not shown. 
 
Amplicons from the first and last rows of the remaining plates were quantified using the 
Quant-iT BR assay prior to pooling and normalisation (Table 3.4). The concentration of HLA-C 
amplifications shown for plate #467 were those obtained from repeat amplification as the 
original PCR had failed due to poor plate sealing.  
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Plate ID HLA-A amplicon mean 
concentration (ng/µl) 
 
HLA-B amplicon mean 
concentration (ng/µl) 
 
HLA-C amplicon mean 
concentration (ng/µl) 
 
#462 20.5 45.9 29.9 
#464 40.1 71.2 28.7 
#467 64.9 82.6 42.8 
#469 68.9 72.4 44.3 
Table 3.4 Mean concentration of PCR amplicons obtained for each HLA locus. A 2µl aliquot of 
each amplicon was taken from the first and last rows of the respective plates following PCR 
amplification. The average concentration was determined from the values obtained for each 
plate. 
 
3.3.2 Library quantification  
Concentration and fragment size determined for each pooled amplicon library are shown in 
Table 3.5. The concentration obtained for each library was quite varied, ranging from 0.6 to 
11.3ng/µl based on Qubit values with no correlation to library preparation method. The 
average fragment size of each library did appear to relate to the kit used, with GenDx library 
preparation producing smaller fragments on average. The fragment size distribution profile 
also looked atypical for PAL produced from plates #424 and #464 with NGSgo® kits, containing 
smaller fragments when compared to those generated by TruSightHLA, shown in Figure 3.3, 
although the reasons for this observation were not clearThis data was not available for the 
remaining plates prepared using NGSgo® kits. 
Plate 
ID 
Qubit® values 
(ng/µl) 
Bioanalyser values 
(ng/µl) 
Fragment size (kb) Library preparation kit 
#457 2.7 3.08 1764 TruSightHLA 
#459 0.6 0.51 1434 TruSightHLA 
#462 2.5 0.998 567 GenDX 
#464 1.9 1.11 576 GenDX 
#467 11.3 n/a n/a GenDX 
#469 8.6 n/a n/a GenDX 
Table 3.5 Mean concentrations and fragment sizes determined for pooled DNA libraries 
prepared from each plate. Concentrations were determined using the Qubit and 2100 
Bioanalyser assays with the fragment size determined using the Bioanalyser assay only. (n/a = 
no data obtained) 
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Figure 3.3 Atypical fragment size distribution for pooled amplicon libraries prepared from 
plates #462 and #464. (A) shows the expected bioanalyser trace, as observed for pooled 
amplicon library (PAL) prepared from plates #457 and #459. The bioanalyser profiles observed 
for PALs prepared from plates (B) #462 and (C) #464 had lower fluorescent units (FU) and had a 
lower and broader size range (bp). 
3.3.3 Sequencing quality  
The cluster density of the flow cell determines the amount of sequencing data generated, with 
lower cluster density producing a lower output. However, over clustering can also result in 
suboptimal data acquisition as fewer reads pass the filter due to reduced signal purity. This 
leads to higher background, poor base calling and, if excessive, over clustering can ultimately 
cause run failure (Illumina, 2016a). Cluster density on the flow cell was variable, ranging from 
345 to 960 K/mm2, with clusters passing filter > 88% on each occasion (Table 3.6).  
Run No. & ID Method of library 
preparation 
Cluster density % CPF Mean read 
depth 
1  #457#459 
 
TruSightHLA 820 94.3% 1695 
2  #462#464 NGSgo 
 
960 88.1% 222 
3  #467#469 NGSgo 
 
345 95.9% 498 
Table 3.6 MiSeq parameters observed for each sequencing run. Cluster density, % clusters 
passing filter (CPF) and mean read depth obtained according to MiSeq run and method used for 
library preparation  
 
A 
B C 
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Following the completion of each run, FASTQ files were generated by MSR for all samples and 
successfully transferred for analysis on the PC using NGSengine. Quality indicators were 
reviewed for each sample and are summarised in Table 3.7. The number of reads analysed 
varied according to sample and HLA locus, with an overall average of 19032 reads processed 
by NGSengine but ranging from the maximum of 200,000 to 0 where no suitable sequence 
data had been generated. For accepted sequences the minimum number of reads processed 
per HLA locus was 998. An average of 862x per base coverage depth was observed, although 
this varied between the three experiments performed, with a mean of 1910, 207x and 369x 
respectively. Read length ranged from 38bp to a maximum of 250bp although for sequences 
that were subsequently accepted the range was narrower with a minimum of 105bp for each 
read.  
Quality parameter  All sequence data Accepted sequences only 
Number of reads 19032 (0-200,000) 18799 (998-200,000) 
Read length (bp) 190 (38-250) 192 (105-236) 
Insert size (bp) 339 (0-633) 340 (59-633) 
% Mappability to HLA genes 74.6% (0-99%) 75.2% (9-99%) 
Read depth (bp) 862 (0-8752) 807 (36-7788) 
No. of phased regions 1.9 (1-39) 1.6 (1-21) 
Table 3.7. Summary of quality parameters observed for HLA sequence data. Results from all 
sequences generated from the three MiSeq runs, regardless of quality, compared with quality 
parameters observed with valid sequences only. Values are shown as mean average for each 
parameter with range in parentheses. 
The percentage of reads that map uniquely to a reference sequence, so called ‘mappability’, 
can have a significant impact on read depth (Sims et al., 2014). The range of mappability 
observed was very wide, even for sequences that met all acceptance criteria. However, there 
was a clear difference between the % mappability of reads generated using the TruSightHLA 
library preparation protocol used for plates #457#459 compared to those prepared using the 
NGSgo® kits, with an average of 94.0% and 64.8% respectively (Figure 3.4).  
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Figure 3.4 Percentage mappability of sequences generated. The range and average 
mappability of reads generated from each sequencing experiment, with the mean value 
represented by the triangle. 
 
3.3.4 HLA typing results 
In this study 540 samples were sequenced for HLA-A, -B and -C using the NGS protocols 
described above. Of the 1620 sequences performed, a total of 1466 (90.5%) met the defined 
quality acceptance criteria (Table 3.8). 
Run ID 
 
HLA-A HLA-B HLA-C 
#457 89    (98.9%) 49    (54.4%) 89    (98.9%) 
#459 86    (95.6%) 90    (100%) 89    (98.9%) 
#462 76    (84.4%) 83    (92.2%) 85    (94.4%) 
#464 83    (92.2%) 85    (94.4%) 82    (91.1%) 
#467 88    (97.8%) 88    (97.8%) 86    (95.6%) 
#469 75    (83.3%) 72    (80%) 70    (77.8%) 
Total 497  (92.0%) 468  (86.7%) 501  (92.8%) 
Table 3.8 The number of successful HLA types obtained per plate. Results are presented 
according to the run identifier (ID) and HLA locus. The percentage of successful results obtained 
for each plate are shown in parentheses. 
In total 441 samples (82.7%) produced an allele level genotype for HLA-A, -B and -C. Of the 
remaining samples 69 failed to sequence one HLA locus, 5 failed for two HLA loci and 25 failed 
to produce valid sequence for any HLA locus, summarised in Figure 3.5. 
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Figure 3.5. The percentage of sequences failing to meet quality acceptance criteria. Results 
are displayed according to HLA locus. The bar labelled ‘all loci’ shows the percentage of 
samples that failed to sequence for any HLA locus. 
 
The number and HLA loci of failed sequences varied between each plate of DNA. Notable 
differences included a high rejection rate for HLA-B sequences in plate #457 and a higher than 
average number of samples failing for all HLA loci on plate #469 (Figure 3.6).  
 
Figure 3.6. The number of samples with rejected sequences. Results are displayed according 
to plate identifier (ID) and HLA locus. 
 
The reasons for rejected sequence also varied according to HLA locus (Figure 3.7). Low 
coverage was the primary reason for samples failing for all HLA loci and for HLA-A sequences 
deemed invalid, whereas HLA-B sequences were predominantly rejected due to the production 
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of ambiguous results. Allele imbalance was observed in some samples for HLA-B and -C but not 
for HLA-A. Three samples were rejected due to the presence of putative novel mutations in 
exon regions of the respective HLA-B or HLA-C genes (see 3.3.4.4). 
 
Figure 3.7 A summary of reasons for sequence rejection. Results are displayed according to 
HLA locus and reason for rejection.  
 
3.3.4.1 Low sequencing depth 
The sequence alignment of all samples with an average per base depth of coverage of <100 
were carefully scrutinised. Where coverage was even and other quality parameters met, the 
result was accepted. However, NGSengine did not assign base calls for positions below the 
20bp default cut-off so these results, or those where other quality flags were present 
alongside low coverage, were rejected. Poor per base depth of coverage was the primary 
reason for samples that failed for all HLA loci. Low coverage was also the cause of all failures at 
the HLA-A locus, for 6 samples for HLA-B and 2 for HLA-C. Variation in read depth was also 
observed for each plate, with those prepared using the TruSightHLA kits resulting in fewer 
rejected sequences due to low coverage compared to the NGSgo kits (Figure 3.8). 
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Figure 3.8 Percentage of sequences rejected due to poor per base depth of coverage. Results 
are displayed according to plate ID. Bars in blue represent libraries prepared with the 
TruSightHLA kits. The red bars signify plates prepared with NGSgo® reagents. 
  
3.3.4.2 HLA ambiguity 
The primary reason for rejected sequences at the HLA-B locus was ambiguity, observed in 32 
samples. Ambiguity was indicated when the number of HLA genotypes matching to the NGS-
generated nucleotide sequence was >1 and all other sequencing criteria were met. All 
examples resulted from TrusightHLA HLA-B amplification products. Of these, 20 sequences 
analysed were unable to resolve HLA-B*44:01:01:01 and B*44:19N due to NGS base calls 
beginning 10 nucleotides from the start of exon 1. In the example shown, one of the alleles 
(B*40:01:02) has been determined but the software cannot unambiguously assign the second 
allele, as it is unable to discriminate between B*44:02:01:01 and the null allele B*44:19N 
which would be defined by Guanine or a deletion at position 5, respectively (Figure 3.9). The 
remaining 12 ambiguous types included three instances of an HLA-B*27:05/B*27:13 ambiguity 
with the remaining HLA-B alleles ambiguous at fourth field. 
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Figure 3.9 Ambiguity with HLA-B*44 alleles observed following TrusightHLA amplification. 
Screenshots from NGSengine showing the beginning of exon 1 in a sample with ambiguity 
between B*44:02:01:01 and B*44:19N. The top panel shows the expected base call at position 
5 if the second allele is a B*44:02:01:01 and the bottom panel shows a deletion at position 5 
required to assign B*44:19N, both circled in blue. The black arrows indicate the beginning of 
the aligned sequences generated by NGS at position 10 of exon 1. 
 
3.3.4.3 HLA allele imbalance 
In cases of imbalanced amplification where heterozygous positions for the minor allele were 
below the default 20% balance threshold, samples typed as apparent HLA homozygotes. 
However, the presence of a ‘hidden’ second allele could be visualized (Figure 3.10) and the 
allele balance threshold subsequently amended, although a lower limit of 10% for imbalance 
was maintained for all analyses.  
 
Figure 3.10 A screen shot of an imbalanced sequence. The ‘hidden’ minor allele base positions 
in red are highlighted by the green box, showing as approximately 10% of the overall sequence. 
The major allele alongside homozygous positions are shown in blue at the top of the image. 
The remaining red base positions towards the bottom of the image represent background 
noise. 
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A total of 15 results were rejected due to apparent bias in amplification, where one allele in a 
heterozygous sample failed to reach the minimum threshold of 10%. Of these, seven were 
HLA-B sequences derived from amplicons generated using TruSightHLA primers from Illumina, 
with the majority resulting from poor amplification of HLA-B*40:02:01. The remaining eight 
imbalanced sequences were observed in samples heterozygous for HLA-C, all due to inefficient 
amplification of HLA-C*07:04:01 using in-house PCR. 
3.3.4.4 Novel exon mutations 
Putative novel mutations in the exon regions of three samples from plates #464 and #469 were 
observed, as detailed in Table 3.9. 
Plate Sample ID HLA allele Nucleotide 
position 
Exon Mutation 
identified 
#464 S142 C*03:03:03 2568 6 G>A 
#467 S70 B*15:10:01 42 1 G>A 
#467 S33 C*03:04:01:01 1810 4 T>A 
Table 3.9 Putative novel mutations observed in plates #464 and #467. Identifiers (ID) of each 
sample containing a putative novel HLA allele along with each respective mutation and its 
location in the HLA allele affected. 
 
3.3.4.5 Intron mismatches 
Mismatches with the reference sequence within introns were observed in 220 sequences 
analysed using NGSengine v1.9 that were otherwise considered acceptable. Reasons for 
intronic mismatching were variable and included the presence of putative novel mutations, 
artefacts or inconclusive base calls and from poor phasing of sequencing fragments. Another 
common reason for apparent mismatch with the reference was lack of sequence data available 
from IMGT/HLA, where GenDx had inserted ‘presumed’ sequences for affected alleles but 
which was discordant with the sequences obtained in this cohort (Figure 3.11). 
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Figure 3.11. Reasons for intron mismatches to the reference sequence. Intron mismatches 
were detected in 220 sequences analysed using NGSengine v1.9. An explanation for these 
observed mismatches are displayed as a percentage of the overall number of intron 
mismatches. 
 
Sequences with intron mismatches were subsequently re-analysed following the release of 
NGSengine v1.10 soon after the original data was produced, resulting in 28 (12.7%) of these 
anomalies being resolved. Of these, two samples were typed following removal of intron 
artefacts.  A further two samples containing the allele HLA-B*44:27 were successfully 
reanalysed using the updated software, both previously having failed to phase correctly. The 
remaining 24 samples were resolved because previously undefined HLA sequences had been 
added to the updated IMGT/HLA database (v3.22) which was included in the v1.10 NGSengine 
release (Table 3.10). 
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HLA alleles resolved with NGSengine v1.10 
 
No. of examples in cohort 
 
 A*03:01:01:05 1 
 A*03:01:01:06 1 
 A*24:02:01:04 1 
A*24:02:01:05 1 
A*68:01:02:03 2 
B*14:02:01:02 1 
B*15:01:01:04 1 
B*15:03:01:02 1 
B*44:03:01:02 1 
B*47:01:01:03 1 
C*04:01:01:06 11 
C*17:01:01:05 2 
Table 3.10 HLA alleles resolved using NGSengine v1.10. The alleles in this table previously 
failed to type using NGSengine v1.9 indicating intron mismatches. Due to the inclusion of 
previously undefined sequences in IMGT/HLA release v3.22, these alleles were subsequently 
resolved. 
3.3.5 HLA Concordance  
Concordance with historical HLA results for the 1555 genotypes determined by NGS was very 
strong, at 99.2%, 97.9% and 97.9% for HLA-A, HLA-B and HLA-C respectively. Of the 26 results 
found to be discordant, 22 NGS derived sequences were of poor quality and were rejected. The 
remaining 4 discrepancies resulted from errors in the original typing, detailed in Table 3.11. 
Sample 
ID 
Batch 
ID 
NGS result Historical Typing result 
S17 PP462 B*27:05:02; 
B*52:01:01:02 
B27; B51 
 
S17 PP462 C*01:02:01; 
C*12:02:02 
Cw1; # 
 
S54 PP462 B*07:02:01; 
B*40:01:02 
B*07:02; B*40:02 
 
S174 PP469 C*04:01:01:01; 
C*08:92 
C*04:01:01:01/*04:01:01:02/*04:01:01:03/*04:01:01:04/*04:01:01:05/*04:01:
02/*04:01:03/*04:01:04/*04:01:05/*04:01:06/*04:01:07/*04:01:08/*04:01:09
/*04:01:10*04:01:12/*04:01:13/*04:01:14/*04:01:15/*04:01:16/*04:01:18/*0
4:01:19/*04:01:20/*04:01:21/*04:01:22/*04:01:23/*04:01:24/*04:01:25/*04:
01:26/*04:01:27/*04:01:30/*04:01:31/*04:01:32/*04:01:33/*04:01:34/*04:01
:35/*04:01:36/*04:01:38/*04:01:40/*04:01:41/*04:01:42/*04:01:43/*04:01:4
4/*04:01:45/*04:01:46/*04:01:47/*04:01:48/*04:01:49/*04:01:51/*04:05/*04
:07/*04:09N/*04:10/*04:18/*04:19/*04:20/*04:23/*04:24/*04:25/*04:27/*0
4:28/*04:30/*04:31/*04:33/*04:35/*04:38/*04:39/*04:40/*04:41/*04:43/*04
:44/*04:45/*04:46/*04:48/*04:49/*04:50/*04:51/*04:52/*04:53/*04:56/*04:
57/*04:59Q/*04:62/*04:63/*04:64:01/*04:64:02/*04:65/*04:66/*04:67/*04:6
9/*04:70/*04:72/*04:73/*04:75/*04:76/*04:78/*04:79/*04:81/*04:82/*04:83
/*04:84/*04:85/*04:86/*04:87/*04:88N/*04:89/*04:91/*04:92/*04:95N/*04:
96/*04:98:01/*04:98:02/*04:99/*04:101/*04:102/*04:104/*04:105N/*04:106
/*04:108/*04:109/*04:111/*04:115N/*04:116/*04:117/*04:118/*04:119/*04:
120/*04:121/*04:123N/*04:124/*04:126/*04:127/*04:128/*04:130/*04:131/
*04:132/*04:133/*04:134/*04:135/*04:136/*04:137/*04:138/*04:139/*04:14
1/*04:142/*04:143/*04:144/*04:146/*04:148/*04:149/*04:150/*04:151*04:1
52; 
 
C*08:02:04/*08:02:07 
 
Table 3.11 Details of NGS results found to be discrepant with the historical typing data. 
Discrepant alleles/antigens are highlighted in red. # = presumed homozygous.  
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3.4 Discussion 
A total of 540 samples obtained from English apheresis platelet donors were sequenced for 
HLA-A, -B and -C using an NGS approach as described above, with over 90% of the 1620 
genotypes performed meeting the stringent acceptance criteria. Reasons for rejection of the 
remaining 154 sequences varied according to amplification protocol and the method used for 
library preparation. 
3.4.1 Amplification failure 
Although the majority of samples amplified successfully, it is likely that some samples failed to 
sequence for one or more HLA locus because of poor amplification. However, only a 
proportion of PCR products were checked either by gel electrophoresis or quantification so it is 
not possible to identify those samples affected. Ideally all amplicons should have been checked 
prior to pooling and library preparation, but it was logistically challenging to repeat adhoc 
failures when all samples are contained within a 96-well plate. Therefore a decision to 
continue with library preparation was made unless the sampling of PCR amplicons indicated 
the entire plate of DNA failed to amplify, such as occurred for plate #467 for HLA-C. 
3.4.2 Ambiguity 
No ambiguous HLA results were produced following amplification with the in-house PCR 
protocol. However, use of the TruSightHLA primers for amplifying DNA from plate #457 
resulted in ambiguity for 12% of HLA-B genotypes. This can be explained by the primers used 
by the Illumina kit. Although the exact binding site and primer sequence is not disclosed by the 
manufacturer, the expected size of amplicon for HLA-B of 2.6kb quoted in the TruSight HLA 
sequencing panel library preparation guide is significantly smaller than the 4.1kb amplicon for 
HLA-A and 4.2kb for HLA-C. Scrutinising the results in more detail it was clear the HLA-B 
primers do not amplify the entire gene and thus some crucial polymorphic positions in exon 1 
were not sequenced, as shown in section 3.3.4.2. Conversely, in-house PCR amplification uses 
primers that bind outside the coding regions for each HLA class I gene, and therefore all 
positions that affect HLA allele assignment are determined. 
As the TruSightHLA primers were provided as part of an early access program, concerns 
regarding this ambiguity were raised with Illumina, noting that the in-house amplification 
protocol was superior to the commercial kit. It is worth noting that the later HLA sequencing 
panel released by Illumina in 2016 (TruSightHLA v2) claimed to amplify exons 1 to 6, producing 
a slightly longer product of 2.8kb for HLA-B (Illumina, 2016b). Although these primers have not 
been tested at NHSBT, a recent paper suggests the ambiguity for HLA-B has been improved in 
the updated protocol, with unambiguous typing at third field increasing from 84% using 
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TruSightHLA v1 PCR primers to 91% with the later version of the TruSightHLA kit (Profaizer et 
al., 2017). 
3.4.3 Allele imbalance 
Both amplification approaches resulted in allele bias for a number of samples, but the affected 
HLA loci differed according to protocol. TruSightHLA amplification produced imbalanced HLA-B 
sequences whereas in-house PCR affected HLA-C. Allele bias during amplification of a biallelic 
system such as HLA is a well documented issue (Lange et al., 2014; Ehrenberg et al., 2014; 
Nelson et al., 2015; Carapito, Radosavljevic and Bahram, 2016). During the optimisation phase 
of the in-house protocol, allele drop out of HLA-C*07:04:01 in heterozygous samples was 
observed. In an attempt to resolve this anomaly, both betaine and DMSO were tried as 
potential additives to the PCR reaction mix as they are well documented PCR enhancing agents 
(Chakrabarti and Schutt, 2001; Kang, Lee and Gorenstein, 2005; Strien, Sanft and Mall, 2013). 
Betaine appeared to have an inhibitory effect for HLA-C as no PCR product was obtained when 
it was added to the reaction mix. Use of 5% DMSO was then tested as modifications such as 
the addition of DMSO in HLA class I amplification reactions using the same primer designs has 
been previously reported to reduce allele bias (Ehrenberg et al., 2014). However although the 
addition of DMSO did result in some successfully amplified HLA-C*07:04:01 alleles, it did not 
produce balanced amplification in all samples, with only 4 of the 12 HLA- C*07:04:01 
amplifications meeting the minimum 10% threshold. This is the subject of further work to 
resolve. 
3.4.4 Low coverage 
Both methods used for library preparation produced even coverage across the HLA class I 
genes, comparing favourably with alternative methods such as the generic Illumina kit, 
Nextera XT, which demonstrates extreme bias across the HLA class I genes with coverage loss 
in GC rich regions (Lan et al., 2015). 
Average per base coverage depth for the majority of samples was above the arbitrary 
threshold of 100bp. This cut off was based on dialogue with colleagues although there is no 
consensus of opinion on minimum coverage depth for HLA typing by NGS (Shiina et al., 2012; 
Wang et al., 2012; Gabriel et al., 2014; Gabriel et al., 2014). The latest amendments to 
accreditation standards from the American Society for Histocompatibility and Immunogenetics 
do not specify a minimum average coverage but stipulate these values must be obtained from 
‘laboratory-generated validation data’ (ASHI, 2014). A more detailed assessment of results 
suggested that read depth <100bp alone did not invalidate the result. Consequently sequences 
with low coverage were accepted if other key quality parameters were met and an 
unambiguous HLA type was assigned. Interestingly, there was a higher percentage of 
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sequences rejected due to low coverage from DNA plates prepared with the NGSgo kits 
compared to the TruSightHLA library preparation protocol. The reasons for this are not clear, 
and do not seem to directly correlate with cluster formation on the flow cell.  
Samples that failed to produce coverage for any HLA locus were most likely due to lack of 
amplicon template or errors made during library preparation. Lack of template may have 
resulted from problems with the initial PCR, amplicon pooling or normalisation. The 
TruSightHLA protocol uses a bead-based normalisation compared to the quantification and 
subsequent dilution of pooled amplicons required prior to NGSgo® library preparation. 
Differences in approach to normalisation for the two protocols may affect the accuracy of 
template added to the tagmentation steps.  The size distribution of the pooled amplicon 
libraries shown in Figure 3.3 certainly suggests that the fragmentation process was less optimal 
when using NGSgo® library preparation kits compared to TruSight™HLA. Lack of sufficient 
template for tagmentation may result in over fragmentation resulting in reduced library yield 
and coverage drop out as small fragments are removed during the purification steps. Likewise, 
insufficient tagmentation may produce larger libraries that do not cluster efficiently on the 
flow cell (Illumina, 2015). It is possible that the bead-based normalisation is more accurate 
than using a manual normalisation process, resulting in a lower failure rate. 
An alternative explanation of the higher failure observed with the NGSgo® protocol might 
relate to the very small reagent volumes used compared to the TruSightHLA protocol, for 
example 1.25µl versus 5µl of each index added, respectively. Difficulties with pipetting during 
library preparation may have caused inaccurate measurement of reagents. Failure to add 
sufficient indexing primers may lead to inefficient amplification or failure of the index PCR 
step, with fragments not attached to the MiSeq I5 and I7 adapter sequences and therefore 
unable to bind to the flow cell. This would lead to reduced sequence generated for some or all 
DNA fragments from affected samples. 
Low coverage may also result from poor mappability of sequences, where short sequences are 
rejected as the software algorithm fails to map them to a unique part of the reference 
sequence because of shared sequence motifs between HLA class I genes (Erlich, 2012). This is 
supported by data shown in figure 3.12 which demonstrates a strong correlation between size 
of sequencing insert and % mappability and the consequence of low mappability on read 
depth.  
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Figure 3.12 Insert size, sequence mappability and read depth. Graph (A) shows insert size 
versus % mappability observed for all HLA sequences in the cohort, indicating that larger 
fragments map more accurately to their respective HLA class I genes. Graph (B) demonstrates 
the effect that % mappability has on read depth, with deeper sequencing observed when a high 
percentage of fragments are mapped to the respective HLA reference sequence. Data circled in 
red was generated using the TruSightHLA library preparation kits with the remainder obtained 
using NGSgo® reagents 
 
Read length will also impact on the ability of the analysis software to phase reads correctly, 
required to determine whether polymorphic positions are in cis or trans in order to avoid 
ambiguity (Tu et al., 2017). Reads of less than 100bp in length are reportedly a problem as they 
are unable to phase non-polymorphic regions between heterozygous positions (Huang et al., 
2015) which will impact on the accuracy of HLA typing (Profaizer et al., 2015). However, it is 
still possible to produce a single genotype, despite lack of phase (Lind et al., 2013). 
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3.4.5 Intron mismatches 
Intron mismatches with the reference sequence were observed in 15% of valid sequences. 
Whereas results with mismatches in the exons were rejected, those high quality sequences 
with intron mismatches were deemed acceptable as this would not impact on amino acid 
sequence. However, the result would only be considered and reported at third field.  
More than half of these ‘mismatches’ were probably artefacts resulting from poor phasing or 
inaccurate mapping to the reference sequence. Intron mismatches identified in 22 sequences 
were due to the analysis software substituting regions of missing reference data with 
surrogate nucleotide sequence leading to erroneous intron mismatches, a known limitation of 
NGSengine (Duke et al., 2016). More recent versions of NGSengine allow these mismatches to 
be ignored by the user.  
A significant proportion (32%) appeared to be genuine novel mutations. HLA class I sequences 
are named by the WHO HLA Nomenclature Committee for Factors of the HLA System following 
attainment of a unique accession number from either EMBL, GenBank or the DDBJ databanks 
(Robinson et al., 2015). Once accepted the submitted sequence are stored in the IMGT/HLA 
database and, until recently, most HLA class I sequences submitted to the IMGT/HLA database 
were based on data from only exons 2 and 3 due to historical sequencing techniques (Lind et 
al., 2013). Although full genomic sequences are available for the most common HLA class I 
types, much of the intronic data is still missing but with more laboratories using NGS for HLA 
typing it is anticipated that many of the gaps in the data will be filled (Robinson et al., 2015). 
Indeed, re-analysing novel sequences with a more up to date version of NGSengine produced 
valid genotypes due to release of identical sequences in IMGT/HLA v3.22. The remaining 
putative novel mutations are discussed in more detail in chapter 5. 
3.4.6 Exon mismatches 
Three sequences were found to contain novel mutations in the exons and are discussed in 
more detail in chapter 5. 
3.5 Conclusions 
The results presented in this chapter demonstrate that NGS has the capacity to accurately HLA 
type 180 platelet donor samples simultaneously at the allele level. The use of stringent 
acceptance criteria supported by a very high level of concordance with historical HLA typing 
indicates that NGS is a valid approach for high throughput, high resolution HLA typing of 
platelet donors. The use of an in-house amplification protocol was shown to be superior to the 
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commercial primers, providing a template for whole gene sequencing of HLA-A, -B and -C. 
Some variability in outcome was observed between the two methods employed for library 
preparation, although insufficient data was available to confidently determine that one 
method was superior to another. Further sequencing experiments using both library 
preparation protocols to prepare DNA from the same starting amplicons would provide a more 
realistic comparison. 
It is worth mentioning that since the experiments described in this chapter were performed, 
the routine laboratory at NHSBT transferred from NGSgo® kits to library preparation with 
TruSightHLA reagents for stem cell registry donor typing. This followed a European tender 
where logistics, data quality and costs were considered. TruSightHLA had the added benefit of 
a developed automated protocol on the Biomek FX robot that was subsequently implemented 
in August 2016. 
The application and benefits of this method for HLA typing apheresis platelet donors to 
support HLA epitope matching of platelet transfusions will be the subject of further analysis 
and discussion in Chapter 4. 
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4. HLA epitope matching: allele prediction or NGS typing? 
4.1 Introduction 
The provision of HLA selected platelets is a proven treatment for patients with immunological 
platelet refractoriness (Kopko et al., 2015) but utilising HLA epitope matching (HEM) may be 
more relevant than matching the whole HLA, with the use of programs such as 
HLAMatchmaker providing an improved evaluation of histocompatibility (Duquesnoy, 2008). In 
addition, HEM may also increase the pool of available donors for patients with HLA 
alloantibodies, which would be of significant benefit as maintaining a large platelet donor 
panel for the provision of HLA matched platelets is costly (Pavenski et al., 2013). 
Epitope matching algorithms require HLA defined at second field i.e. at the amino acid level to 
accurately determine the HLA epitopes present in a donor or patient (Duquesnoy, 2008). As 
the majority of English platelet donors are currently typed using Luminex PCR-SSOP, it would 
be necessary to convert the medium resolution HLA-types obtained to the second field level, 
an approach used in previous studies reporting on the efficacy of HEM (Brooks, MacPherson 
and Fung, 2008; Pai et al., 2010). Results discussed in Chapter 3 demonstrate that it is possible 
to define HLA to the allele level using NGS but this is likely to incur additional costs over 
conventional HLA typing technology. Since second field HLA resolution can be achieved using a 
computer algorithm, an assessment of the accuracy of allele prediction from medium 
resolution typing is required to determine the cost benefit of moving to NGS for routine 
platelet donor typing (Brooks, MacPherson and Fung, 2008; Pai et al., 2010; Nambiar et al., 
2006). 
At NHSBT, the laboratory information management system (LIMS) used by the H&I department 
is Hematos IIG (Savant, Cumbria UK). This system enables users to search NHSBT stocks for 
suitable platelet donations for patients requiring HLA and or HPA selected platelets 
(Mwandoro et al., 2015). Currently the standard search determinates are based on 
conventional HLA match grades (Brown and Navarrete, 2011). However, Hematos also has the 
capability of using HEM for platelet selection, with the intention of routine implementation 
following the successful outcome of an ongoing double blind, non-inferiority trial 
(ISCTRN23996532). The current Hematos algorithm for platelet donor searching using HEM 
defaults to the ‘most likely HLA allele’, deemed to be the first allele in the string, whenever the 
HLA type of the donor or patient is not typed to at least second field (Kallon, 2015).  
In this chapter, the HLA typing results from 540 random apheresis platelet donors were used 
to determine the accuracy of HLA allele prediction. HLA alleles were predicted from their 
respective historical low to medium resolution HLA types and compared with the alleles 
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determined for each donor by NGS to assess the accuracy of allele prediction and the potential 
impact of any observed disparity.  
4.2 Materials and methods 
The HLA typing results were obtained from 540 random apheresis platelet donor samples, as 
described in Chapter 3.  
4.2.1 HLA allele prediction 
Historical HLA types were used to predict the HLA-A, -B and -C alleles for each donor using the 
algorithms described in 4.2.1.1 and 4.2.1.2. Both methods of prediction were performed 
manually and all predicted HLA alleles were defaulted to second field due to lack of available 
frequency data at third and fourth field. 
4.2.1.1 Selecting the first allele in the HLA string 
Where historical results consisted of an HLA string, the first allele in the string was selected as 
the most likely HLA allele. This algorithm was based on the current HLA allele prediction 
approach embedded in the Hematos epitope matching program. 
4.2.1.2 Selecting the most frequent allele 
The most frequent allele for each historical HLA type was predicted using the EpHLA-Converter 
component of the on-line software application ‘EpHLA’ (Sousa,Luiz Cláudio Demes da Mata et 
al., 2011). This software enabled conversion of low to medium resolution results into second 
field HLA alleles. The population ‘EUR’ was selected for each HLA type converted, which 
employed Caucasian HLA allele frequency data based on American populations (Maiers, 
Gragert and Klitz, 2007). This algorithm was based on the approach used by HLAMatchmaker 
(Brooks, MacPherson and Fung, 2008). 
4.2.2 Comparison of predicted versus defined HLA alleles 
HLA typing for HLA-A, -B and -C was performed by NGS on DNA extracted from 540 English 
apheresis platelet donors, as described in Chapter 3, section 3.2. The sequencing results 
obtained were compared with the HLA alleles predicted using both algorithms described in 
4.2.1 to determine if the prediction was correct. Comparisons were performed at second field 
only. 
4.2.3 Determining the impact of HLA allele prediction 
Any discrepancies between the HLA alleles predicted from the historical typing and NGS 
defined alleles were scrutinised to determine the reason for the inconsistency. Differences due 
to poor sequencing were excluded from any further analysis. The remaining allele 
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discrepancies were investigated for any potential mismatched HLA epitopes between the 
predicted and NGS results using the ABC database from the International Registry of Antibody-
Defined HLA Epitopes (Duquesnoy et al., 2013b). Each HLA locus was inspected separately with 
the predicted allele entered as the recipient type and the NGS result entered into the search 
field. Following application of the filter, mismatched epitopes displayed were recorded, noting 
in particular whether any mismatches were against exposed epitopes and if they were 
antibody verified (Duquesnoy, 2014). 
 
4.3 Results 
4.3.1 HLA allele predictions 
HLA predictions based on historical HLA types were performed on all 540 samples in the 
cohort. Of these, a comparison of the predicted results with NGS defined alleles was 
performed on 501, 503 and 509 results for HLA-A, -B and -C respectively, with remaining 
samples missing data. Discrepant predictions were either due to (a) the historical HLA type 
containing a rare allele as its first allele in the string, (b) the NGS result being a less frequent 
allele, (c) poor sequencing data or (d) errors with the historical typing. The overall number of 
discrepancies between the predicted and NGS defined alleles was greater when the first allele 
in the string algorithm was used, compared to those based on allele frequencies and 
regardless of the HLA locus (Figure 4.1).  
 
Figure 4.1 Discrepancies in HLA allele prediction. The percentage of samples with 
discrepancies observed between the predicted allele and the NGS result, using algorithms 
based on either the first allele or the most frequent allele contained within the historical HLA 
string for HLA-A, -B and -C. 
0.0% 
2.0% 
4.0% 
6.0% 
8.0% 
10.0% 
12.0% 
14.0% 
16.0% 
HLA-A HLA-B HLA-C 
%
 o
f 
sa
m
p
le
s 
w
it
h
 p
re
d
ic
ti
o
n
 e
rr
o
rs
 
First allele in string 
Most frequent allele 
76 
 
Table 4.1 shows examples of allele predictions for each HLA locus made using both the first 
allele in the string and HLA frequency algorithms based on second field results. Those alleles 
determined as the most frequent in their respective allele group were HLA-A*29:02, -B*44:02 
and -C*07:01, having a frequency of 3.279%, 9.011% and 16.658%, respectively. This compares 
with the second most common alleles in the same allele groups, namely HLA-A*29:01, -*44:03 
and -C*07:02, which have frequencies of 0.216%, 4.963% and 15.006%, respectively (Maiers, 
Gragert and Klitz, 2007). 
Historical medium resolution type First HLA 
allele in string 
Most frequent 
HLA allele 
A*29:01:01:01/29:01:01:02N/29:01:02/29:01:04/29:01:05/29:02:01:
01/29:02:01:02/29:02:02/29:02:04/29:02:06/29:02:07/29:02:08/29:
02:09/29:02:10/29:02:13/29:04/29:06/29:08N/29:10/29:12/29:16/2
9:17/29:21/29:23/29:25/29:26/29:27/29:29/29:36/29:38/29:41/29:4
2/29:43/29:44/29:45/29:46/29:50/29:54/29:55/29:58 
 
A*29:01 
(0.00216) 
A*29:02 
(0.03279) 
B*44:02:11/*44:03:01/*44:03:03/*44:03:04/*44:03:05/*44:03:07/*
44:03:08/*44:03:09/*44:03:10/*44:03:11/*44:03:12/*44:03:14/*44:
03:18/*44:13/*44:26/*44:35/*44:36/*44:38/*44:39/*44:73/*44:85/
*44:89/*44:92/*44:94/*44:98/*44:103/*44:108N/*44:114/*44:115/
*44:122/*44:125/*44:141/*44:142/*44:147/*44:155/*44:157/*44:1
59/*44:161/*44:164/*44:165/*44:167/*44:174/*44:175/*44:178 
 
B*44:02 
(0.09011) 
B*44:02 
(0.04963) 
C*07:01:25/*07:02:01:01/*07:02:01:02/*07:02:01:03/*07:02:01:04/
*07:02:01:05/*07:02:02/*07:02:04/*07:02:05/*07:02:06/*07:02:07/
*07:02:08/*07:02:09/*07:02:11/*07:02:12/*07:02:14/*07:02:15/*0
7:02:16/*07:02:17/*07:02:18/*07:02:19/*07:02:21/*07:02:22/*07:0
2:23/*07:02:24/*07:02:25/*07:02:26/*07:02:27/*07:02:29/*07:02:3
0/*07:02:31/*07:02:32/*07:02:33/*07:02:36/*07:02:37/*07:02:38/
*07:02:39/*07:05/*07:13/*07:27:01/*07:29/*07:31:02/*07:38:01/*
07:38:02/*07:39/*07:42/*07:46/*07:47/*07:48/*07:50/*07:51/*07:
54/*07:56:01/*07:56:02/*07:61N/*07:62/*07:66/*07:72/*07:74/*0
7:75/*07:80/*07:84/*07:85/*07:87/*07:88/*07:90/*07:97/*07:99/*
07:100/*07:105/*07:117/*07:123/*07:125/*07:126/*07:130/*07:13
3/*07:135/*07:137:01/*07:137:02/*07:143/*07:144/*07:145/*07:1
46/*07:147/*07:152N/*07:155/*07:157/*07:159/*07:160/*07:163/
*07:167/*07:168/*07:169/*07:172/*07:174/*07:175/*07:178/*07:1
83/*07:185/*07:187/*07:192/*07:193/*07:195/*07:198N/*07:202/
*07:208/*07:209/*07:211/*07:213/*07:217/*07:218/*07:221/*07:2
25/*07:226/*07:229/*07:234/*07:239/*07:240/*07:243/*07:244/*
07:245/*07:251/*07:252/*07:258/*07:259/*07:261/*07:262/*07:27
0/*07:273/*07:274/*07:275/*07:283/*07:284/*07:286/*07:287/*0
7:288/*07:289/*07:290/*07:291/*07:292 
 
C*07:01 
(0.16658) 
C*07:02 
(0.15006) 
Table 4.1 Example of HLA alleles predicted from a medium resolution HLA type. Alleles were 
predicted from the same historical HLA result based on either the first allele in the HLA string or 
the most frequent allele, defaulted to second field. The respective allele frequencies are shown 
in parentheses (Maiers, Gragert and Klitz, 2007). Predicted allele(s) are underlined in bold in 
the historical HLA string. 
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Figure 4.2 shows the number and type of discrepancies observed for each HLA locus. The 
dominant discrepancy for HLA-A, using the ‘first allele in the string’ algorithm was observed in 
29 samples typed originally as an HLA-A*29 string by Luminex, resulting in an allele prediction 
of A*29:01, but where the NGS result was determined as A*29:02. However, this discrepancy 
was not observed when utilising frequency data for allele prediction. Conversely, when using 
allele frequencies, the opposite occurred in three samples, where NGS typed as HLA-A*29:01 
but the most frequent and therefore predicted allele was actually HLA-A*29:02. For HLA-B, the 
most common discrepancy was the incorrect prediction of B*44:02 instead of B*44:03. This 
disparity between predicted HLA allele and NGS result was observed in 17 samples using either 
algorithm, as HLA-B*44:02 was both the first allele and the most frequent in the respective 
HLA-B string.  
HLA-C had the highest allele prediction error of the three loci. The two most common 
discrepancies observed were between the predicted alleles HLA-C*07:01 and -C*03:02 and 
their respective NGS defined types of HLA-C*07:02 and -C*03:04. The HLA-C*03:02 vs C*03:04 
prediction error was observed in 30 samples when using the first allele in the string. However, 
this discrepancy was resolved using allele frequency data, as HLA-C*03:04 is more common 
than HLA-C*03:02 with a frequency of 8.215% compared to 0.146%, respectively. Thirty four 
samples were incorrectly predicted to be HLA-C*07:01 rather than -C*07:02 using either 
algorithm due to C*07:01 being both the first allele in the string and the most frequent HLA-
C*07 allele. 
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Figure 4.2 Discrepant alleles observed and number of samples affected.  The discrepancies 
observed between the HLA type determined by NGS and the predicted allele.  The number of 
samples affected by the respective prediction errors are shown in graph (A) for HLA-A, (B) for 
HLA-B and (C) for HLA-C. 
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4.3.2 Ethnicity and allele predictions 
Allele prediction based on HLA frequencies employed data obtained from the American 
Caucasian population (Maiers, Gragert and Klitz, 2007).  However, because allele frequencies 
are known to differ between ethnic groups (Dyer, 1988), the donor ethnicity was interrogated 
for all samples indicating prediction errors using the allele frequency algorithm. In cases where 
the ethnicity was other than white, HLA frequency data was further scrutinised using EpHLA 
converter  (Sousa,Luiz Cláudio Demes da Mata et al., 2011) to determine whether the allele 
prediction would have changed when considering the ethnic origin of the donor.  
Although 13 of the 75 samples with prediction discrepancies using the allele frequency 
algorithm came from donors with a self declared ethnicity that was not Caucasian, only three 
predictions would have changed if donor ethnicity was considered (Table 4.2). Allele prediction 
for the other nine samples remained the same, regardless of the donor’s ethnic origin. 
Historical HLA 
result 
Donor 
Ethnicity 
Predicted allele: 
Caucasian frequency 
data≠ 
Predicted allele: 
Donor ethnicity 
frequency data≠ 
NGS result  
A*29 allele string Asian A*29:02 A*29:01 A*29:01:01 
C*07 allele string Chinese C*07:01 C*07:02 C*07:02:01:01 
C*15 allele string Black C*15:02 C*15:05 C*15:05:02 
Table 4.2 Impact of donor ethnicity on HLA allele prediction using population frequencies. 
Three occurrences where the allele prediction using HLA frequency data based on the donor’s 
ethnicity differed to that using Caucasian frequencies ≠frequency data obtained from (Maiers, 
Gragert and Klitz, 2007) 
 
4.3.3 Haplotype frequencies and allele prediction 
In order to determine if using HLA haplotype frequencies would improve the accuracy of allele 
prediction, the most frequent errors observed for HLA-A and HLA-B when applying the allele 
frequencies algorithm for prediction were re-examined. Frequency data employed was based 
on haplotypes determined from a north west England cohort of 298 individuals (Alfirevic et al., 
2012), obtained from www.allelefrequencies.net, selected because it was the largest English 
population with haplotype frequencies available. Each HLA type affected was reviewed and the 
most frequent haplotype used to predict the allele from the historical HLA strings. As when 
employing allele frequencies, all results were considered at second field resolution only. For 
the three samples typed as HLA-A*29:01 by NGS but predicted to be the more frequent allele 
HLA-A*29:02, no additional benefit was gained by using haplotype frequency data. Two 
contained presumed haplotypes that indicated the presence of HLA-A*29:02 and the third 
sample did not appear to contain a haplotype including HLA-A*29 that was present in the 
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North West England cohort. Therefore allele prediction based on haplotype frequencies was 
not possible for this sample (Table 4.3) 
Sample 
ID 
Historical HLA-A type Presumed haplotype and predicted HLA-
A*29 allele 
6883 A*01,*29; B*44,*57; C*06,*16 A*29:02-B*44:03-C*16:01 
711N A*11,*29; B*07,*55; C*03,*07 A*29:02-B*07:02-C*03:03 
0993 A*02,*29; B*07,*07; C*07,*15 N/A 
Table 4.3 Prediction of HLA-A*29 alleles from presumed haplotypes. The HLA type of each 
sample is displayed as first field for presentation purposes only, with the presumed haplotype 
shown in red; prediction was based on historical medium resolution HLA typing. The predicted 
haplotype and respective HLA-A*29 allele for each sample were based on the most frequent 
haplotypes found in North West England (Alfirevic et al., 2012). N/A = no haplotype  data 
available 
 
Using haplotype data proved more accurate than allele frequencies alone for samples typing as 
HLA-B*44:03 but predicted as the more frequent HLA-B*44:02. Twelve of the seventeen 
samples affected (70.5%) were correctly predicted as HLA-B*44:03 when employing haplotype 
data. It was not possible to predict the HLA-B*44 allele for the remaining five samples as there 
was no appropriate haplotype present in the west English cohort (Table 4.4) 
Sample ID Historical HLA-A type north Presumed haplotype and predicted 
HLA-B*44 allele 
614X A*02,*02; B*27,*44; C*01,*04 N/A 
496J A*02,*23; B*27,*44; C*02,*04 A*23:01-B*44:03-C*04:01 
6891 A*02,*23; B*27,*44; C*02,*04 A*23:01-B*44:03-C*04:01 
152P A*02,*24; B*27,*44; C*02,*04 N/A 
1927 A*01,*29; B*44,*57; C*06,*16 A*29:02-B*44:03-C*16:01 
642O A*01,*23; B*44,*52; C*04,*12 A*23:01-B*44:03-C*04:01 
753C A*02,*23; B*15,*44; C*04,*04 A*23:01-B*44:03-C*04:01 
2201 A*02,*32; B*44,*56; C*01,*16 A*02:01-B*44:03-C*16:01 
6883 A*01,*29; B*44,*57; C*06,*16 A*29:02-B*44:03-C*16:01 
597T A*26,*30; B*13,*44; C*06,*16 N/A 
871X A*23,*29; B*44,*44; C*04,*16 A*23:01-B*44:03-C*04:01 
A*29:02-B*44:03-C*16:01 
078E A*02,*29; B*35,*44; C*04,*16 A*29:02-B*44:03-C*16:01 
188N A*32,*32; B*27,*44; C*01,*04 N/A 
021F A*02,*23; B*40,*44; C*03,*04 A*23:01-B*44:03-C*04:01 
629B A*02,*23; B*15,*44; C*04,*07 A*23:01-B*44:03-C*04:01 
793D A*24,*31; B*14,*44; C*04,*08 N/A 
494J A*01,*23; B*44,*57; C*04,*06 A*23:01-B*44:03-C*04:01 
Table 4.4 Prediction of HLA-B*44 alleles from presumed haplotypes. The HLA type of each 
sample is displayed as first field for presentation purposes only, with the presumed haplotype 
shown in red; prediction was based on historical medium resolution HLA typing. The predicted 
haplotype and respective HLA-B*44 allele for each sample were based on the most frequent 
haplotypes found in north west England (Alfirevic et al., 2012). N/A = no haplotype data 
available 
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4.3.4 Impact of HLA allele prediction errors 
For each prediction error, the number of potential epitope mismatches between the two 
alleles was determined, with results summarised in Figure 4.3. Of the 25 different predicted 
allele discrepancies identified, 10 (40%) were found not to differ at the epitope level. Of the 
remaining 15 mismatched allele pairs, only two mismatched alleles (both HLA-C) were found to 
have mismatches with antibody verified epitopes. However, one of these (HLA-C*07:02 vs. 
C*07:01) was the most frequently observed discrepancy, with 34 donors affected. This 
mismatched pair also had five other epitope mismatches, four of which were in exposed 
regions of the HLA molecule.  
 
Figure 4.3 Number and type of epitope mismatches between NGS type versus predicted HLA 
allele. For those mismatched pairs, epitope mismatches have been catagorised into antibody 
verified, exposed and non-exposed epitopes. 
 
Overall, 40% of prediction errors were found to have mismatches to exposed epitopes, with 
five, three and two mismatches determined at HLA-A, -B and -C, respectively. Eight (32%) 
predicted allele discrepancies also had mismatches to inaccessible epitopes. The epitopes 
mismatched between each predicted allele versus NGS-defined type are listed in Table 4.5. 
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NGS vs. predicted allele  Antibody verified 
epitopes 
Exposed epitopes Inaccessible epitopes 
A*02:11 vs. A*02:01  73ID   
A*24:03 vs. A*24:02  163TEW   
A*24:07 vs. A*24:02  69AQT; 70QT; 
71QS 
  
A*29:02 vs. A*29:01  102DV   
A*33:03 vs. A*33:01  170RY   
B*13:02 vs. B*13:01    94TW; 97T 
B*18:03 vs. B*18:01  72QTD; 73TDE   
B*35:05 vs. B*35:01    94TL; 97S 
B*39:06 vs. B*39:01     94TW; 97T 
B*40:06 vs. B*40:04   102DV 94TW; 97T 
B*44:03 vs. B*44:02   156LA 156L 
C*03:04 vs. C*03:02     94II; 116Y 
C*07:02 vs. C*07:01 65QKR+76VS 62RK; 63EK; 
65QKR; 66K 
99S 
C*15:05 vs. C*15:02     116F 
C*16:02 vs. C*16:01 80K; 80K+14R 71ATN; 73TN; 
73TVN 
 
Table 4.5 Mismatched epitopes for each allele prediction discrepancy observed. Epitopes for 
each mismatch were obtained from the ABC database located within the International Registry 
of Antibody-Defined HLA Epitopes (Duquesnoy et al., 2013a). 
 
4.4 Discussion 
Apheresis platelet donors recruited by NHSBT are currently HLA typed using Luminex PCR-
SSOP technology (Brown and Navarrete, 2011) which defines HLA to medium resolution, 
reporting ambiguous results in the form of allele strings (Marsh et al., 2010). However, to 
accurately employ HEM for the selection of platelets for patients with immune platelet 
refractoriness, HLA needs to be defined at high resolution (Duquesnoy, 2008). Previous studies 
investigating HEM for platelet selection have reported using HLA allele predictions from the 
Luminex results as an alternative to allele level typing (Brooks, MacPherson and Fung, 2008; 
Pai et al., 2010; Nambiar et al., 2006). This chapter investigated the accuracy of HLA allele 
prediction when compared to typing by NGS. 
4.4.1 Accuracy of allele prediction 
The prediction algorithm programmed in the NHSBT LIMS system Hematos, is currently based 
on the first allele contained within an HLA string when an allelic type is unavailable. Results 
from this study demonstrate the inherent inaccuracy of this approach, producing an overall 
error rate of 11.1%. In 2015, NHSBT provided 19,493 doses of HLA selected platelets. Based on 
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this data, if HLA epitope matching had been exploited, HLA type predictions would have been 
incorrect for 2,163 units if the first allele of the Luminex string was used to determine the HLA 
type and defining epitopes. However, this error rate reduces to 4.9%, equivalent to 961 doses 
of HLA selected platelets, when using HLA frequencies from Caucasian populations to predict 
the high resolution type. 
The high discrepancy rate for predicted versus NGS allele using the first allele in the string 
algorithm was due to the first allele being the less common HLA allele, although this varied 
dependant on donor ethnicity. For example, the HLA-A*29 string shown in table 4.2 contained 
A*29:01:01:01 as the first allele in the string but in the Caucasian population HLA-A*29:02 is 
more common than HLA-A*29:01, with a frequency of 3.28% compared to 0.15%, respectively 
(Maiers, Gragert and Klitz, 2007). This resulted in 29 donors predicted to be A*29:01 when 
they were actually A*29:02. Conversely, when alleles were predicted based on population 
frequencies, the majority of predictions were accurate. Of the three samples that did type by 
NGS as A*29:01, one donor self declared as Asian and would have been predicted correctly if 
ethnicity was considered alongside allele frequencies, as A*29:01 is more common in the Asian 
population than A*29:02 (Maiers, Gragert and Klitz, 2007). The other two donors were 
recorded as Caucasian so the prediction would have remained unchanged. However, it is 
worth noting that studies exploring ancestral informative markers question the reliability of 
self-declared ethnicity as indicators of genomic ancestry (Ramos et al., 2016; Cardena et al., 
2013). 
Even when the most frequent allele appears to be the first in the Luminex string, errors still 
occurred. For example, the allele B*44:02 from a HLA-B*44 string was incorrectly predicted in 
17 donors using either algorithm rather than B*44:03, as determined by NGS. HLA-B*44:02 is 
the more common B*44 allele, being nearly twice as frequent in Caucasians as HLA-B*44:03 
(Maiers, Gragert and Klitz, 2007). However, the Luminex string began with B*44:02:11 which, 
based on the NGS data obtained from this cohort, is not a common allele in the English 
population; none of the 540 donors typed as B*44:02:11 but over 100 donors sequenced as 
either B*44:02:01:01 or B*44:02:01:03 by NGS. A similar error also occurred with a Luminex 
HLA-C*07 string, where the first allele in the string was C*07:01:25 but NGS typed as 
C*07:02:01:01 or C*07:02:01:03, with both prediction algorithms calling the discrepant 
C*07:01 allele, being both the allele first in the string and the most frequent at second field 
(Maiers, Gragert and Klitz, 2007). If the third field result had been considered in either case, 
prediction based on allele frequencies would have been correct the majority of the time but 
unfortunately the EpHLA converter software only provided frequency data at second field 
(Sousa,Luiz Cláudio Demes da Mata et al., 2011). The Allele Frequencies Net Database (Santos 
et al., 2016) does contain some population data at third or fourth field but a decision not to 
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utilise this information was based on the populations included (none were from the UK or 
Northwest Europe) and or the small cohort when compared to data available from EpHLA 
converter, which is based on over 6000 European Americans (Maiers, Gragert and Klitz, 2007). 
A recent publication reporting common and well-documented HLA alleles in Europe was also 
consulted but this reference defaulted frequency data to second field (Sanchez-Mazas et al., 
2017). 
The use of haplotype frequencies was investigated to determine if this was a more accurate 
approach for prediction of HLA alleles compared to using allele frequency data. Due to the 
complexity of the analysis, which was performed manually, only a small data set was examined 
for the purposes of this study. Consequently, investigation was restricted to the most frequent 
prediction errors for HLA-A and HLA-B only. Use of haplotype frequencies did not prove useful 
for the HLA-A*29 prediction error. This may have been by chance, as only three samples were 
affected and otherwise using HLA-A allele frequency data only proved reliable in most cases. 
However, for the HLA-B*44 prediction error example, haplotype analysis proved to be 
significantly more accurate than using allele frequencies, with over two thirds of prediction 
errors resolved. 
Haplotype frequency data used was obtained from a North West English population, although 
it is acknowledged the cohort was small, consisting of less than 300 individual HLA types. It 
might have been more appropriate to use a similar data source as used for HLA allele 
frequencies (i.e. American Caucasians data). However, although this cohort included HLA types 
from over 1.2 million bone marrow donors available from www.allelefrequencies.net, there 
were a very limited number of haplotypes at second field compared to the North West England 
population (Santos et al., 2016) and was therefore less informative.  
Despite the limited data set examined, use of haplotype frequencies does appear to provide 
accurate allele prediction, certainly for HLA-B*44. This approach for allele prediction is 
supported by Geneugelijk et al. who recently reported development of PIRCHE II software, 
designed to estimate risk of solid organ transplants based on HLA epitopes. PIRCHE II requires 
high resolution HLA types to accurately analyse risk and has embedded algorithms that convert 
low resolution types into HLA alleles using haplotype frequencies (Geneugelijk et al., 2017). 
However, despite the stated reliability of PIRCHE II estimations, the group acknowledged that 
this approach was not suitable for all donor-recipient pairs. They suggest that additional NGS-
based data is required for determining HLA haplotype frequencies, particularly if sequences 
are extended beyond exons 2 and 3 for HLA class I alleles, leading to more reliable epitope 
matching (Geneugelijk et al., 2017). However, use of NGS for HLA typing donors and recipients 
would completely negate the need for HLA allele prediction.  
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4.4.2 Impact of prediction errors 
Twenty five HLA allele predictions were found to be incorrect, affecting 209 HLA types at HLA-
A, -B or -C when using the first in the HLA string algorithm, compared to 75 HLA types when 
alleles were determined from HLA frequency data.  
Following interrogation of the International Registry of Antibody-Defined HLA epitopes 
(Duquesnoy et al., 2013b), forty percent of the allele prediction errors did not translate to 
epitope mismatches. A proportion of these were found to have mismatches within HLA ‘G 
groups’, such as HLA-C*07:01, -C*07:06 and -C*07:18, where nucleotide sequences are 
identical in exons 2 and 3 of the respective gene that encodes the peptide binding domain of 
the HLA molecule (Marsh et al., 2010). Others lacked epitope data for a particular HLA allele, 
including HLA-B*18:40 and HLA-C*08:92 and in these cases it is possible epitope mismatches 
were present but have not yet been defined. Although the HLA Epitope Registry is regularly 
updated, its curators admit that data is incomplete and acknowledge the need for more 
studies (Duquesnoy et al., 2016). The two HLA-A prediction errors, namely A*02:07 vs. A02:01 
and A*33:05 vs. A*33:01 appear to have identical epitopes, despite amino acid differences in 
the 1 and 2 domain protein sequence (Robinson et al., 2015). The one other example of 
zero epitope mismatches was due to the presence of HLA-C*04:09N instead of the predicted 
HLA-C*04:01 allele. As a null allele, HLA-C*04:09N would result in lack of expression of the HLA 
molecule on the cell surface so any donor specific antibodies present would not give cause for 
concern if a donor with this type was transfused into a patient with antibodies to epitopes 
expressed on HLA-C*04:01 (Wang et al., 2002). 
Sixty percent of prediction errors would have resulted in epitope mismatches if they had been 
subsequently used to select platelets for transfusion. The majority of epitope mismatches 
identified were against exposed regions of the HLA molecule and are potentially clinically 
relevant being in antibody-accessible regions, although only three were antibody verified 
epitopes (Duquesnoy, 2014).  The most frequently observed example of epitope mismatching 
using either algorithm resulted from the prediction of HLA-C*07:01 instead of -C*07:02, 
affecting 34 donors (6.7% of the cohort). HLA-C is not generally currently considered when 
using HLA match grading to select platelets for refractory patients as the relevance of HLA-C 
antibodies in platelet refractoriness is still undetermined (Stanworth et al., 2015). However, 
two of the six epitopes mismatched between HLA-C*07:01 and -C*07:02, namely 62EK and 
66K, are also present on common HLA-A antigens such as HLA-A2 ((Duquesnoy, 2014). It is 
therefore important to consider all HLA class I compatibility when using HEM (Duquesnoy, 
2017). Even if HLA-C antigens prove less relevant in platelet transfusion, antibodies to HLA-C 
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epitopes may still cross react with those expressed by HLA-A and or HLA-B and thus could be 
clinically relevant. Indeed, Lomago and colleagues reported a case of an HLA-C*07:04 induced 
alloantibody cross reacting with shared epitope 156DA expressed by HLA-B*44:02 in a renal 
transplant recipient typing as HLA-B*44:03 who had never been exposed to HLA-B*44:02 
leading to an episode of acute cellular rejection (Lomago et al., 2010). Others have similarly 
postulated antibody mediated rejection can result from shared epitopes with the immunising 
antigen (Mongkolsuk et al., 2014).  
The most frequent HLA-B prediction error affected 17 donors, with two epitope mismatches 
between B*44:02 and the NGS defined allele B*44:03, although only one of the two 
mismatches was against exposed epitopes. For HLA-A, the most frequent discrepancy was 
between A*29:02 and A*29:01, with just one exposed epitope mismatch between the two 
alleles. The second most common HLA-C prediction error, with C*03:02 predicted instead of 
C*03:04, occurred in 30 donors using the first allele in the string algorithm. However, the two 
epitope mismatches between these alleles appear inaccessible to antibody. The clinical 
relevance of such non-exposed epitopes is questionable, but it has been suggested that 
because they reside in the peptide binding groove these polymorphic positions may affect the 
conformation of adjacent residues leading to the creation of antibody-recognisable epitopes 
(Duquesnoy et al., 2014). However it is not clear whether such positions would be 
immunogenic (Duquesnoy, 2014). 
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5. HLA frequencies and population analysis 
5.1 Introduction 
As discussed in Chapter 4, there is a lack of HLA allele and haplotype frequency data available 
beyond second field resolution in the English population. Limited frequency data can prevent 
accurate allele prediction from HLA types defined at a lower resolution (Geneugelijk et al., 
2017).  In addition, the availability of HLA frequencies at the allele level will provide useful data 
to the wider community, including the investigation of HLA allele associations with adverse 
drug reactions and in anthropology studies (Gonzalez-Galarza et al., 2015b). HLA frequency 
data can also provide estimates for the likelihood of finding an HLA compatible donor in the 
transplantation and transfusion settings (Pingel et al., 2013). 
NGS has the capability of HLA typing to the allele level (Erlich, 2015) and a protocol was 
developed and used to type 540 English apheresis platelet donors, as described and discussed 
in Chapter 3. The aim of this part of the study was to determine the HLA allele and haplotype 
frequencies of the platelet donor cohort based on HLA types obtained by NGS. Results from 
this analysis would then be submitted to an international database that stores allele 
frequencies from polymorphic areas in the human genome (Gonzalez-Galarza et al., 2015b).  
However, as the initial sequencing only produced complete HLA-A, -B and -C genotypes for 441 
(81.7%) donors, a decision was taken to re-sequence as many samples as possible that had 
previously failed for one or more HLA locus. This was to ensure that the maximum number of 
samples was included in the frequency data analysis. In addition, because some of the rejected 
sequences described in Chapter 3 were associated with particular alleles or allele groups, 
resolution was necessary to avoid skewing frequency analysis by excluding particular allele 
groups with poor sequence data. All sequences containing putative mutations in the first 
round of NGS typing were also repeated to confirm the presence of novel sequences. 
 
5.2 Materials & Methods 
HLA Typing was performed on DNA obtained from 540 apheresis platelet donors, as described 
in Chapter 3. Collected at English blood donor centres, the individuals in this cohort were of 
fixed ethnicity, with the majority (91.1%) of donors self declaring as white (Figure 5.1). In order 
to produce sufficient data for determining valid HLA allele and haplotype frequencies in this 
cohort, samples that originally failed to type for one or more HLA locus and those containing 
putative novel mutations were re-sequenced. 
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Figure 5.1 Self-declared ethnicity of the 540 apheresis platelet donors HLA typed in this study. 
 
5.2.1 Confirmatory sequencing of samples with putative novel mutations 
5.2.1.1 Sample selection 
From the original results described in Chapter 3, a total of 45 samples were identified as 
containing putative novel mutations in one or more HLA sequence that was otherwise valid. 
Fifty micolitres of each DNA was transferred from their original plates into a clean 96-well 
plate (#RPT1) using a bespoke cherry-picking program designed for the epMotion® 5075 liquid 
handling robot (Eppendorf).  
5.2.1.2 DNA preparation, PCR amplification and amplicon pooling 
DNA was purified manually using AMPure beads as previously described. However, due to the 
low DNA concentrations observed following the original DNA purification, it was decided not to 
normalise the DNA but use it neat. PCR amplifications for HLA-A, -B and -C were then set up for 
all 45 samples using the in-house PCR protocol, as described in 2.6.1.2. Success of amplification 
was determined by agarose gel electrophoresis (section 2.6.2.1), followed by pooling of 7µl of 
each amplicon into respective wells of a clean plate. 
5.2.1.3 Library preparation and sequencing 
Pooled amplicon was prepared for sequencing using the NGSgo® protocol as described in 
2.6.3.2. The PAL was assessed using both the Qubit and Bioanalyser and subsequently 
denatured and diluted before loading onto the MiSeq and sequencing using 2 x 251 chemistry 
(section 2.6.6). 
White Asian  Black Chinese Mixed Other Unknown 
% donors 91.1% 2.1% 0.2% 0.2% 1.5% 0.4% 4.5% 
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5.2.2 Re-sequencing of samples with HLA types previously rejected 
5.2.2.1 Sample selection 
Eighty nine samples that previously failed to sequence for one or more HLA locus had sufficient 
DNA remaining for re-sequencing. Fifty micolitres of each DNA sample was transferred from 
their original plates into a clean 96-well plate (#RPT2) using the epMotion® 5075 liquid 
handling robot as described in 5.2.1.1. 
5.2.2.2 DNA preparation, PCR amplification and amplicon pooling 
DNA was purified on the Biomek FX liquid handling robot using AMPure beads as previously 
described and neat purified DNA was used to set up PCR amplifications for HLA-A, -B and -C 
using in-house PCR. Success of amplification was determined using agarose gel electrophoresis 
and was followed by the pooling of 7µl of amplicon from each HLA locus into respective wells 
of a clean plate. 
5.2.2.3 Library preparation and sequencing 
Pooled amplicon was prepared for sequencing using the TruSightHLA protocol, as described in 
2.6.3.1. This approach was selected because, at the time this experiment was performed, the 
Illumina library preparation kits were in routine use at NHSBT. The TruSightHLA protocol was 
initiated on a Biomek FX robot but due to a power interruption during the amplicon 
normalisation step, the remainder of the method was performed manually. To ensure that 
library preparation had not been adversely affected by failure of the robotics, the PAL was 
assessed using both the Qubit and Bioanalyser.  Following denaturation and dilution of the 
PAL, sequencing was performed on the MiSeq as before but this time using 2 x 151 paired end 
sequencing on a standard flow cell, which was cheaper and quicker than the 2 x 251 chemistry 
used previously and had been shown by the routine laboratory to provide acceptable results. 
5.2.3 Sequence data analysis 
FASTQ files generated by MSR were analysed using NGSengine v2.1, IMGT/HLA 3.24. Samples 
with remaining intron or exon mismatches were subsequently reanalysed following the later 
release of NGSenginev2.4 in January 2017, to check against sequences from IMGT/HLA v3.26. 
Analysis preferences were as described in section 2.6.7 and success of sequencing was 
determined using the acceptance criteria discussed in Chapter 3. 
5.2.4 Population data analysis 
5.2.4.1 HLA allele frequencies 
Allele frequencies for HLA-A, -B and -C were calculated from data obtained from 519 donors 
sequenced. Frequencies were determined at third field only and calculated by direct counting. 
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5.2.4.2 HLA haplotype frequencies 
Arlequin software v3.5, an integrated software package for population genetics analysis 
(Excoffier and Lischer, 2010), was employed to determine both HLA haplotype frequencies and 
calculate Hardy-Weinberg equilibrium (HWE). Haplotype frequencies were estimated using the 
expectation-maximum algorithm and the exact test using the Markov chain method (Guo and 
Thompson, 1992) was used for HWE, as recommended in the Arlequin35 user guide. HLA allele 
frequencies were also subsequently confirmed using Arlequin. 
 
5.3 Results 
5.3.1 Repeat amplifications 
Agarose gel electrophoresis indicating successful amplification was achieved for the majority of 
samples, based on an aliquot of each amplicon taken from the first and last rows of each 
repeat plate. Although the molecular weight marker was mistakenly omitted from the gel, all 
visible bands were of the same size and intensity indicating a successful amplification for all 
but one sample (Figure 5.2). 
 
 
 
Figure 5.2 Gel images of amplicons taken from the first and last row of each repeat plate. 
Image (A) shows amplicons from plate #RPT1 taken from row 1 and row 6 of each plate for 
HLA-A, -B and –C. (B) shows amplicons from plate #RPT2, taken from row 1 (wells 1 to 8) and 
row 12 (rows 89-96) of each plate for HLA-A, -B and -C. Note that for each row 12, a PCR 
product was only expected in lane 89. All wells contain a visible band of the same size, except 
for sample taken from well 1 of the HLA-A second repeat plate (white arrow) where no band 
was present. Note that no molecular weight markers were run. 
A 
B 
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5.3.2 Sequencing libraries 
Bioanalyser results indicated that each library was an acceptable size, with an average of 
1781bp and 1323bp obtained for plates #RPT1 and #RPT2, respectively. The first plate #RPT1 
had a slightly higher concentration of 3.7ng/µl when compared to 2.7ng/µl obtained for plate 
#RPT2, with both values determined using the Qubit. The cluster density achieved on the flow 
cell was similar for each MiSeq run, with 1251 K/mm2 and 1361 K/mm2 for #RPT1 and #RPT2, 
respectively.  The percentage of clusters passing the filter was 83% for both sequencing 
experiments. 
5.3.3 HLA sequencing results 
5.3.3.1 Confirmatory sequences of samples with putative novel mutations 
All 45 samples with previously identified novel sequences were successfully retyped for HLA-A, 
-B and -C. The average read depth was 1985bp (range 225-4391bp) with a mean insert size of 
419bp (range 307-563bp) with an average of 90% of sequences mapping to reference data. 
Nine of the 45 samples were subsequently resolved for all HLA loci due to the designation of 
new HLA alleles since the original sequencing was performed, detailed in Table 5.1.  
Table 5.1 HLA alleles resolved following re-sequencing. HLA sequences containing nucleotide 
mismatches at the positions indicated that were subsequently resolved following re-sequencing 
and analysis with NGSengine v2.4.  
 
Of the remaining 36 samples, mutations were confirmed in 38 HLA sequences with three 
identified in exons, 20 in the intronic regions and 15 mutations located in the UTRs, 
summarised in Table 5.2. 
Locus Substitution Deletion Insertion 
HLA-A 12 1 0 
HLA-B 10 0 5 
HLA-C 10 0 0 
Table 5.2 Number of HLA sequences observed with novel mutations. Samples are shown 
according to HLA locus and the category of mutation observed. 
ID Original closest 
matched allele  
Position of mutation New allele designation 
S30 A*02:01:01:01 2798 A*02:01:01:08 
S10 A*31:01:02:01 2486 A*31:01:02:04 
S39 A*31:01:02:01 2486 A*31:01:02:04 
S17 B*08:01:01 2803 B*08:01:01:02 
S36 B*08:01:01 2803 B*08:01:01:02 
S41 B*15:01:01:01 2324 B*15:01:01:06 
S24 B*56:01:01:02 2988 B*56:01:01:03 
S23 B*56:01:01:02 2988 B*56:01:01:03 
S12 C*02:02:02:01 3005 C*02:02:02:03 
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Twenty seven of these 38 mutations were confirmed in fully phased sequences (Table 5.3) with 
the remaining sequences failing to separate completely into two alleles for the length of the 
respective genes due to poor phasing. Lack of sequence phase across an entire gene was 
generally observed when there were large regions of homozygous sequence between the 
defining heterozygous positions, as illustrated in Figure 5.3.  
 
ID Affected allele Nucleotide 
position of 
mutation 
Gene 
Location 
Expected 
nucleotide 
Observed 
nucleotide 
Mutation 
S6 A*01:01:01:01 1049 INT 3 C A Substitution 
S5 A*02:01:01:01 2949 UTR C T Substitution 
S8S2 A*02:05:01 657/670 INT 2 A/G G/T Substitution 
S7  A*11:01:01:01 -116 UTR A G Substitution 
S14  A*23:01:01 multiple INT 2 MULTIPLE - Deletion 
S43 A*23:01:01 -219 UTR T C Substitution 
S22  A*24:02:01:01 -17 UTR C T Substitution 
S22  A*29:02:01:01 2338 INT 5 C A Substitution 
S16  A*30:02:01:02 2922 UTR G C Substitution 
S31  A*68:02:01:01 2263/2266/2268 INT 5 T/A/C G/T/T Substitution 
S26 B*07:02:01 1426 INT 3 C T Substitution 
S21  B*08:01:01:01 1051 INT 3 C T Substitution 
S11  B*18:01:01:02 3010.2 UTR - C Insertion 
S28  B*44:02:01:01 -31 UTR A/A C/C Substitution 
S20  B*51:01:01:01 666 INT 2 C T Substitution 
S45  B*51:01:01:01 666 INT 2 C T Substitution 
S18  B*51:01:01:01 2978 UTR T C Substitution 
S3  B*51:01:01:01 2978 UTR T C Substitution 
S33  B*51:01:01:01 2289 INT 5 C G Substitution 
S34 C*03:03:01:01 2568 EX 6 G A Substitution 
S29 C*03:04:01:01 1810 EX 4 T A Substitution 
S46  C*05:01:01:02 1505 INT 3 C A Substitution 
S9 C*05:01:01:02 3057 UTR C T Substitution 
S32  C*06:02:01:01 2426 INT 5 G T Substitution 
S13  C*07:02:01:01 -44 UTR T C Substitution 
S25 C*07:02:01:03 189 INT 1 C T Substitution 
S37  C*08:02:01:01 1117 INT 3 G C Substitution 
Table 5.3 Novel HLA alleles with fully phased sequences. Details of the mutations observed for 
each fully phased novel allele detected, including gene location, change to nucleotide sequence 
and mutation category. 
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Figure 5.3 Example of sequence containing a novel mutation with lack of phase. The novel 
mutation is marked with the blue triangle but, due to large homozygous regions between the 
heterozygous positions (circled in black), this sequence is not fully phased across the gene. Lack 
of phase is illustrated by the parallel grey lines between the heterozygous positions. 
 
5.3.3.2 Impact of Exon mutations 
Of the three sequences identified with novel exon mutations, two would result in changes to 
amino acid sequence when compared to the reference sequence, with the third being a 
synonymous substitution (Table 5.4).  
Allele Substitution Position Exon Codon change Amino acid change 
B*15:10:01 G>A 42 1 TCG>TCA Ser>Ser 
C*03:03:01:01 G>A 2568 6 GCG>ACG Ala>Thr 
C*03:04:01:01 T>A 1810 4 TGC>AGC Cys>Ser 
 Table 5.4 Effect of nucleotide substitutions for the three novel exon mutations identified.  
 
5.3.3.3 Re-sequencing samples with HLA types previously rejected 
A total of 239 of the 267 sequences performed met the acceptance criteria, resulting in 74 
(89.5%) samples producing a valid allele level type for HLA-A, -B and -C with the remaining 15 
samples having sequences rejected for one or more HLA locus (Figure 5.4). The majority of 
sequences in plate #RPT2 were rejected due to lack of phase, with an average of 12 phased 
regions per sequence, resulting in ambiguous allele assignment. Many of the accepted 
sequences were also poorly phased, with six phased regions per sequence on average (Figure 
5.5), despite a mean coverage depth of 1080bp.  
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Figure 5.4 The percentage of sequences rejected for each HLA locus in plate #RPT2. Results 
are presented according to HLA locus. 
 
 
Figure 5.5. The number of phased regions observed for sequences in plate #RPT2. Results are 
presented according to quality of sequence, with the mean value represented by the triangle 
 
Sequences that were rejected consisted of smaller fragments, although the mean insert size 
was not markedly difference from the valid sequences, with a mean of 345bp and 372bp, 
respectively. Of note was the uneven coverage observed in sequences from plate #RPT2 
(Figure 5.6), suggesting that sequences were either missing or they had failed to map correctly 
in regions with low sequencing depth. As the average mappability of sequences in both 
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accepted and rejected sequences were similar (82.8% and 80.6%, respectively), it suggested 
that sequences in the regions of low coverage had not been generated. 
 
 
Figure 5.6 An example of uneven coverage and the resulting poor phasing across the gene. 
Uneven coverage observed in a sample from sequencing run #RPT2. Phased regions are 
indicated by the solid red line, with grey lines in between representing regions with incomplete 
phasing, particularly noticeable in regions of low coverage. 
 
 
5.3.4 Population data analysis 
From the starting cohort of 540 donors, a total of 519 samples produced valid sequences for 
HLA-A, -B and -C, either during the original experiments described in Chapter 3 or in the re-
sequence data detailed above. Data from 21 samples were excluded from population analysis 
due to incomplete HLA sequence information for reasons summarised in Table 5.5.  
 
Reasons for exclusion 
 
No. of samples 
Insufficient DNA for repeat 7 
All HLA loci failed  3 
HLA-A failed  1 
HLA-B failed  6 
HLA-C failed  4 
Table 5.5 Reasons for exclusion of donors from the population data analysis. 
 
Due to the high number of sequences with one or more mismatches to the reference intron 
data, allele frequencies were determined at third field only, listed in Table 5.6. 
 
 
 
 
 
 
Coverage 
Phasing 
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HLA-A type Freq % 
individuals 
HLA-B type Frequency % 
individuals 
HLA-C type Frequency % 
individuals 
A*01:01:01 0.2062 37.38% B*07:02:01 0.1329 25.43% C*01:02:01 0.0250 5.08% 
A*02:01:01 0.3035 50.48% B*07:05:01 0.0010 0.19% C*02:02:02 0.0424 8.59% 
A*02:03:01 0.0010 0.19% B*08:01:01 0.1339 25.63% C*02:10 0.0010 0.20% 
A*02:05:01 0.0067 1.35% B*13:02:01 0.0231 4.62%  C*03:02:02 0.0019 0.39% 
A*02:06:01 0.0029 0.58% B*14:01:01 0.0116 2.31% C*03:03:01 0.0655 13.28% 
A*02:07:01 0.0010 0.19% B*14:02:01 0.0260 5.01% C*03:04:01 0.0838 15.82% 
A*02:11:01 0.0039 0.77% B*15:01:01 0.0684 13.49% C*04:01:01 0.0857 16.80% 
 A*02:13 0.0010 0.19% B*15:02:01 0.0010 0.19%  C*04:09N 0.0019 0.39% 
A*03:01:01 0.1320 24.86% B*15:03:01 0.0010 0.19% C*05:01:01 0.1060 21.09% 
A*03:02:01 0.0010 0.19% B*15:16:01 0.0010 0.19% C*06:02:01 0.1002 18.55% 
A*11:01:01 0.0578 11.37% B*15:17:01 0.0058 1.16% C*07:01:01 0.1618 30.86% 
A*23:01:01 0.0231 4.62% B*15:39:01 0.0019 0.39%  C*07:01:02 0.0048 0.98% 
A*24:02:01 0.0645 12.33% B*18:01:01 0.0270 5.39% C*07:02:01 0.1484 28.13% 
A*24:03:01 0.0010 0.19% B*18:03:01 0.0010 0.19%  C*07:04:01 0.0125 2.54% 
A*24:07:01 0.0010 0.19% B*18:40 0.0010 0.19% C*07:06 0.0029 0.59% 
A*25:01:01 0.0077 1.54% B*27:02:01 0.0010 0.19%  C*07:18 0.0067 1.37% 
A*26:01:01 0.0193 3.85%  B*27:03 0.0010 0.19%  C*08:01:01 0.0010 0.20% 
A*29:01:01 0.0010 0.19% B*27:05:02 0.0376 7.32% C*08:02:01 0.0356 6.45% 
A*29:02:01 0.0308 5.97% B*27:05:04 0.0019 0.39%  C*08:92 0.0010 0.20% 
A*30:01:01 0.0116 2.31% B*27:10 0.0010 0.19%  C*12:02:02 0.0106 2.15% 
A*30:02:01 0.0067 1.35% B*35:01:01 0.0491 9.44%  C*12:03:01 0.0202 4.10% 
A*30:04:01 0.0019 0.39% B*35:02:01 0.0019 0.39%  C*14:02:01 0.0087 1.76% 
A*31:01:02 0.0299 5.97% B*35:03:01 0.0048 0.96%  C*15:02:01 0.0270 5.27% 
A*32:01:01 0.0356 6.74% B*35:05:01 0.0010 0.19%  C*15:05:02 0.0010 0.20% 
A*33:01:01 0.0048 0.96% B*35:08:01 0.0029 0.58%  C*15:29 0.0010 0.20% 
A*33:03:01 0.0029 0.58% B*37:01:01 0.0212 4.05%  C*16:01:01 0.0356 7.23% 
 A*33:05 0.0010 0.19% B*38:01:01 0.0087 1.73%  C*16:02:01 0.0010 0.20% 
A*66:01:01 0.0029 0.58% B*39:01:01 0.0077 1.54%  C*16:04:01 0.0019 0.39% 
A*68:01:01 0.0077 1.54% B*39:06:02 0.0087 1.73%  C*17:01:01 0.0019 0.39% 
A*68:01:02 0.0193 3.47% B*40:01:02 0.0578 10.60%  C*17:03 0.0029 0.59% 
A*68:02:01 0.0087 1.73% B*40:02:01 0.0135 2.70%  1.0000  
 A*69:01 0.0010 0.19% B*40:06:01 0.0029 0.58%    
A*74:01:01 0.0010 0.19% B*41:01:01 0.0019 0.39%    
 1.0000  B*41:02:01 0.0029 0.58%    
   B*44:02:01 0.1098 21.39%    
   B*44:03:01 0.0549 10.79%    
   B*44:03:02 0.0029 0.58%    
   B*44:05:01 0.0029 0.58%    
   B*44:27:01 0.0019 0.39%    
   B*45:01:01 0.0048 0.96%    
   B*46:01:01 0.0010 0.19%    
   B*47:01:01 0.0010 0.19%    
    
B*49:01:01 
0.0145 2.89%    
    0.0039 0.77%    
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B*50:01:01 
   B*51:01:01 0.0424 8.29%    
   B*52:01:01 0.0096 1.93%    
   B*52:01:02 0.0010 0.19%    
   B*53:01:01 0.0039 0.77%    
   B*55:01:01 0.0250 5.01%    
   B*56:01:01 0.0019 0.39%    
   B*57:01:01 0.0462 8.86%    
   B*58:01:01 0.0087 1.73%    
    1.0000     
Table 5.6 HLA-A, -B and -C allele frequencies in English platelet donors. The HLA allele 
frequencies and the % of individuals containing each allele in a cohort of 519 samples collected 
from English apheresis platelet donors.  
 
A comparison of the three most frequent allele groups from each HLA locus showed similar 
frequencies observed in 400 healthy volunteers from North West England (Alfirevic et al., 
2012). However, this paper did not report unambiguous allelic level HLA types, so some alleles 
and their respective frequencies were grouped together according to their shorthand ‘G’ codes 
e.g. HLA-C*07:01:01, C*07:01:02, C*07:06 and C*07:18 as C*07:01g, which puts together HLA 
alleles with identical nucleotide sequences across exons 2 and 3 (Marsh et al., 2010), for 
comparison purposes (Figure 5.7) 
 
 
 
Figure 5.7 A comparison of the three most frequent HLA allele groups. Data is presented per 
locus by percentage frequency in English platelet donors with HLA frequencies reported by 
Alfirevic et al., 2012 in 400 healthy volunteers from North West England. 
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Haplotype frequency estimation determined a total of 1423 haplotypes, with 281 having a 
frequency of >0.05% in this population. The three most frequent haplotypes observed were 
HLA-A*01:01:01-B*08:01:01-C*07:01:01 (11.2%), HLA-A*02:01:01-B*44:02:01-C*05:01:01 
(6.6%) and HLA-A*03:01:01-B*07:01:01-C*07:02:01 (5.8%). When performed at third field 
resolution, HLA-A, -B and -C genotypes deviated from the expected Hardy-Weinberg 
equilibrium. However, when the typing resolution was reduced to the antigenic level, no 
significant deviation from HWE was observed, with the exception of HLA-B where the 
deviation is borderline (Table 5.7).  
 
HLA locus HWE – third field 
(p-value) 
HWE – first field 
(p-value) 
HWE – antigen level 
(p-value) 
HLA-A 0.00071 0.25938 0.56895 
HLA-B 0.00369 0.01432 0.04535 
HLA-C 0.02545 0.07630 0.07129 
Table 5.7  P-values observed for deviation from Hardy-Weinberg equilibrium (HWE). Results 
for HWE calculation are shown following analysis of HLA types at third field, first field and 
antigenic level of resolution 
 
 
5.4 Discussion 
Following the re-sequencing of samples that originally failed to produce an allele level type for 
HLA-A, -B and -C, the HLA allele and haplotype frequencies were determined for the platelet 
donor cohort HLA typed by NGS in this study.  
5.4.1 Outcome of re-sequencing 
The majority of samples were successfully re-amplified for HLA-A, -B and -C using the in-house 
PCR protocol, although because only a sample of amplicons were checked, it was not possible 
to determine the exact percentage of amplification success. Examining the first and last rows 
of each amplified plate of DNA by gel electrophoresis indicated that just one out of seventy 
five (1.3%) amplifications had failed, highlighting the robustness of this approach. 
The subsequent library preparation and sequencing was equally successful for the first plate, 
#RPT1, with all samples producing a sequence of acceptable quality. Unfortunately this was 
not the case with plate #RPT2, which generated sequences with uneven coverage resulting in 
poor phasing and low coverage across parts of the gene. This poor quality data was probably 
due to the failure of automation during the normalisation stage of the library preparation 
which is likely to have affected the amount of amplicon added to the subsequent tagmentation 
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step. Adding insufficient template into a tagmentation reaction is known to result in smaller 
fragments which can lead to coverage drop out (Illumina, 2015). Another possible explanation 
for the difference is that plate #RPT2 used 2 x 150bp chemistry compared to the 2 x 250 cycle 
kits employed for all other experiments. However this is not the experience observed by 
others (Profaizer et al., 2015) or in the routine NHSBT laboratory, where HLA typing results are 
comparable using either MiSeq chemistry.  
 
5.4.2 Confirmation of novel mutations 
Nine of the 45 putative novel mutations confirmed by re-sequencing were found to have 
designated HLA alleles following re-analysis using later releases of NGSengine and IMGT/HLA. 
The number of ‘novel’ sequences subsequently resolved by re-analysing with up to date 
software, detailed both here and in Chapter 3, is noticeable and can be attributed to the rapid 
rise of novel full length class I sequences added to the IMGT/HLA database in recent years. This 
is largely due to the increasing use of NGS for HLA typing (Robinson et al., 2015), enabling 
characterisation of regions outside exons 2 and 3 of the HLA class I genes that were not 
previously sequenced by the majority of laboratories using conventional technology (René, 
Lozano and Eliaou, 2016). 
Of the remaining samples, 27 of the 38 novel sequences determined were fully phased and 
should meet the strict criteria for submission to the IMGT/HLA database once accession 
numbers have been obtained for each unique sequence , which will be the subject of future 
work. In order for the ten sequences not ‘in-phase’ to be assigned a name by the WHO HLA 
nomenclature committee, samples will need re-sequencing using an alternative approach that 
is able to produce full length sequence across the HLA class I gene without the need for 
assembly of shorter reads, as phasing of heterozygous positions is required for IMGT/HLA 
submission (Lind et al., 2013). This would require the use of an NGS platform such as the 
PacBio RS II, which has been applied for novel allele confirmation by others (Cereb et al., 
2015), but this technology is currently not available at NHSBT.  
Of those samples containing novel mutations in exon regions of the HLA class I genes, two of 
the three identified would result in changes to the amino acid sequence of their respective 
HLA-C molecules. Whilst the relevance of polymorphism outside exons 2 and 3 is currently 
unknown (Lamb et al., 2015), of particular interest was the mutation at position 1810 in exon 4 
of HLA-C*03:04:01:01 which produces an amino acid substitution of cysteine to serine in the 
alpha 3 domain of the expressed HLA-C molecule. A recent paper suggested that mutations in 
the alpha 3 domain of an HLA molecule may affect the binding of CD8 molecules, required by 
cytotoxic T cells to exert their effect (Zaimoku et al., 2017).  
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The relevance of the synonymous substitution detected in an HLA-B*15:10:01 allele, as well as 
those mutations identified outside the coding regions in other samples, is also unclear. Whilst 
it is possible that these may impact on mRNA expression, very little is known about the effect 
that HLA polymorphism has on the splicing mechanism because the majority of HLA alleles are 
identified based on DNA sequence analysis only (Voorter et al., 2016).  
5.4.3 Population data analysis 
Due to the high number of samples with either novel mutations or artefacts contained within 
the intronic regions of each gene, it was decided to analyse HLA frequencies at third field to 
avoid having to exclude a significant proportion of data generated. Nevertheless, it is believed 
that this is the first reported UK population cohort with HLA typing at a resolution beyond 
second field. It has been submitted to Allele Frequencies Net database (Gonzalez-Galarza et 
al., 2015a) under the population name ‘England Blood Donors of Mixed Ethnicity’, identifier 
3392. This data is classed as ‘gold standard’ with allele frequencies adding up to 1, HLA typing 
determined to at least second field and a sample size of ≥50 (Santos et al., 2016).  
HLA allele frequencies were comparable with previous published English data. For example, 
the genotype frequency of HLA-A*01:01g reported by Alfirevic et al. 2012 in 400 volunteer 
donors was 38.6%, similar to the 37.4% of platelet donors typing as HLA-A*01:01:01 in this 
study. HLA-A, -B and -C genotypes determined at third field deviated from HWE. This is likely 
due to the presence of alleles such as A*74:01:01, B*18:40 and C*15:29, that occurred only 
once in this cohort, resulting in excess heterozygosity which is a known factor causing HWE 
deviation (Single et al., 2002). Many of the low frequency alleles observed are neither common 
nor well documented in European populations (Sanchez-Mazas et al., 2017) and may reflect 
the mixed ethnicity of English platelet donors which is typical of the blood donor population 
(Lattimore, Wickenden and Brailsford, 2015). However, this is not reflective of the more 
diverse ethnic distribution of the region, with only 84.9% of individuals in England (and Wales) 
self declaring as white in 2011 (Office for National Statistics, 2012) compared to 91.1% of 
platelet donors in this study. 
As reported by others, no significant deviation from HWE was observed when HLA genotypes 
were defaulted to antigen level (Schafer et al., 2016), apart from HLA-B which still deviated 
significantly. This was probably due to greater variability observed for HLA-B when compared 
to HLA-A and -C (Single et al., 2002), with 22, 11 and 13 antigens, respectively. Population data 
reported in this chapter has formed the basis of a short population report (Davey et al., 2017) 
which provides a structured description of populations along with genetic data and restricted 
analysis for HLA, KIR, cytokine and MIC genes (Mack and Middleton, 2015).   
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6. HPA genotyping by NGS 
6.1 Introduction 
Human platelet antigens (HPA) are located on glycoproteins expressed on the surface of 
platelets (Curtis and McFarland, 2014). There are currently twenty nine HPA systems 
described, encoded by the six genes  ITGB3, ITGA2B, ITGA2, GP1BA, GP1BB and CD109 
(Robinson et al., 2015). With the exception of HPA-14bw (which is defined by a three base pair 
deletion), each HPA is characterised by a single nucleotide polymorphism (SNP) resulting in an 
amino acid substitution in the corresponding protein (Lucas, 2013).  
A variety of molecular techniques have been employed to define the HPA systems (Nogués, 
2011), with the majority of HPA typing methods restricted to defining HPA-1, HPA-2, HPA-3, 
HPA-4, HPA-5 and HPA-15, selected originally for their frequency and clinical relevance (Lucas, 
2013). However, due to increasing reports of maternal alloantibodies against ‘rare’ HPA 
antigens (Poles et al., 2013; Peterson et al., 2012; Jallu et al., 2013; Bertrand et al., 2013b) it 
has been suggested that genotyping techniques should be expanded to include all known HPA 
systems (Santoso and Tsuno, 2015).  
Ideally, a single method capable of both detecting all known HPA SNPs and identifying novel 
mutations implicated in FNAIT should be employed. This would avoid the two tiered approach 
often required when investigating a rare or possibly unique HPA which can lead to protracted 
and costly laboratory investigations, requiring full length Sanger sequencing of one or more 
HPA defining gene (Poles et al., 2013; Wihadmadyatami et al., 2015). However, to date no 
published HPA genotyping has reported the capacity to define all known HPA systems in a 
single assay. 
Next Generation Sequencing (NGS) has the capacity to produce large amounts of sequence 
data relatively quickly and cheaply when compared to Sanger sequencing (Metzker, 2010). 
Lane et al. recently described the potential use of whole genome sequencing by NGS for 
predicting red cell and platelet antigens. They indicated that a targeted NGS approach might 
be a more affordable option for laboratories with novel DNA bar-coding technology enabling 
the simultaneous sequencing of specific regions of the genome in multiple individuals (Lane et 
al., 2016).  
In this study, a targeted NGS approach was designed to define all known HPA systems in either 
patient or donor samples, and assessed for its suitability as a routine approach for patient and 
donor genotyping, including novel allele detection.  
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6.2 Materials and methods 
6.2.1 Samples 
A total of 47 previously HPA genotyped DNA samples were used in this study, as detailed 
below. 
6.2.1.1 Control DNA 
Eleven DNA samples were obtained from NHSBT archives of external quality assessment (EQA) 
material. Samples were selected to ensure they covered as many HPA systems as were 
available, and included both heterozygous and homozygous examples of HPA genotypes 
commonly observed in the UK population. An additional fourteen anonymised control DNA 
samples were provided by the Australian Red Cross Blood Service and tested blind. The 
Australian samples included those with rarer HPA genotypes not available locally (Figure 6.1).  
 
Figure 6.1 HPA genotypes of control DNA. HPA genotypes represented by the external quality 
assessment (EQA) control DNA and the DNA provided by the Australian Red Cross blood service 
(AUS). EQA samples had not been previously tested for HPA-7, -8, -10 or -11. All HPA genotypes 
not represented in this figure were not defined in these control samples before being used in 
this study. 
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6.2.1.2 Patient DNA 
DNA was provided by the NHSBT Filton H&I laboratory. It had been previously extracted from 
patient blood samples originally referred for investigation, with informed consent obtained by 
the clinical team. Blind testing of these 22 samples was performed to assess targeted NGS as a 
potential method for clinical application. Included in this patient sample cohort were duplicate 
DNA from three patients and archive material of mother and baby from an unresolved 
suspected case of FNAIT which had previously undergone investigation by sequencing based 
typing. 
6.2.2 Historical HPA genotyping 
All samples in this study had been previously genotyped for HPA-1 to HPA-5 and HPA-15 by 
TaqMan real-time PCR, PCR-SSP and or PCR-SBT, with some control DNA additionally tested for 
HPA-6bw and HPA-9bw by the same method.  A number of samples were also defined for HPA-
7bw, -8bw, -10bw, -11bw, -27bw and or HPA-28w by either PCR-SSP or PCR-SBT (Table 6.1). 
HPA 
system  
HPA-1 to 
HPA-5 and 
HPA-15 
HPA-6w HPA-7w HPA-8w HPA-9w HPA-10w HPA-11w HPA-27w HPA-28w 
Typing 
method 
TaqMan/ 
PCR-
SSP/SBT 
TaqMan/ 
PCR-SSP/ 
SBT 
PCR-SSP PCR-SSP TaqMan/ 
PCR-SSP/ 
SBT 
PCR-SSP PCR-SSP SBT SBT 
No. of 
samples  
47 17 3 3 16 3 3 1 6 
 
Table 6.1 HPA systems previously defined in the sample cohort. The number of DNA samples 
defined for each HPA system indicated and the methods employed.  
 
6.2.3 Assay Design 
A panel of probes to detect the six genes known to encode HPA capturing all exons and 
flanking regions was designed to determine the feasibility of targeted NGS for HPA genotyping 
and assess its ability to detect novel HPA, as described in Section 2.7.1. 
6.2.4 Targeted enrichment and sequencing 
6.2.4.1 DNA sample preparation 
Each DNA sample was quantified using either the Quant-iT™ or Qubit® assay, as previously 
described (Section 2.4). A 50µl aliquot of each DNA sample was then prepared by diluting to 
1.8ng/µl with in 10mM Tris buffer pH 8.5 (Buffer EB, Qiagen).  
6.2.4.2 DNA library preparation 
Indexed DNA libraries were prepared from 50ng of genomic DNA (gDNA) using the bespoke 
HaloPlex HS target-enrichment assay for Illumina sequencing (Agilent Technologies, UK) as 
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described in Section 2.7.2. Three separate experiments were set up, with variable sample 
numbers tested each time (Table 6.2).  
Experiment Sample type No. of 
samples 
Expt 1 EQA  11 
Expt 2 Patient DNA (NHSBT Filton) 21 
Expt 3 Control DNA (Australian Red Cross Blood Service) 
plus one patient (NHSBT Filton) 
15 
Table 6.2 Detail of samples used for each HaloPlex HS experiment. Sample origin and the 
number included in each of the three HaloPlex HS experiments performed in this study 
 
The first experiment was performed using EQA samples to ensure the HaloPlex design had the 
capability of defining the common HPA genotypes. Second and third experiments were set up 
with DNA provided by external laboratories, which was tested blind and subsequently checked 
for concordance with the historical HPA genotype determined by the originating centre.  
Following preparation, for each experiment individual indexed libraries were combined into 
pools for downstream sequencing. Equimolar pooling was employed for the first experiment 
but subsequent pooling was based on equal volumes of each sample, to reduce costs and 
handling time. Each pooled library was then validated with a Bioanalyser 2100 (section 2.6.5.1) 
to assess fragment size and concentration and then normalised to approximately 4nM. Pooled 
libraries were sequenced separately on a MiSeq as described in section 2.7.4, using a Nano 
Cartridge for the first experiment and the Standard v2 cartridge for subsequent MiSeq runs. 
The type of cartridge was determined by the number of samples in each MiSeq run to ensure 
sufficient read depth was obtained. 
6.2.5 Data analysis 
Primary data analysis was performed using MSR to generate a pair of FASTQ files for each 
sample. FASTQ files were then analysed with SureCall NGS data analysis software v3.0.3.1 
(Agilent Technologies, UK) using the following pipelines:- 
6.2.5.1 HPA genotyping 
Single sample analysis was performed using the Default HaloPlex Method and chromosomal 
positions scrutinised using triage view for the respective positions for each HPA system. 
Nucleotides observed were used to manually assign genotypes for HPA-1 to HPA-29w, in 
accordance with data available from IPD-HPA. (Robinson et al., 2015) All HPA genotypes 
generated by NGS were then compared with those HPA systems previously defined in each 
sample and concordance determined.  
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6.2.5.2 Novel mutation detection 
FASTQ files from both the mother and baby from a suspected FNAIT case were analysed using 
HaloPlex default for pair analysis (Tumour Normal Method), allowing direct comparison of 
both sequences. Observed nucleotide differences between mother and baby for the six genes 
sequenced were examined, in particular those positions where the mother was homozygous 
and the baby was heterozygous, and therefore may encode a potential target of maternal 
alloantibody. 
6.3 Results 
6.3.1 Assay design 
The initial HaloPlex HS design based on the HPA gene targets described in section 2.7.1 used 
the ‘maximise specificity’ level of stringency to ensure target specificity. However, the HaloPlex 
design report indicated this would not provide 100% coverage of all six HPA genes, predicting 
99.74% and 98.05% coverage for target ID NM_000212 (ITGB3) and NM_002203 (ITGA2B), 
respectively. Although none of the affected regions encoded known HPA SNPs (Table 6.3), an 
additional probe group was designed using the ‘Maximise coverage’ stringency option to 
ensure sequence was obtained for all coding regions of the six genes, regardless. In total, 1241 
amplicons were created, with predicted 100% coverage of 108 target regions covering 
27,084kb for design ID 28048-1446018088 (Table 6.4).  
 
Region of interest not amplified TargetID 
CHR5:52351784-52351814 NM_002203 
CHR5:52358587-52358587 NM_002203 
CHR5:52371095-52371114 NM_002203 
CHR5:52385865-52385939 NM_002203 
CHR17:45364593-45364602 NM_000212 
Table 6.3 Regions not amplified by the original HaloPlex HS design. Target regions of interest 
that would not be amplified using stringency set to ‘Maximize Specificity’ 
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Gene Genomic 
Interval 
No. of 
Regions  
Size bp Databases Coverage High 
Coverage* 
Low 
Coverage** 
Stringency 
GP1BA chr17:4835850-
4837908 
1 2059 RefSeq 100 1 0 Maximise 
specificity 
ITGB3 chr17:45331178-
45387620 
15 3867 RefSeq 99.74 15 0 Maximise 
specificity 
GP1BB chr22:19711043-
19712037 
2 821 RefSeq 100 2 0 Maximise 
specificity 
ITGA2B chr17:42449682-
42466891 
24 6046 RefSeq 100 24 0 Maximise 
specificity 
ITGA2 chr5:52285249-
52386479 
29 6529 RefSeq 98.05 27 2 Maximise 
specificity 
CD109 chr6:74405889-
74533407 
32 7625 RefSeq 100 32 0 Maximise 
specificity 
ITGB3 chr17:45364593-
45364602 
1 10 CustomRegion 100 1 0 Maximise 
coverage, 
optimised for 
FFPE 
ITGA2 chr5:52351784-
52385939 
4 127 CustomRegion 100 4 0 Maximise 
coverage, 
optimised for 
FFPE 
Table 6.4 Summary of final HaloPlex HS Design ID 28048-1446018088. *High Coverage = 
number of regions where analysable amplicon overlap >= 90%.**Low Coverage= number of 
regions where analysable amplicon overlap < 90% 
 
Following manufacturing of the bespoke HaloplexHS design for HPA genotyping, quality control 
data provided by Agilent Technologies indicated that amplicons obtained from an enrichment 
of high-quality DNA were of the expected size range and concentration with no excessive high 
or low molecular weight product (Figure 6.2). 
 
Figure 6.2 Custom HaloPlex HS design quality control. A Bioanalyser electropherogram 
provided by Agilent Biotechnologies of the PCR product prepared from an enrichment of high-
quality DNA amplified with design ID 28048-1446018088 
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6.3.3 Restriction enzyme digestion 
Success of the restriction digest was confirmed by analysing the enrichment control DNA 
sample (ECD), set up with each experiment. An example of the results obtained from this 
validation can be seen in Figure 6.3, with each of the eight double digests showing discrete 
bands at the positions indicated in the HaloPlex HS protocol, version C0 December 2015. 
 
Figure 6.3 Validation of restriction enzyme digestion using the Bioanalyser 2100. Enrichment 
control DNA (ECD) was digested with a panel of 16 restriction enzymes in the form of two 
double digests provided with the HaloPlexHS kit. A 1:1 dilution of each ECD digest is shown, run 
using the Agilent high sensitivity kit on the Bioanalyser 2100, with results comparable to 
expected profile indicated in the protocol vC0 December 2015. Lane ‘L’ contains a 50bp ladder; 
lanes 1-8 contain 1:1 dilutions of the eight EDC restriction digests. Lanes 9-11 contain size 
markers only. 
 
6.3.4 Validation of DNA library preparation 
Pooled DNA libraries were assessed to determine the concentration and molarity using a 
Bioanalyser 2100 prior to dilution and loading onto the MiSeq platform. The concentration was 
determined by integration under the peak between 175 and 625bp, with any peak observed 
below 175bp excluded from the calculation. Peaks at approximately 140bp were observed and, 
according to the HaloPlex HS protocol, were associated with an adapter-dimer product and 
could be ignored if less than 10% of the overall peak value. A typical profile obtained is shown 
in Figure 6.4. 
Molarities of the pooled DNA libraries prepared in the first and second experiments were 
similar, with values of 34.88nM and 32.92nM respectively. However, the third DNA library 
prepared was approximate half the molarity of the first two, at 18.58nM, although this 
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difference did not appear to have any consequence given all pooled libraries were eventually 
diluted to 20M prior to loading onto the MiSeq. 
 
Figure 6.4 Validation Bioanalyser profile of the pooled DNA library from experiment 3. The X 
axis indicates the fragment size in base pairs. The blue bars (region 1) represent the peak 
range used to determine concentration and molarity. Values obtained for the peak at ~140bp 
were less than 10% of the overall concentration and were therefore ignored. 
 
 
6. 3.4 HPA genotyping 
Forty six of the forty seven samples sequenced were successfully genotyped for all currently 
defined HPA systems using the HaloPlex HS assay (Figure 6.5), with one sample excluded due 
to possible contamination.  
All HPA genotypes produced were 100% concordant with historical data. The majority of HPA 
systems tested were homozygous for the more common ’a’ allele observed in the UK 
population. However, both ‘a’ and ‘b’ alleles were represented in one or more sample for HPA-
1 to HPA-7bw, HPA-9bw, HPA -15, HPA-27bw and HPA-28bw (Figure 6.6). Unfortunately, it was 
not possible to test all potential combinations of HPA alleles due to the rarity of many HPA 
genotypes   
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Figure 6.5 HPA genotyping results determined using the bespoke HaloPlex HS design. Forty 
six samples were successfully sequenced, defining alleles for all 29 HPA systems. Blue blocks 
represent homozygous ‘aa’ HPA genotypes, yellow blocks indicate heterozygous ‘ab’ HPA 
genotypes and the red blocks denote ‘bb’ HPA genotypes for each HPA system. 
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Figure 6.6 Polymorphisms of the HPA systems sequenced using HaloPlexHS. The range of 
HPA alleles observed in forty six samples sequenced using HaloPlex HS.  
 
6.3.5 Sequence quality 
The quality parameters of each sequence obtained by our HaloPlex HS method were 
scrutinised to verify the accuracy of each HPA genotype assigned.  
6.3.5.1 Sequencing coverage 
Cluster density on the flow cell ranged from 1115 to 1226K/mm2 for the three experiments, 
with clusters passing filter greater than 87% on each occasion. On average, the per base depth 
of coverage (DoC) of 1144x was obtained for each sample, although the mean value varied 
between the three HaloPlex experiments performed, with an average of 584x, 1582x and 978x 
respectively. Variability in DoC between samples was minimal in the first experiment, but was 
wider in subsequent experiments (Figure 6.7).  
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Figure 6.7 Range of mean per base depth of coverage observed for each sample. Average 
DoC achieved per sample for each HaloPlex HS experiment, with the overall mean represented 
by the triangle. 
 
 
6.3.5.2 Coverage per HPA system 
The average DoC observed between each HPA system was quite varied, although this 
variability appeared to be consistent between experiments (Figure 6.8). The highest average 
DoC was achieved for HPA-23bw, with 2615x (range 469-5849), and the HPA system with 
lowest average coverage of 335x (range 18-664) was HPA-20bw.  
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Figure 6.8 Depth of coverage observed for each HPA system. Chart A shows the average and 
range of per base DoC observed for each HPA system, with the mean value represented by the 
triangle. Graph B shows the difference in average coverage observed per HPA with each 
experiment. 
 
6.3.6 Impact of GC content on read depth 
Table 6.5 lists the percentage GC content of each exon that encodes each of the respective 
twenty nine HPA systems, along with the mean DoC observed for each SNP. Fisher’s exact test 
showed a significant correlation between the mean depth DoC of 1144bp and the GC content 
of exons encoding each HPA SNP, with a lower read depth associated with a higher GC content 
(Figure 6.9).  
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GP1BA Gene Exon Total no. of nucleotides %GC Mean read depth 
(bp) 
HPA-1 ITGB3 3 196 61% 926 
HPA-2 GP1BA 2 2432 55% 1018 
HPA-3 ITGA2B 26 126 65% 915 
HPA-4 ITGB3 4 253 52% 675 
HPA-5 ITGA2 13 144 42% 1411 
HPA-6w ITGB3 10 430 59% 439 
HPA-7w ITGB3 10 430 59% 918 
HPA-8w ITGB3 12 101 48% 1990 
HPA-9w ITGA2B 26 126 65% 925 
HPA-10w ITGB3 3 196 61% 1028 
HPA-11w ITGB3 12 101 48% 1568 
HPA-12w GP1BB 2 921 73% 718 
HPA-13w ITGA2 20 142 35% 949 
HPA-14w ITGB3 11 223 61% 942 
HPA-15 CD109 19 118 43% 853 
HPA-16w ITGB3 4 253 52% 674 
HPA-17w ITGB3 5 163 53% 865 
HPA-18w ITGA2 17 152 40% 1325 
HPA-19w ITGB3 12 101 48% 675 
HPA-20w ITGA2B 20 148 66% 302 
HPA-21w ITGB3 12 101 48% 2202 
HPA-22w ITGA2B 5 50 60% 362 
HPA-23w ITGB3 12 101 48% 2393 
HPA-24w ITGA2B 15 105 55% 1194 
HPA-25w ITGA2 28 90 42% 494 
HPA-26w ITGB3 11 223 61% 1157 
HPA-27w ITGA2B 26 126 65% 922 
HPA-28w ITGA2B 23 81 61% 668 
HPA-29w ITGB3 2 86 63% 1817 
Table 6.5 Mean read depth and percentage CG content in the encoding exon for each HPA 
system.   
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Figure 6.9 Correlation between mean per base depth of coverage and % CG content. The 
higher the GC content the lower the mean read depth for each HPA SNP. Significant p value 
determined using Fishers exact test.  
 
6.3.7 Allele balance 
The ratio of sequence depth obtained for individual SNPs in all heterozygous samples was 
even, with a mean of 51% for allele ‘a’ and 49% for allele ‘b’, ranging from 41-60% and 40-50% 
respectively. Those HPA with fewer heterozygous examples in our cohort, such as HPA-6bw, 
tended to have slightly uneven allele balance (Figure 6.10). However, all heterozygous samples 
were well within the 20:80 balance ratio used by HLA analysis software for calling 
heterozygous positions (Section 2.6.7).  
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Figure 6.10 Mean allele balance observed for each heterozygous HPA system. The 
percentage read depth for allele ‘a’ is shown on the left hand side and allele ‘b’ on the right. 
 
6.3.8 Novel allele detection 
Full HPA genotyping of both the mother and baby from the unsolved FNAIT case was 
performed along with other patient samples in the second experiment. HPA-15 was potentially 
clinically significant, with the mother typing as HPA-15aa and baby determined to be HPA-
15ab. However, this HPA system had been previously excluded by NHSBT Filton as causing 
FNAIT in the original investigation. Consequently, all coding regions of the six genes sequenced 
were examined using SureCall pair analysis to search for any other potential mutations that 
might be implicated in FNAIT. 
The HaloPlex Tumour Normal method, using the maternal sample as the reference, indicated a 
total of twenty six differences between mother and baby, with 10 mutations of interest 
identified where mother was homozygous but the infant was heterozygous (Table 6.6). One of 
these mutations of interest was the previously discounted HPA-15 disparity, five were 
excluded as they were non-coding and three mutations were SNPs with no known association 
to FNAIT (National Center for Biotechnology Information SNP database) so were also ruled out.  
The remaining difference between mother and baby indicated a novel SNP in the ITGB3 gene 
(NM_000212.2:c.1373A>G) present in baby’s sample, resulting in an amino acid change from 
aspartic acid to glycine. Although there was insufficient DNA to sequence the historical 
paternal sample, retrospective analysis of original Sanger sequencing data performed by the 
originating laboratory was able to confirm inheritance of this mutation in baby (A. Poles, 
personal communication). 
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Chrom Pos ID Baby Mother HGVS(Coding) HGVS(Protein) 
chr5 52337908 rs3212441 T/C T/C NM_002203.3:c.186-34C>T  
chr5 52338083 rs1363192 G/T G/T NM_002203.3:c.295+32T>G  
chr5 52344610 rs1421933 G G/A NM_002203.3:c.630+10A>G  
chr5 52347369 rs1126643 T T/C NM_002203.3:c.759C>T NP_002194.2:p.Phe253= 
chr5 52351413 rs1062535 A A/G NM_002203.3:c.825G>A NP_002194.2:p.Thr275= 
chr5 52355854 rs2303127 C C/T NM_002203.3:c.1312+12T>C  
chr5 52356692 rs3212538 C/T T NM_002203.3:c.1313-39T>C   
chr5 52366138 rs2112290 A A/G NM_002203.3:c.2235+48G>A  
chr5 52368922 rs984966 A A/T NM_002203.3:c.2430-26T>A  
chr5 52370174 rs3212591 A A/G NM_002203.3:c.2572-41G>A  
chr5 52379277 rs2303122 T T/C NM_002203.3:c.3252C>T NP_002194.2:p.Phe1084= 
chr6 74432923 rs56093139 T/C C NM_001159587.2:c.248-51C>T   
chr6 74440104 rs143082026 A/G A/G NM_001159587.2:c.314G>A NP_001153059.1:p.Arg105His 
chr6 74466377 rs6453696 T/C T NM_001159588.2:c.414C>T NP_001153060.1:p.Tyr138= 
chr6 
 (HPA-
15) 
74493432 rs10455097 C/A C NM_001159588.2:c.1877A>C NP_001153060.1:p.Tyr626Ser 
chr6 74497009 rs2351528 G/A G NM_001159588.2:c.2159A>G NP_001153060.1:p.Asn720Ser 
chr6 74497152 rs5023688 A/G A NM_001159588.2:c.2302G>A NP_001153060.1:p.Val768Ile 
chr6 74521947 rs2917862 T/C C NM_001159588.2:c.3491C>T NP_001153060.1:p.Thr1164Met 
chr6 74528293 rs3005506 G/A A NM_001159587.2:c.4008+35A>G   
chr6 74533192 rs2917887 G G NM_001159588.2:c.3942G>T NP_001153060.1:p.Ala1314= 
chr17 4835895 rs2243093 C/T C NM_001165417   
chr17 45360730 rs5918 C C/T NM_000212.2:c.176T>C NP_000203.2:p.Leu59Pro 
chr17 45368337 rs15908 C C/A NM_000212.2:c.1143A>C NP_000203.2:p.Val381= 
chr17 45369617   G/A A NM_000212.2:c.1373A>G NP_000203.2:p.Asp458Gly 
chr17 45369777 rs4642 G G/A NM_000212.2:c.1533A>G NP_000203.2:p.Glu511= 
chr17 45369789 rs4634 A A/G NM_000212.2:c.1545G>A NP_000203.2:p.Arg515= 
Table 6.6 Nucleotide differences identified by SureCall using pair analysis between samples 
from mother and baby of a suspected FNAIT case. Lines highlighted in yellow are the 
mutations of potential interest where mother is homozygous and baby heterozygous, with the 
novel causative mutation highlighted in green. 
 
 
6.4 Discussion 
This is the first reported HPA genotyping method able to simultaneously detect and define all 
known HPA systems in a targeted NGS-based genotyping assay (Davey, Navarrete and Brown, 
2017). 
6.4.1 Assay design 
A panel of HaloPlex HS probes to detect the six genes that encode all currently defined HPA 
systems was designed to determine the feasibility of using targeted NGS for HPA genotyping.  
However, rather than just target the regions containing a restricted set of HPA SNPs, as 
reported by others (Orzinska et al., 2017), probe groups were designed to capture all exons 
and 50 base pair flanking regions to determine if this NGS-based approach might also be 
clinically useful for the investigation of FNAIT, including novel allele detection.  
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The original design used the ‘maximise specificity’ stringency option of the SureDesign 
HaloPlex Advanced Design Wizard; high specificity is important to avoid capturing highly 
similar but irrelevant regions (Nagy and Mansukhani, 2015). However, this design approach 
indicated that some target regions in chromosomes five and seven would not be amplified. 
Although the missed regions did not include those containing HPA SNPs, it was considered 
important to include all coding regions of each gene sequenced to facilitate detection of both 
known and novel HPA. Therefore design parameters were modified accordingly to ensure 
regions had analysable amplicon overlap of ≥90%, resulting in 100% predicted coverage for the 
six genes. 
Validation of both the restriction digestion and library preparation using data from the 
Bioanalyser indicated the efficacy of the bespoke HaloPlex HS design with regards sample 
preparation, although not the specificity of the probe library. 
6.4.2 Sequence quality 
Sequencing parameters observed, including cluster density and percentage of clusters passing 
filter, indicated an optimal amount of library had been loaded for each MiSeq run, based on 
Illumina’s recommended values (Illumina, 2016a).  
6.4.2.1 Depth of coverage 
Sufficient per base depth of coverage (DoC) is critical for NGS to ensure reliable base calling 
and subsequent alignment to the reference genome by analysis software. It is generally 
accepted that average depth in excess of x30 is acceptable for the detection of SNPs (Sims et 
al., 2014), although there is no consensus for a minimum DoC required. A recent study 
reported that the accuracy of sequencing actually improves once the read depth goes beyond 
10 times. (Pirooznia et al., 2014). For all three HaloPlex experiments, the mean DoC achieved 
was well above these minimum acceptable levels, although data generated by each MiSeq run 
was quite disparate. 
6.4.2.2 Depth of coverage per HPA system 
Substantial variation in the mean DoC for each HPA SNP was observed, and was consistent in 
each of the three experiments. One factor that might have affected coverage of each SNP is 
the GC content of the respective region sequenced. It has been reported that sequences with a 
higher proportion of G and C nucleotides are less likely to denature during PCR (Veal et al., 
2012) and this may have affected the efficiency of the enrichment stage of the HaloPlex HS 
protocol. Indeed, exon 20 of the ITGA2B gene that encodes HPA-20w exhibited the lowest 
mean coverage and has a GC content of 66%. Conversely, HPA-23bw had the highest observed 
DoC in each experiment, with just 48% GC content in the encoding exon 12 of the ITGB3 gene. 
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When all HPA SNPs were considered, Fishers exact test indicated a significant association 
between mean DoC for each HPA SNP and the GC content of the respective encoding exon 
(p=0.0317). 
6.4.2.3 Mean Depth of coverage per sample 
As well as variability between each HPA, the overall mean DoC differed markedly between 
each experiment. The variability of the overall mean DoC observed might be explained by the 
different number of samples sequenced in each experiment as well as the MiSeq cartridge 
selected and the amount of PAL loaded for each run. However, differences observed in the 
second and third experiment are more likely explained by the method used for library pooling. 
For the first experiment samples were pooled in equimolar amounts. If an outlier sample 
(which was at a very low concentration) is excluded, the variability of DoC was negligible, 
ranging from just 539-775bp compared to 185-775bp observed in the 11 samples overall. In 
contrast, the range of coverage depth increased considerably in subsequent experiments when 
samples were pooled by equal volume, suggesting that equimolar pooling is beneficial. Pooling 
in equimolar concentration required the use of a Bioanalyser 2100 to determine the molarity 
of each library. Whilst the Bioanalyser offered the additional benefit of assessing the quality of 
each library, this process is both time consuming and expensive when compared to pooling by 
equal volumes (De Leeneer et al., 2015). The costs further increase when experiments contain 
more than 11 samples due to the limited number of libraries that can be loaded onto a single 
bioanalyser chip. An alternative approach might be to estimate the molarity, given all libraries 
should be a similar composition as a result of AMPure bead size selection. By using an 
estimation of molarity, quantification of each library could be performed using a Qubit or 
similar fluorescent based technology which is quicker and cheaper. Subsequent pooling could 
then be performed by equal concentration rather than molarity or volume. This is likely to 
produce similar results to those observed using equimolar pooling without the additional cost 
of individual library assessment using a Bioanalyser.  
Others have also reported lack of coverage uniformity across regions using the HaloPlex target 
enrichment system (Sutton et al., 2015; Wendt et al., 2016; Zhang et al., 2016). The impact of 
uneven coverage can be limited by ensuring the DoC reaches the required minimum for the 
regions with the lowest coverage, although this may restrict the number of samples that can 
be multiplexed. Reducing variability between samples will allow a better estimate of the 
maximum number of samples that can be pooled and still maintain the deep sequencing 
required to produce accurate SNP detection. 
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6.4.2.4 Allele balance 
As well as ensuring there is sufficient read depth for each HPA SNP, the accuracy of base calls 
for heterozygous positions is dependent on allele balance, with errors increasing as the ratio of 
alleles falls below 20:80 (Pirooznia et al., 2014). The allele balance observed for all 
heterozygous HPA observed in the samples sequenced was well within this acceptable range, 
with the least balanced HPA-6bw still maintaining an allele ratio of 41:59. Although 
heterozygous examples were not available for all HPA systems in the sample cohort, the 
evenness in allele balance observed with those sequenced suggests rarer HPA would be 
detected. 
6.4.3 HPA genotyping  
Forty six samples were successfully HPA genotyped using the custom design HaloPlex HS target 
enrichment assay, with all results produced being 100% concordant with historical data.  
Although it was not possible to test all permutations of  HPA polymorphism using this HaloPlex 
HS assay due to the scarcity of samples with rarer HPA genotypes, the results generated 
provides compelling evidence that a targeted NGS approach is a viable option for 
simultaneously HPA typing both patient and donor samples for all known HPA systems.  
There are several advantages of a targeted NGS approach when compared to conventional 
Sanger sequence-based HPA typing. As well as being a one-hit assay, benefits include the 
requirement for only 50ng of genomic DNA (Xu et al., 2009), which is particularly important for 
clinical investigations where patient material may be very limited due to neutropenia or in the 
case of a neonate.  Another benefit of this approach is that NGS should not be adversely 
affected by rare mutations that have been known to interfere with the accuracy of some 
conventional PCR-based HPA genotyping techniques (Curtis and McFarland, 2009) as it is not 
reliant on sequence specific oligonucleotide primers or probes. 
The ability to sequence many samples simultaneously is one of the key benefits of NGS, with 
up to twenty one samples HPA genotyped simultaneously in this study. However, the HaloPlex 
HS assay enables up to 96 samples to be sequenced in a single experiment using the current 
index combinations provided. It is anticipated that optimisation of sample pooling will increase 
the capacity to multiplex for HPA genotyping, although the actual number of DNA libraries that 
can be combined without compromising overall sequence quality has yet to be determined.  
6.4.4 Novel mutation detection 
Included in the sample cohort was DNA from a mother and her baby from an historical 
unsolved FNAIT case originally investigated by NHSBT Filton. A comparison of the six gene 
sequences revealed a putative novel mutation in exon 10 of the ITGB3 gene, resulting in an 
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amino substitution in the glycoprotein GPIIIa. This region also encodes HPA-6w and HPA-7w 
(Figure 6.11), suggesting this novel mutation may have clinical significance and be implicated in 
FNAIT. This is currently the subject of further investigation by the originating laboratory.  
 
Figure 6.11 Cartoon showing the location of novel SNP in exon 10 of the ITGB3 gene 
detected in patient BB. The arrows indicate the proximity of HPA-6w and HPA-7w encoded by 
the same exon. 
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7. Discussion 
This study investigated the development and implementation of NGS technology to enhance 
the transfusion support provided to patients with either HLA and or HPA alloantibodies who 
require appropriately compatible products. Chapters 2 to 6 describe the successful design and 
development of two distinctive NGS-based methods to define the divergent nature of the HLA 
and HPA genetic systems and demonstrate the potential clinical application of these novel 
genotyping approaches. 
7.1 HLA typing and NGS 
The development of NGS technology has proved to be a paradigm shift in many areas of 
molecular biology and this is certainly true for the field of histocompatibility and 
immunogenetics (H&I), where use of NGS for HLA typing has been reported by many groups in 
recent years (Shiina et al., 2012; Lange et al., 2014; Hosomichi et al., 2013; Ehrenberg et al., 
2014). The unique benefit offered by NGS for HLA definition is the ability to produce 
unambiguous allele level genotypes from a fully phased nucleotide sequence (Erlich, 2015). 
Application of NGS in H&I laboratories has primarily focused on supporting haematopoietic 
stem cell transplantation (HSCT) due to the requirement for a high level of matching between 
donor and recipient (Bravo-Egana and Monos, 2017). The high throughput capability of NGS, 
alongside economies of scale, makes it particularly suitable for unrelated HSCT donor registry 
typing and assists scientists and clinicians in identifying suitably matched donors in a timely 
manner (Lange et al., 2014). It also negates the need for additional extended HLA typing, as 
may be required for donors defined on registries at low or medium HLA resolution only. Not 
only does this remove the costs associated with extended typing, but access to allele level 
donor genotyping data can also significantly reduce the time interval from initiating a donor 
search to selection of the final donor (Davey et al., 2016).  Availability of allele level HLA donor 
types on registries can also aid clinicians with an options appraisal for a patients’ treatment, 
should a fully matched donor be unavailable (van Rood and Oudshoorn, 2008).  
7.1.1 HLA typing platelet donors by NGS 
Until now, the clinical application of HLA typing by NGS to support the selection of platelets for 
transfusion has not been reported. The majority of patients requiring platelet support receive 
random platelet transfusions but for those patients who fail to respond due to the presence of 
alloantibodies a specialist product is necessary to avoid HLA and or HPA antigens to which the 
patient has become sensitised (Brown and Navarrete, 2011). Traditionally, selection of suitable 
platelets for these patients has consisted of HLA matching based on serologically defined 
antigens which can be a complex process and requires access to a large panel of HLA typed 
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platelet donors (Pavenski, Freedman and Semple, 2012). This conventional approach is also 
limited by considering each HLA locus in isolation, excluding HLA-C from the selection 
algorithm and assuming homozygosity where only one antigen has been identified at an 
individual locus. 
An alternative option for the selection of platelets for patients with IPR is the use of HLA 
epitope matching which is currently the subject of a non-inferiority trial (ISCTRN23996532). 
Benefits of HEM include a theoretically more accurate matching by selecting donors expressing 
epitopes shared with the recipient thereby avoiding both DSA and risk of further sensitisation. 
This increases the number of acceptable donors for patients that would otherwise appear 
mismatched using conventional HLA selection algorithms (Brooks, MacPherson and Fung, 
2008). A reduction in the number of platelet donations provided by apheresis is a strategic 
objective within NHSBT due to the high costs of producing platelet products by apheresis 
compared to pooled products manufactured when processing red cells. Plans have already 
been implemented to reduce the proportion of platelets units collected by apheresis from 80% 
to 60% with further reductions likely in the future (Ronaldson and Ashford, 2014). The 
implementation of HEM should ensure that patients continue to receive therapeutically 
beneficial platelet transfusions, despite fewer single donor platelet packs on the shelf. 
The matching algorithm for HEM requires both patient and donor HLA types defined to the 
allele level in order to accurately determine the epitopes expressed (Duquesnoy, 2011) so 
where HLA types are reported at a lower resolution, conversion into second field results is 
necessary. Whilst others have indicated this is an acceptable approach (Pai et al., 2010), results 
presented in chapter 4 show that conversion from low or medium resolution HLA types is error 
prone. Disparity between predicted and actual alleles present in an individual was found to be 
particularly high when the first allele in the HLA string is selected as the defined type, with 
6.6%, 13.5% and 13.3% errors for HLA-A, -B and -C respectively. This was of concern, as it is the 
method employed for allele prediction by Hematos (NHSBT’s laboratory information 
management system) when applying HEM for donor selection. This could lead to a platelet unit 
being selected inappropriately and either fail to improve the patient’s platelet count due to 
the presence of DSA or result in stimulating the production of de novo antibodies. 
Further analysis of the data obtained from Chapters 3 & 4 showed that the accuracy of 
conversion to second field genotypes could be improved by considering HLA allele frequencies 
to predict alleles from an HLA string, and further still when utilising HLA haplotype frequencies.  
However, this would require a more complex algorithm embedded in Hematos for allele 
conversion and would need information on the ethnicity of the donor and patient, which is not 
always available or reliable. This would then require the use of default Caucasian frequency 
data, which may not represent the ethnicity for the respective donor or patient, potentially 
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leading to inaccurate HLA allele predictions. Published HLA allele and in particular haplotype 
frequencies is also very limited (Geneugelijk et al., 2017), particularly for the UK population. 
Furthermore, frequencies are often based on data obtained from exons 2 and 3 rather than 
whole gene analysis (Geneugelijk et al., 2017) and therefore do not always represent the level 
of resolution required. Frequency data would also need to be regularly updated for any 
conversion algorithm to ensure the most current allele and haplotype frequencies were 
utilised.  
It is possible to avoid these allele prediction errors altogether by employing NGS for HLA 
typing. This would provide allele level definition of the HLA class I genes, removing the 
requirement for allele conversion by Hematos and thus ensuring accurate HEM of platelet 
donors. In this thesis, chapter 3 described a novel approach to NGS HLA typing that was 
applied to type 180 platelet donors in a single run on a MiSeq for HLA-A, -B & -C, producing 
results to third or fourth field resolution. Design of the described pipeline for HLA typing 
platelet donors occurred alongside development and implementation of an in-house NGS 
protocol at NHSBT for adult and cord blood donor typing as a service provision for the British 
Bone Marrow Registry. Some modifications were required to maximise the number of samples 
typed simultaneously and make optimal use of the sequencing capacity of a MiSeq flow cell. 
Adaptations included a reduction in the number of steps for DNA preparation, changes to the 
amplicon pooling process and use of an increased number of indices to facilitate additional 
multiplexing. In addition, two different approaches for DNA library preparation were trialed, 
the results of which helped inform the change to reagents kits used by the routine laboratory.  
Some of these modifications could also be applied to the existing HSCT donor workflow which 
would lead to a reduction in the number of steps performed without compromising data 
quality or quantity (Figure 7.1). This would represent a cost saving due to a reduction in both 
DNA quantification reagents and in hands-on time. However, HSCT donors are also typed for 
HLA class II alleles which, based on observations in the Colindale H&I laboratory since 2015, 
may be more susceptible to variations in DNA quality and concentration in the initial PCR 
reactions, particularly for HLA-DRB1. This is probably due to the size of the HLA-DRB1 gene 
which is considerably larger than the HLA class I genes, spanning over 11,000kb compared to 
HLA-A, -B and -C which are approximately 3500, 4000 and 4300kb in length, respectively 
(Robinson et al., 2015). Therefore removal of the DNA quantification and normalisation step 
for HLA class II amplification would need to be carefully validated to ensure it does not 
adversely affect allele detection or result in amplification bias. 
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Due to the success of this study, the laboratory is currently in the process of implementing 
NGS for routine HLA-A, -B and -C typing of all apheresis platelet donors. While much of the 
workflow is similar to that used for HSCT donors, some modifications to the laboratory process 
will be necessary including adaptation of the Biomek robots for automated library preparation. 
This is to ensure the liquid handling robots are able to manage a reduced volume of pooled 
amplicon library for each sample and process 180 samples concurrently, compared with the 
existing 96 sample batch to form the final pooled amplicon library. Despite the variation in 
NGS protocols required, processing both HSCT and platelet donors samples using the same 
technology will bring some operational benefits for the laboratory. This will include the ability 
to dedicate equipment for a single process rather than having to schedule multiple methods 
within the one laboratory alongside the release of bench space. The training of staff will also 
be simplified if all samples are processed via the same work stream, although this brings its’ 
own challenges as NGS is a technically demanding process compared to methods such as PCR-
SSP or PCR-SSOP.  
DNA purification DNA purification 
DNA quantification 
DNA normalisation 
PCR amplification PCR amplification 
Amplicon quantification Gel electrophorsis 
 
Amplicon pooling Amplicon pooling 
Library preparation Library preparation 
Sequencing        
(n=96) 
( 
Sequencing       
(n=180) 
HSCT donors Platelet donors 
 
Figure 7.1 The current NGS 
process flow for HSCT donors 
alongside the NGS protocol 
designed for platelet donors in 
this study. All steps highlighted 
in green are the same for both 
protocols. Those parts of the 
process highlighted in orange 
differ between HSCT donors 
and platelet donor type, with 
gel electrophoresis replacing 
amplicon quantification in the 
platelet donor work stream 
and variation in the total 
number of samples sequenced 
simultaneously. Steps shown in 
red (DNA quantification and 
normalisation) are not required 
when processing platelet 
donor samples. 
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7.1.2 HLA typing platelet recipients by NGS 
NGS is not currently employed for HLA typing patient samples at NHSBT laboratories. The 
reason is primarily one of logistics as the current work flow has been designed for high 
throughput. Although a system has been devised to manage requests for ad hoc samples for 
NGS typing within the routine laboratory, these samples feed into the high throughput donor 
typing pipeline to maximise the use of sequencing reagents; processing less than 96 samples 
per batch increases the cost per test significantly. This approach is not compatible with the 
service level agreement with service users, which is currently 5 working days from receipt of 
sample to reporting the result. A 5 day turnaround time would be challenging using the 
existing NGS work flow and does not allow time for any re-work should the initial sequence fail 
to produce a valid result. However, use of NGS for HLA typing could be appropriate for some 
patients that require life long HLA matched platelet support. 
As discussed at a recent NGS special interest group meeting organised on behalf of the British 
Society for Histocompatibility and Immunogenetics, other UK laboratories have started to 
implement NGS for patient HLA typing. However, the majority are using shared sequencing 
facilities with other departments or employing nearby university sequencing platforms to 
maximise cost effectiveness. Some laboratories have opted to type all samples by NGS to 
streamline their workflow as a high resolution HLA type can benefit both HSCT and solid organ 
transplant programs, although NGS is not suitable for urgent deceased donor typing in its 
current form (Monos and Maiers, 2015). Of those laboratories using NGS, all but one have 
chosen to use commercial HLA typing kits which are now readily available, including NGSgo® 
(GenDx), TruSight HLA (Illumina), Holotype HLA™(Omixon) and NXType™ (One Lambda). These 
are generally designed for a lower throughput and claim a faster processing time than would 
be possible sequencing larger numbers of samples. Until HLA typing is performed by NGS for 
platelet recipients it could be argued that defining platelet donors at a higher resolution is of 
little benefit when HLA allele prediction will still be required for the majority of patients 
receiving platelets selected using HEM. A counter argument is that having one individual of the 
donor recipient pair defined to the allele level improves the overall accuracy of HEM and is still 
preferable to using prediction algorithms alone (Geneugelijk et al., 2017). NGS could also be 
performed alongside the faster techniques to enable provision of subsequent products based 
on allele level HLA typing. 
 
7.2 Impact of NGS on HEM 
Results from Chapter 3 have shown that NGS for HLA typing produces accurate allele level 
typing of platelet donors. Implementation of NGS for routine platelet donor typing will ensure 
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that the correct epitopes are considered for each donor when using HEM to select donors for a 
particular patient. The principle of the HEM algorithm for transfusion is to select the platelet 
donor with the lowest number of epitope mismatches to the patient. Ideally the number of 
mismatches would be zero but it is not always possible to find a fully matched donor, 
regardless of the matching algorithm, and there is evidence to suggest that epitope 
mismatches can be tolerated below a certain threshold (Brooks, MacPherson and Fung, 2008). 
In reality it is more likely that the type of mismatch is more critical than the actual number per 
se, as there have been reports of an alloresponse to a single epitope mismatch (Lomago et al., 
2010). Whilst NGS will not guarantee to identify donors without any epitope mismatches, it 
should over time inform scientists about acceptable and unacceptable mismatches. To date, 
much of the research into HEM and its clinical impact has been around solid organ 
transplantation. There are clear indications that not all HLA mismatches are clinically 
significant but understanding which mismatches are permissive is a significant challenge for 
the discipline; it is hoped the HEM will provide an opportunity to evaluate the immunogenicity 
between donor and recipient and optimise outcome (Wiebe and Nickerson, 2016).  Knowing 
the exact amino acid sequence of each individual HLA for both donor and recipient will allow 
scrutiny at the molecular level to hopefully provide more insight into acceptable mismatching 
(Erlich, 2012). A recent paper by Duquesnoy and Marrari explored the use of a program called 
ElliPro and demonstrated its potential to predict alloantibody responses to HLA-ABC eplets. 
They reported that ElliPro scores were indicative of an eplets’ ability to induce a specific 
antibody response and that a low ElliPro score assigned to some theoretical eplets suggested 
they were incapable of inducing an alloantibody response and therefore should be re-classified 
as ‘non-epitopes’ (Duquesnoy and Marrari, 2017; Duquesnoy, 2017). Interestingly, some of 
these so called ‘non-epitopes’ included 97T and 116F which were identified as mismatched 
epitopes in some allele prediction discrepancies discussed in Chapter 4 (refer to Table 4.3), 
suggesting that the mismatches identified are probably not clinically relevant.  
Analysis of the impact of HLA epitope matching and mismatching will form part of the ongoing 
clinical trial into use of HEM for platelet transfusion. It is hoped that results may provide some 
insight into permissive HLA epitope mismatching in the transfusion setting. In an attempt to 
find some preliminary evidence of the impact of HEM for platelet selection, the medical history 
and response to transfusions was examined for a highly sensitised immune refractory patient 
who was provided HEM selected platelets at the request of their clinician over a period of 
several months. Initial indications suggested that the patient had an improved platelet 
increment following HEM selected platelets compared to conventional matching. However, at 
the time of transfusion with conventionally HLA matched platelets the patient was suffering 
from sepsis. This co-morbidity is as likely to explain the poor platelet increments as the 
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approach taken for platelet selection because sepsis is a known cause of thrombocytopenia 
(Brown and Navarrete, 2011). In addition, the patient had become sensitised to additional HLA 
antigens as a result of mismatched transfusions but because the patients’ HLA antibody 
screening was not up to date at the time the units were allocated, platelets to which the 
patient had DSA were provided, resulting in poor increments. This single case serves as a note 
of caution when interpreting outcome data following platelet transfusions; patient responses 
are likely to be multi-factorial and results must be considered in their clinical context. 
7.3 The wider impact of HLA typing by NGS 
Due to the rapidly expanding number of HLA alleles, ensuring that PCR-SSOP and PCR-SSP 
techniques are able to detect all new alleles will become increasingly challenging and is more 
likely to require additional testing to resolve the resulting ambiguity (Tait, 2011). The use of 
NGS for HLA typing resolves these dilemmas, producing a high resolution or allele level result 
first time. 
7.3.1 Whole gene HLA sequencing 
The decision to use whole gene amplification in this study rather than taking a restricted exon 
based approach results in sequencing data for both the coding and non-coding regions of the 
HLA class I genes. As well as producing an unambiguous HLA genotype, sequencing beyond the 
conventional exons 2 and 3 includes the transmembrane and cytoplasmic regions of the HLA 
class I gene, improving the overall characterisation of HLA genes. Sequencing entire HLA genes 
should eventually provide more insight into the roles these regions play in the immune 
response, as well as the effect of intronic variation on gene regulation and expression (Monos 
and Maiers, 2015). Generation of whole gene sequence data may eventually provide other 
benefits, including application in phylogenetic studies and in assay design, for example in the 
design of primers located in intronic regions (Lind et al., 2013).  
7.3.2 HLA allele and haplotype frequencies 
Chapter 5 discussed the HLA-A, -B and -C allele and haplotype frequencies in 519 platelet 
donors HLA genotyped by NGS. This data was submitted to the Allele Frequency Net Database 
(Santos et al., 2016) as the first reported cohort of HLA class I frequency data at third field 
resolution in an English donor population (Davey et al., 2017). One of the anticipated benefits 
of NGS typing is an increase in the knowledge of allele and haplotype frequencies. Results 
submitted based on information from this study will hopefully provide impetus to submit more 
frequency data as it becomes available, particularly from the adult and cord blood populations 
typed by NHSBT where both HLA class I and class II sequences are produced by NGS. This will in 
turn assist allele prediction where it is still required, either for patient samples or legacy 
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donors HLA typed before the implementation of NGS. This will require HLA conversion 
algorithms that include allele and ideally haplotype frequencies to assist with allele prediction. 
Indeed, the algorithm employed by Hematos is currently being reviewed by NHSBT in light of 
data analysed and discussed in Chapter 4 in order to improve accuracy over the existing 
approach of selecting the first allele in the HLA string.  
7.3.3 Novel HLA allele detection 
The number of novel mutations discovered in the platelet donors typed by NGS as part of this 
study was also discussed in Chapter 5, with 38 HLA sequences confirmed as having previously 
unreported mutations in either exon, intron or UTR regions. Although these putative new HLA 
alleles have yet to be submitted to the IMGT/HLA database, once complete this additional 
sequencing data will contribute to the knowledge of HLA polymorphisms.  
7.4 HPA genotyping by NGS 
This study has resulted in the first published application of a targeted NGS assay to 
simultaneously genotype patients and donors for all known HPA systems and provides proof of 
concept that NGS for HPA genotyping can be applied in the clinical setting (Davey, Navarrete 
and Brown, 2017). One of the initial objectives of this study was to design a method for HPA 
genotyping platelet donors to replace the existing method using the Taqman assay which is 
currently limited to defining HPA-1 to -5 and -15. Once designed, it was anticipated that this 
method would then be applied to the 540 platelet donor cohort to determine HPA-1 to -29 
frequencies in the English platelet donor population. Unfortunately due to time and cost 
constraints this was not possible but will hopefully form part of future work. Understanding 
the frequencies of the HPA systems not currently defined in platelet donors will inform the 
strategy for HPA donor genotyping at NHSBT. If the rarer HPA systems cannot be detected in a 
cohort of over 500 donors it could be argued that it is not necessary to type donors routinely 
for these less common SNPs. However, until the frequencies are determined it is possible that 
some of the HPA systems are more frequent than first thought. Indeed, one of the EQA 
samples used to validate the targeted NGS assay was found to be HPA-28wab, which was 
unexpected given the HPA-28w system had only been defined relatively recently and had not 
been detected in 100 blood donors screened for the HPA-28w SNP (Poles et al., 2013).  
If the strategic decision is to implement targeted NGS for platelet donor HPA genotyping, a 
number of developments will be required to facilitate a high throughput workflow, essential to 
type the 5000 samples received per annum by NHSBT. These will include the automation of the 
laboratory process in order to minimise hands on time and reduce the risk of sample transfer 
error. This should be possible using existing Biomek robots installed as the method is based on 
a 96 well plate format but would require support from the manufacturers of both the kits and 
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robotics to implement such a protocol. For some of the steps e.g. AMPureXP bead-based clean 
up, automated protocols already exist in the laboratory. Other processes including the 
restriction digests are specific to the HaloPlex HS protocol and would need automated 
programs to be designed. Another critical requirement will be the development of the data 
analysis pipeline. Although the SureCall software is adequate for limited SNP interpretation, it 
would be time consuming and potentially error prone if used for high throughput, as 
navigating to the respective SNPs for each HPA relies on manually entering the chromosomal 
positions. SureCall does have the capacity to determine user parameters for automated 
mutation calling and although this option has been discussed with Agilent Technologies as part 
of this study, time constraints have thus far prevented further investigation. If NGS is to be 
employed for high throughput HPA typing, additional IT developments will also be required in 
order to provide an interface between SureCall and the existing LIMS system and enable 
automated data download, thereby avoiding manual transcription to ensure accuracy of data 
transfer and reporting of results. 
7.5 Identification of platelet donors with rare genotypes  
A more limited application of donor HPA genotyping could be used to specifically search for 
platelet donors with rare HPA genotypes. Screening patients for the presence of HPA 
antibodies requires techniques such as the monoclonal immobilisation of platelet antigens 
(MAIPA) assay, which uses a panel of HPA typed platelets (Lucas, 2013). Due to the increasing 
number of reports of maternal alloimmunisation against rare HPA, it could be argued that 
focusing only on the more common antigens when investigating suspected FNAIT is 
inadequate (Santoso and Tsuno, 2015). Genotyping donor samples using targeted NGS could 
identify apheresis donors with rare HPA genotypes who could be used to supplement the 
existing HPA typed platelet panel used for antibody screening by MAIPA. In order to reduce 
costs, one consideration might be to limit NGS genotyping to non-Caucasian donors to increase 
the likelihood of finding rare HPA genotypes although, as data on HPA frequencies in different 
populations is very limited (Robinson et al., 2013), this approach might be misguided. A strong 
argument for implementing NGS for HPA genotyping for all platelet donors would be to 
increase the knowledge of HPA frequencies in the English population (Robinson et al., 2013), 
as discussed in section 7.3. Whilst the cost of NGS is more expensive than the existing in-house 
Taqman technique, because NGS defines all twenty nine HPA systems alongside the potential 
for novel mutation detection, the cost per HPA is more economical and so could be justified. 
7.6 Novel HPA allele detection 
By sequencing all exons and flanking regions of the 6 genes included in the HaloPlex design, it 
was anticipated that this approach would enable detection of novel sequences, as well as 
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defining all known HPA. To challenge this theory, DNA samples extracted from a mother and 
her baby from a previously unresolved case of FNAIT were included in this study and 
sequences compared using the SureCall software paired analysis application for the detection 
disease variants. An exciting development of this study was the discovery of a novel SNP in the 
baby’s sample in a region of the ITBG3 gene between two known HPA suggesting a likely 
causative mutation of FNAIT (Davey, Navarrete and Brown, 2017). Further testing, including 
recombinant expression, by NHSBT laboratories in Bristol have since confirmed that the 
mutation identified in this study is a novel HPA, although this still requires ratification by the 
Platelet Nomenclature Committee. A report is currently in preparation for submission to the 
journal Transfusion, which will reference the NGS investigations completed as part of this 
study (Poles, A. and Lucas, G., personal communication). This was a significant discovery and it 
is hoped that targeted NGS developed during this study will be implemented for the detection 
of rare or novel HPA in NHSBT laboratories as part of routine FNAIT investigation.  
7.7 Conclusions 
This study demonstrates that NGS can significantly improve the definition of both HLA and HPA 
genetic systems. If implemented routinely for platelet donor genotyping and for the 
investigation of FNAIT, these novel approaches will provide a number of tangible benefits for 
laboratories and the patients they support, as well as the wider community. These include 
 Allele level HLA definition to accurately select donor platelets for patients using HEM 
 Detection of novel HLA class I polymorphisms, in both coding and non-coding regions 
 Increased knowledge of HLA intronic sequences  
 Increased knowledge of HLA allele and haplotype frequencies  
 Definition of all known HPA systems in a single test 
 Increased knowledge of HPA frequencies  
 Detection of rare or novel HPA polymorphisms in cases of suspected FNAIT 
Some additional development is still required for both HLA and HPA genotyping, particularly in 
respect of automation, data analysis and reporting of results, but none of these issues are 
insurmountable. Indeed, it is anticipated that NGS for HLA typing platelet donors will be fully 
implemented by autumn 2017. The timeline for introducing targeted NGS for routine definition 
of HPA is less clear but the potential benefits are undeniable, particularly for the detection of 
rare and novel HPA. 
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